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ABSTRACT.
An attempt was made to improve the sensitivity and efficiency of the Enzyme 
Multiplied Immumoassay Technique by introducing a specific cysteine residue into 
Escherichia coli malate dehydrogenase to act as a unique ligand coupling site. The 
structural gene encoding dimeric Escherichia coli malate dehydrogenase encodes three 
reduced cysteines per identical subunit at residues 109, 113 and 251. Initial attempts 
to produce a malate dehydrogenase devoid of cysteines by site directed mutagenesis 
were unsuccessful.
Conserved substitution of cysteine to serine were made to the codons at positions 113 
and 109, singly and in tandem to produce two mutant malate dehydrogenases. The 
gene encoding the single substitution of cysteine 113 (pUCl 13S) when expressed in an 
Escherichia coli strain which is devoid of malate dehydrogenase, produced a 
malate dehydrogenase which was comparable in activity to that observed for wild type 
Escherichia coli malate dehydrogenase. The gene encoding substitutions to cysteines 
109 and 113 (pUC109S/113S), resulted in low levels of expressed malate 
dehydrogenase with a specific activity of only 5% of the wild type.
Amino acid sequence alignment of malate dehydrogenases and analysis of the crystal 
structure of porcine cytoplasmic malate dehydrogenase indicated that arginine 81, 
glycine 84 and leucine 90 of the pDaD surface loop would be solvent accessible in the 
Escherichia coli malate dehydrogenase. Substitution of these residues to cysteine 
resulted in the absence of malate dehydrogenase activity.
Model building of the Escherichia coli malate dehydrogenase using the porcine malate 
dehydrogenase as a template indicated that threonine 64 and serine 222 were suitable 
sites for substitution to cysteine. Expression of the malate dehydrogenase with 
threonine 64 substituted for cysteine resulted in a low level of the malate
III
dehydrogenase in the cell-extract and a specific activity similar to that observed for the 
wild type malate dehydrogenase. The Km for coenzyme and substrate (oxaloacetate) 
for this mutant was similar to that observed for the wild type malate dehydrogenase. 
Attempts to derivatize the introduced cysteine with DTNB were unsuccessful.
Expression of malate dehydrogenase with serine 222 substituted for cysteine (222C) 
resulted in similar levels of expression as that observed for wild type. However, 222C 
malate dehydrogenase had a specific activity of only 3.5% of that observed for the wild 
type enzyme with an increased Km for substrate (oxaloacetate) of 0.94 mM as 
opposed to 0.04 mM. Attempts to derivatize the introduced thiol groups resulted in a 
decrease in the activity of the enzyme in excess of 95% making this enzyme unsuitable 
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(1.1) Recombinant DNA technology.
Gene cloning, whereby a fragment of DNA to be cloned is inserted into a circular 
DNA molecule called a vector to produce a recombinant DNA molecule, has led to 
extraordinary advances in molecular biology and biochemistry. The recombinant DNA 
molecule when inserted into host cells multiplies to produce numerous copies of itself 
(cloned gene). When the inserted DNA fragment encodes a protein, the host can often 
be made to produce the protein in large quantities.
Techniques have been developed which enable manipulation of the DNA insert and 
subsequent modification of the expressed protein. Until recently these techniques have 
been primarily used for the elucidation of the structure and function relationship of 
residues in proteins. For example Wilks et al, (1992) replaced a surface polypeptide 
loop in lactate dehydrogenase with longer and shorter polypeptides and ascertained the 
effect of substitution upon catalysis. This technique is now being employed in such 
diverse fields as protein purification, biosensors and therapeutic proteins. Persson et 
al, (1990) incorporated cysteines into glucose dehydrogenase enabling rapid 
purification from cell-extracts using thiol-affinity chromatography. BOlow and 
Mosbach, (1991) have developed polyfunctional enzymes via gene fusion. The gene 
encoding human insulin, which is responsible for controlling blood glucose level, has 
been synthesised and expressed in Escherichia coli {E.coli) (Goedall et al, 1979). This 
has enabled the production of large amounts of insulin suitable for the treatment of 
diabetes mellitus. It is now feasible to design and express monoclonal antibodies with 
defined antigen specificity which has been determined by manipulation of the gene 
sequence encoding the antibody variable domain polypeptide sequence (Winter and 
Milstein, 1991). Antibodies have also been "humanised" whereby epitopes on the
1
antibody surface which are recognised as "foreign" by the recipient of the antibody are 
removed to produce a non-immunogenic antibody (Sandhu, 1992). Diagnostic assays 
often require enzymes. Enzymes such as DNA polymerase which is used in the 
polymerase chain reaction (PCR) are produced via recombinant DNA technology, and 
have been modified to improve their efficiency by gene manipulation. Some enzymes 
like malate dehydrogenase (MDH), lysozyme and glucose-6-phosphate dehydrogenase 
have been used in enzyme "linked" assays where the enzyme activity forms an intimate 
part of the assay. These enzymes although produced using recombinant DNA have not 
been optimised for use in the enzyme "linked" assay. Optimisation using recombinant 
DNA technology could significantly improve the performance of these assays.
(1.2) The enzyme multiplied immunoassay technique (EMIT).
Radio immunoassay (RIA) and enzyme immunoassay (EIA) have been successfully 
used to detect and quantify many drugs and metabolites in biological fluids and tissues 
(Table 1.1). The disadvantage of RIA products are the short shelf life and the 
problems of storage and disposal of radio-chemiclal wast. In general EIA products 
have a longer shelf life, with storage and disposal conditions being less stringent
A novel type of EIA is the homogeneous EMIT assay (Van Weemen and Schuurs, 
1971). In this assay the ligand is covalently bound to an enzyme such that the enzyme 
retains activity. However, when an antibody recognising both free and bound ligand 
interacts with the covalently bound ligand, the enzyme is inhibited (Fig 1.1). In the 
assay, the analyte (free ligand) to be tested is mixed with modified enzyme, and 
incubated with sufficient antibody to just inhibit the enzyme in the absence of free 
ligand (Fig 1.2). Free ligand competes with the enzyme for the limited amount of 
antibody, reducing the amount of antibody available for inactivation of the enzyme. 
Enzyme activity remaining will then be proportional to the amount of free ligand in the
2







~3 pmol Urine Cleeland et al, 1976
RIA Thyrotropin 0.01 fmol Serum Odell et al, 1986





Kawasaki et al, 1992
EIA 6P-Hydroxycortisol 14 fmol Serum/urine Zhiri eta l, 1986
EIA Immunoglobulin G 40 pmol Serum Papadeaefa/, 1985
EIA Morphine 2 pmol Rowley etal, 1975
EIA Theophylline 2.5 pmol Chang et al, 1982
Table 1.1: Some applications of RIA and ETA.
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Fig 1.1: The basis of the EMIT assay.
(1) Formation of the enzyme-ligand complex does not inhibit enzyme activity.
(2) and (3) introduction of the ligand specific antibody inhibited enzyme activity.
Fig 1.2: The EMIT assay.
(1) In the assay sufficient antibody was used to just inhibit the enzyme.
(2) Addition of free ligand (analyte), competed with enzyme bound ligand for the 













NADH N A D ^













L 4  .NADH NAD 
L
NADH N A D ^




+ Y Y ______ .
y y y
V  J
L ^  VNADH N A D ^  y  
Q  NADH NAD*
Y  ?  
y  Y
sample (Voller et al, 1978). It has been proposed that inactivation of the 
ligand-enzyme complex with antibody could be due to steric interference by the 
antibody, inhibition of conformational change required for enzyme function, or 
antibody induced conformational change of the enzyme (Rowley et al, 1975).
Porcine NAD-dependent mitochondrial malate dehydrogenase and bacterial 
glucose-6-phosphate dehydrogenase (Leuconostoc mesenteroides) have been widely 
used in the ligand-enzyme complex (Chang et al, 1982; Rowley et al, 1975), because 
of their high stability (extending the shelf-life of the EMIT assay kit), ease of 
purification and the ability to detect pmol quantities of active enzyme via spectroscopy 
at 340nm. However, even with attachment of up to 26 ligands per enzyme, only 
partial inactivation of the enzyme in the ligand-enzyme complex with excess antibody 
was achieved (Rowley et al, 1975).
The decrease in the activity of the complex has been attributed to the binding of a 
single antibody to a specific ligand (Rowley et al, 1975). However, the ligand may not 
be in a strategically important position on the enzyme for complete inactivation and 
incomplete inactivation reduces the sensitivity of the EMIT assay. An excess of 
ineffective ligands bound to the enzyme requires an excess of antibody to cause 
inactivation of the enzyme and reduces the sensitivity and efficiency of the assay. 
Ideally a unique ligand bound to the enzyme which is capable of complete inactivation 
of the enzyme upon formation of the antibody-ligand-enzyme complex would provide 
maximum sensitivity and efficiency in the EMIT assay.-
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(1.3) Malate dehydrogenase.
MDH catalyses the inter-conversion of L-malate and oxaloacetate, using nicotinamide 
adenine dinucleotide (NAD) as a coenzyme. Eukaryotes possess dimeric 
mitochondrial and cytoplasmic MDH, and in certain cases glyoxysomal MDH, while 
eubacteria possess a single form, with varying numbers of identical subunits. With a 
few exceptions, the size of all forms of subunit are between 30,000 and 35,000 
Daltons.
All eukaryotic and eubacterial MDHs have the same reaction mechanism; transferring a 
hydride ion to and from the 4 position of the A face of the nicotinamide ring (Davies et 
al, 1972; Noyes et al, 1974). The MDHs can be characterised in vitro by the type and 
extent of their allosteric regulation. High concentrations of L-malate stimulate the 
production of oxaloacetate in mitochondrial MDH, while high concentrations of 
oxaloacetate inhibit the production of L- malate. Cytoplasmic MDH is inhibited to a 
lesser extent by the effect of high concentrations of oxaloacetate (Bernstein et al,
1978; Datta et al, 1985), but exhibits greater inhibition with high concentrations of 
L-malate (Kitto and Kaplan, 1966). Citrate has a dual effect on the enzyme, acting as 
an activator and an inhibitor of the enzyme in the direction NAD+—>NADH, depending 
on the substrate concentration (Gelpi et al, 1992). At high concentrations of NAD+ 
MDH activity is enhanced with citrate, however when the NAD+ concentration is low 
citrate acts as an inhibitor. Eubacteria appear to mirror some of the characteristics of 
eukaryotes, showing marked allosteric inhibition, possibly reflecting the control 
mechanism in a non-compartmentalised system (Sanwal, 1969). Examples of allosteric 
inhibition in eukaryotic and eubacterial MDH are shown (Table 1.2).
Immunological cross-reactivity tests on dimeric and tetrameric MDHs suggests that 
there are common antigens (Smith and Sundaram, 1988) (Table 1.3). However, 
cross-reactivity was only observed between partially denatured MDHs of different
6
Soecies Inhibitors References
Chicken mitochondrial oxaloacetate Kito and Kaplan, 1966
Chicken Cytoplasmic L-malate Kito and Kaplan, 1966
Porcine mitochondrial oxaloacetate and 
citrate.
Gelpi et al, 1992
Porcine Cytoplasmic L-malate Kitto and Kaplan, 1966
E.coli NADH, oxaloacetate, 




oxaloacetate Novotny and Perry, 1990
Methanothermus fervidus oxaloacetate. Honika et al, 1990
Coccochloris peniocystis oxaloacetate, citrate, 
ATP, and CoA.
Norman and Colman, 1991










Dimer Dimer V V Smith and 
Sundaram, 1988
Dimer Tetramer X V
Tetramer Tetramer V V
Tetramer Dimer X V
Table 1.3: Immunological cross-reactivitv of dimeric and tetrameric MDHs.
Table 1.3 indicates that immunological cross-reactivity was only observed between 
partially denatured MDHs of different oligomeric forms.
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oligomeric forms (Smith and Sundaram, 1988). This suggests that greater primary 
structure homology exists within the dimeric and tetrameric forms than between the 
dimeric and tetrameric forms.
Mitochondrial, cytoplasmic and glyoxysomal MDHs form part of a complex interactive 
compartmentalised system (Fig 1.3). There is evidence to suggest that MDH exists as 
a multi-enzyme cluster in eukaryotes and eubacteria (Barnes and Weitzman, 1986; 
Beeckmans and Kanarek, 1981; Robinson et al, 1987), with other tricarboxylic acid 
cycle (TCA) enzymes and aspartate aminotransferase. Cytoplasmic and mitochondrial 
MDHs have been found associated with fumarase, citrate synthase and aspartate 
aminotransferase (Beeckmans and Kanarek, 1981; Robinson et al, 1987). E.coli MDH 
has been isolated in a multi-enzyme cluster with fumarase, citrate synthase, aconitase 
and isocitrate dehydrogenase (Barnes and Weitzman, 1986). The standard free energy 
of the conversion of oxaloacetate to L-malate with NADH as a coenzyme lies in favour 
of L-malate formation. It is believed that the formation of the TCA enzyme complex 
drives MDH in the direction of oxaloacetate, by facilitating the transfer of oxaloacetate 
from MDH to citrate synthase (Beeckmans and Kanarek, 1981).
(1.4) Aims of the project.
The initial objective was to prepare a genetically modified enzyme suitable for 
modification, and eventual use in the EMIT assay. E.coli MDH was chosen, as it has a 
similar structure and properties to porcine mitochondrial MDH, and the gene encoding 
the structural protein was available and could be expressed in E.coli MDH' strains 
(Vogel etal, 1987).
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Fig 1.3: Schematic representation of the interaction between the TCA cvcle. glvoxvlate cvcle and the aspartate-malate Shuttle.
Enzymes are indicated in italics,bold indicates glyoxylate cycle, uppercase aspartate-malate shuttle and lower case indicates TCA cycle.
(1.5) Homology modelling of E.coli MDH.
To identify potential sites on the E.coli MDH surface to allow attachment of ligands it 
was necessary to determine the three dimensional (3D) co-ordinates of solvent exposed 
residues. A homology model was built of the E.coli MDH using the porcine 
cytoplasmic MDH structure as a template. The crystal structure of porcine 
cytoplasmic holo-MDH (enzyme with coenzyme) had been determined and the 3D 
co-ordinates deposited into the Brookhaven protein data bank (Birktoft et al, 1989; 
Roderick and Banaszak, 1986). A crystal structure of E.coli apo-MDH (enzyme with 
substrate analogue) has recently been published, since the work described here was 
carried out. Comparison of the E.coli crystal structure with porcine MDH confirmed 
that the secondary, tertiary and quaternary structures were homologous (Hall et al, 
1992). However greater structural homology was observed between E.coli and 
mitochondrial MDHs (root mean square (RMS) deviation of E.coli and mitochondrial 
MDH polypeptide backbone was 0.76A), than between E.coli and cytoplasmic MDHs 
(RMS deviation 1.88A). The core structures of these proteins displayed the greatest 
homology, while surface turns were less homologous (Hall et al, 1992). The greater 
deviation between the E.coli and cytoplasmic MDH structures can be attributed to 
lower sequence identity; E.coli and mitochondrial MDH have a sequence identity of 
55%, whereas E.coli and cytoplasmic MDH have a sequence identity of approximately 
20%. Although porcine mitochondrial MDH was a better candidate as a template 
structure for modelling, the 3D co-ordinates had not been deposited into the 
Brookhaven protein data bank and therefore were not available for use.
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(1.6) The E.coli MDH.
(1.6.1) E. coli MDH structural gene.
The deduced amino acid sequences of E.coli MDH structural genes have been 
obtained by three groups (McAlister-Henn et al, 1987; Nicholls et al, 1989; Vogel et 
al, 1987). The sequences are in agreement, except for the insertion of a cytosine at 
position +910 which would cause a frame-shift at amino acid position 305 (W) and 
lead to a change in the carboxy terminal from WAKSSILSN COOH to 
LGEEFVNK COOH (Fig 1.4). However, this deviation is a sequence artefact since 
the clone with which I was provided had the extra base, contrary to the literature 
source and the group providing the clone (Vogel et al, 1987). This gene encodes all 
312 residues of a single polypeptide subunit of 32,500 Daltons containing three 
reduced cysteines at residues 109,113 and 251. A ribosome binding site 5'AGGA is 
located six nucleotides upstream of the ATG initiation codon of Met 1. Promoter 
regions -10 promoter (5'TAAGGT) and -35 promoter (5'TTGTAA) are located at 
nucleotide positions -57 to -52 and -70 to -65 respectively. Vogel et al, (1987) has 
proposed that the G nucleotide, 44 base pairs upstream of the ATG initiation codon 
corresponds to the transcription initiation site. The 5TITTTTGTTTT at nucleotide 
positions 980 to 990 preceded by G and C residues indicates a rho termination site 
(Vogel etal, 1987).
E.coli MDH' strain W945T1-2 has a mutation within the regulatory gene controlling 
MDH expression. This regulatory gene has been mapped to the histidine operon. The 
strain spontaneously reverts with a frequency of 10"  ^to 10"^ (Courtright and Henning, 
1970). However, growth of E.coli on glucose minimal medium under anaerobic 
conditions suppresses the TCA cycle and the subsequent production of chromosomally 
encoded MDH (Gray et al, 1966). Therefore, anaerobic growth of E.coli W945T1-2 
on glucose minimal media will prevent the expression of MDH in revertants, thus
11
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- 3 4 0  - 3 3 0  - 3 2 0  - 3 1 0  - 3 0 0  - 2 9 0  - 2 8 0  - 2 7 0
a g t g a a t t  CGAGCTCGGT ACCCGGGGAT CCTCTAGAGT CGACCTGCAG GCATGCAAGC T T g c a a a t t c  t g c t t a a a a g  
- 2 6 0  - 2 5 0  - 2 4 0  - 2 3 0  - 2 2 0  - 2 1 0  - 2 0 0  - 1 9 0  - 1 8 0  - 1 7 0  - 1 6 0  - 1 5 0  - 1 4 0
t a a a t t a a t t  g t t a t c a a a t  t g a t g t t g t t  t t g g c t g a a c  g g t a g g g t a t  a t g t c a c c a c  c t g t t g g a a t  g t t g c g c t a a  t g c a t a a g c g  a c t g t t a a t t  a c g t a a g t t a  g g t t c c t g a t  t a c g g c a a t t  
- 1 3 0  - 1 2 0  - 1 1 0  - 1 0 0  - 9 0  - 8 0  - 7 0  - 6 0  - 5 0  - 4 0  - 3 0  - 2 0  - 1 0
a a a t g c a t a a  a c g c t a a a t t  g c g t g a c t a c  a c a t t c t t g a  gatgtggtca ttgtaaacgg c a a t t t t g t g  g a t t a a g g t c  a c a a c a q c a a  a a c a a c a t a t  c t t a g t t t a t  c a a t a t a a t a  a g g a t t t a g g  
10  20  30 40 50 60 70 80 90 100
ATG AAA GTC GCA GTC CTC GGC GCT GCT GGC GGT ATT GGC CAG GCG CTT GCA CTA CTG TTA AAA ACC CAA CTG CCT TCA GGT TCA GAA CTC TCT CTG TAT GAT ATC GCT 
M K V A V L G A A G G I G Q A L A L L L K T Q L P S G S E L S L Y D I A  
1 10 20 30
1 1 0  1 2 0  1 30  1 40  150  1 60  170  180  1 90  2 0 0  210
CCA GTG ACT CCC GGT GTG GCT GTC GAT CTG AGC CAT ATC CCT ACT GCT GTG AAA ATC AAA GGT TTT TCT GGT GAA GAT GCG ACT CCG GCG CTG GAA GGC CGA GAT GTC 
P V T P G V A V D L S H I P T A V K I L G F S G E D A T P A L E G R D V  
40  50 60 70
2 2 0  2 3 0  2 40  2 5 0  2 60  2 7 0  280  2 90  3 0 0  3 1 0  320
GTT CTT ATC TCT GCA GGC GTA CGG CGT AAA CCG GGT ATG GAT CGT TCC GAC CTG TTT AAC GTT AAC GCC GGC ATC GTG AAA AAC CTG GTA CAG CAA GTT GCG AAA ACC 
V L I S A G V R R K P G M D R S D L F N V N A G I V K N L V Q Q V A K T
80 90 100
3 3 0  3 4 0  350 360  370  380  390  4 00  4 1 0  4 20  430
TGC CCG AAA GCG TGC ATT GGT AAT ATC ACT AAC CCG GTT AAC ACC ACA GTT GCA ATT GCT GCT GAA GTG CTG AAA AAA GCC GGT GTT TAT GAC AAA AAC AAA CTG TTC 
C P K A C I G N I T N P V N T T V A I A A E V L K K A G V Y D K N K L F
1 1 0  120  1 3 0  140
4 40  4 50  460  470 480  490  5 00  510 5 20  530  540
GGC GTT ACC ACG CTG GAT ATC ATT CGT TCC AAC ACC TTT GTT GCG GAA CTG AAA GGC AAA CAG CCA GGC GAA GTT GAA GTG CCG GTT ATT GGC GGT CAC TCT GGT GTT 
G V T T L D I I R S N T P V A E L K G K Q P G E V E V P V I G G H S G V
1 5 0  1 60  1 70  180
5 50  560  5 70  580  590 600  610  620 630  640
ACC ATT CTG CCG CTG CTG TCA CAG GTT CCT GGC GTT AGT TTT ACC GAG CAG GAA GTG GCT GAT CTG ACC AAA CGC ATC CAG AAC GCG GGT ACT GAA GTG GTT GAA GCG 
T I L P L L S Q V P G V S P T E Q E V A D L T K R I Q N A G T E V V E A
190 2 00  210
650 6 60 6 70 680 690 700 710 720 730 740 7 50
AAG GCC GGT GGC GGG TCT GCA ACC CTG TCT ATG GGC CAG GCA GCT GCA CGT TTT GGT CTG TCT CTG GTT CGT CGA CTG CAG GGC GAA CAA GGC GTT GTC GAA TGT GCC
K A G G G S A T L S M G Q A A A R F G L S L V R A L Q G E Q G V V E C A
2 2 0 230 240 250
7 60 7 7 0 780 790 800 810 820 830 840 850 860
TAC GTT GAA GGC GAC GGT CAG TAC GCC CGT TTC TTC TCT CAA CCG CTG CTG CTG GGT AAA AAC GGC GTG GAA GAG CGT AAA TCT ATC GGT ACC CTG AGC GCA TTT GAA
Y V E G D G Q Y A R F F S Q P L L L G K N G V E E R K S I G T L S A F E
2 60 2 70 2 8 0
870 880 890 900 910 920 930 940 950 960 970
CAG AAC GCG CTG GAA GGT ATG CTG GAT ACG CTG AAG AAA GAT ATC GCC TGG GCG AAG AGT TCG TTA ATA AGT a a t  t  g a t t a a g c g g  ataataaaaa a c c a a a g c a c  a
E N A L E G M L D T L K K D I A W A K S S L I S N
L G E E F V N K
2 90 300 3 10
J80 990 1 0 0 0 10 1 0 102 0 1030 1040 1050 106 0
a t  t t t t t a t t t t  g a g c g c a c g t  c t t a a t t g g t  t g c c g g a t a t  t c c t g a a t g g  t g a c c a a g c t  t g g c g t a a t c  a t g g t c a t a g  c t g t t t ____
Fig 1.4: The nucleotide sequence of a single subunit of the E.coli MDH gene.
The nucleotide sequence of the 1344 bp DNA fragment containing the MDH structural gene encoding 312 residues and part of pUC19 polylinker 
(italics, -279 to -338). Uppercase letters (1 to 939) indicate coding region. Below each codon is the single letter amino acid code (uppercase). 
Amino acid sequence deviation is depicted in bold. Bold lowercase indicates the putative -10 and -35 promoter recognition sites. RBS is the 
ribosome binding site, g and rho are the transcription initiation site and putative termination site.
enabling expression of plasmid encoded MDH without contamination from 
endogenous MDH.
(1.6.2) Comparison of the secondary, tertiary and quaternary structures of E.coli and 
porcine cytoplasmic MDH.
The underlying organisation of E.coli and porcine cytoplasmic dimeric MDHs are 
similar, with the subunits being divided into a coenzyme-binding domain and catalytic 
domain. The coenzyme-binding domaine, consists of the N-terminal half of the 
polypeptide chain. In the E.coli (Fig 1.5) and porcine MDHs these are residues 1-150. 
The main structural motif of this domain in E.coli MDH is a centrally located six- 
stranded parallel p-sheet (p-sheet I) flanked by five a-helices (Birktoft et al, 1989; 
Birktoft et al, 1989b; Hall et al, 1992) (Fig 1.6). The C-terminal half of the 
polypeptide chain (E.coli residues 151-312 (Fig 1.5); porcine residues 151-332) is the 
catalytic domain (Birktoft and Banaszak, 1983). The predominant structural features 
are two anti-parallel P-sheets (P-sheets II and HI) (Fig 1.6). Beta sheets II and III are 
interspersed with five a-helices (Birktoft et al, 1989; Hall et al, 1992).
Minor deviations are apparent between the E.coli and porcine MDHs in the length of 
the polypeptide chain in the surface turn motif segments which connect the a-helices 
and p-strands structures and the initiation and termination points of the joining turns. 
Beta-Sheet I consists of P-strands PA to PF and is flanked on one side by a-helices 
aB, aC  and aC' and on the other by aDE and a  IF. Beta-Sheet I displays a degree of 
right handed twist. All the p-strands and a-helices in the nucleotide binding domain 
with the exception of pC and aDE (which are located on the surface of the protein), 
are buried within the interior of the protein. A turn motif of seven residues between 
aB and pB in the porcine MDH (Birktoft et al, 1989b) is diminished (three residues) in 
E.coli MDH (Hall et al, 1992).
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Fig 1.5: The deduced amino acid sequence of a single subunit of E.coli MDH. 
Sequence and secondary Structure based on that obtained by Hall et al, (1992) and 
Vogel et al, (1987). Nomenclature for secondary structure description follow the 
system adopted for LDHs and MDHs (Rossmann et al, 1975). Elements of secondary 
structure are indicated with (3 indicating p-strand and a  signifying a-helix. Bold 
lettering indicates deviation in sequence.
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INTERFACE
Fig 1.6: Schematic representation of the secondary and tertiary structure of E.coli 
MDH subunit.
The portion of the structure represented by arrows are (3-strands, and coiled ribbons 
signify a-helices. Parallel p-sheet I (p-strands A to F) is indicated by numbering 1 to 6. 
Anti-parallel p-sheet II (P-strands G and H) is indicated by numbering 7 and 8. 
Anti-parallel p-sheet III(p-strands K, L and M) is indicated by numbering 9 to 11. 
Reproduced from Hall et al, (1992).
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Beta-Sheet II is made up of two anti-parallel P-strands, PG and PH. This sheet has a 
degree of right handed twist greater than that observed in p-sheet I. Beta strand G and 
pH are connected by a hairpin turn which points into the interior of the protein. This 
turn forms part of the active site and contains a histidine which is important in catalysis 
CE.coli residue 177; porcine residue 180). Beta-Sheet II is connected to the nucleotide 
binding domain by a-heiix a2F and to P-Sheet IQ by a-helix alG/a2G. This 
a-helix (alG/a2G) is located on the surface of the MDH.
Beta-sheet HI consists of three anti-parallel P-strands, pK, pL and pM and is 
positioned between P-sheets I and n. Beta-Sheet QI has a twist of approximately 90° 
and is flanked by two a-helices at its initiation (a3G) and termination (aH). Beta 
strand M and aH are solvent exposed as are the turn motifs connecting the p-strands. 
Porcine MDH has a turn situated between a3G and PK of six residues (Birktoft et ah 
1989b) which is only three residues in E.coli MDH (Hall et ah 1992).
The crystal structures indicate that the subunit:subunit interactions differ between 
E.coli and porcine cytoplasmic MDHs (Birktoft et ah 1989; Hall et ah 1992).
Bleile et ah (1977) has demonstrated that at low pH (pH <5.0) the structurally 
homologous porcine mitochondrial MDH dissociates into monomers, whereas porcine 
cytoplasmic MDH did not. It was concluded that a histidine at the mitochondrial 
MDH subunit inter-face was responsible for this acid dissociation. The mitochondrial 
MDH was also shown to be more susceptible to dissociation into its monomers at low 
concentrations (0.2 jj. M). This is due to different residues at the subunit interface 
contributing to subunit: subunit stability and is manifest in the crystallographic 
symmetry observed at the subunit interfaces. Porcine MDH displays approximately 
two fold rotational symmetry at the subunit interface whereas E.coli has exact 
symmetry through the same axis (Birktoft et al, 1989; Hall et al, 1992). In E.coli, 
MDH subunit:subunit interactions are through polar and non-polar contacts. Alpha 
helix B interacts with a3G and with aB of the other subunit, aC  interacts with the
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amino terminal portion of a2F and the carboxy terminal of a3G. Polar and non-polar 
interactions between subunits in porcine MDH are between different elements of the 
secondary structure. Alpha helix B, aC and a2G of one subunit interact with aB, aC 
and a2G of the other subunit. Alpha helix 2F of one subunit interacts with aC  of the 
other subunit.
(1.6.3) Binding of coenzyme and substrate in the active site of MDH.
Citrate has a similar structure to L-malate, differing only by the addition of a methyl 
carboxyl group, as indicated below.
C^OO"
I
h o c 2 h
I
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c 3 h 2
I
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Citrate
Citrate acts as an analogue, hydrogen bonding to the putative active site residues in 
MDH (Hall et al, 1992). Substrate specificity is thought to arise through the 
conformation of the substrate binding site and through hydrogen bonding (Clarke et al, 
1987; Hall et al, 1992). Modelling of L-malate in the substrate binding site of E.coli 
MDH using the co-ordinates of citrate as a template, suggests that specificity is partly 
brought about by hydrogen bonding with arginine residues (Hall et al, 1992). The 
terminal guanidino nitrogens of arginine 153 are thought to hydrogen bond with the C* 
carboxyl moiety of L-malate and the Epsilon (e) nitrogen of arginine 81 is thought to 
hydrogen bond with the C* carboxyl moiety (Fig 1.7). However Clarke et al, (1987) 
and Nicholls et al, (1992) have proposed that the C* carboxy moiety interacts with 
arginine 81 terminal guanidino nitrogens. The C2  hydroxyl moiety of L-malate is 









Fig 1.7: Proposed hypothetical ternary model of E.coli MDH active site.
Proposed ternary model of E.coli MDH active site of Hall et al (1992). Residues and 
atoms involved in hydrogen bonding of substrate are labelled. Stippled lines indicate 
hydrogen bond.
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al, (1987) has shown that the homologous substrate binding site of lactate 
dehydrogenase (LDH) can be modified to alter the substrate specificity from 
pyruvate/lactate (R = -CH3 ) to oxaloacetate/L-malate (R = -CH2 -C^OO") by 
increasing the volume of the substrate binding site. Greater specificity was obtained 
for oxaloacetate/malate when an arginine homologous to E.coli MDH arginine 81 was 
introduced into the PD/aD loop. This residue was capable of hydrogen bonding with 
the C* carboxyl moiety. Comparison of the active sites of E.coli apo-MDH and 
porcine holo-MDH indicated that the citrate and nicotinamide ring of the NAD are in 
close proximity of each other (Birktoft et al, 1989b; Hall et al, 1992). This 
observation has been substantiated by comparison of the crystal structures of LDH 
binding substrate analogues and coenzyme (Grau et al, 1981; Abad-Zapatero et al, 
1987). NAD is thought to interact with the coenzyme binding site in an extended 
conformation (Webb et al, 1973). The nicotinamide and purine ring of the coenzyme 
are stabilised through hydrophobic interactions with the active site, while the ribose 
and phosphate moieties are stabilised through hydrogen bonding (Birktoft et al, 1989). 
Hydrogen bonding between the carboxamide group of the nicotinamide ring and the 
coenzyme binding pocket is thought to provide the stereospecificity of MDH for NAD 
(Rossmann etal, 1975) (Fig 1.8).
(1.7) The action of MDH in catalysis.
MDH exhibits a compulsory ordered binding mechanism in the forward and reverse 
directions, with the coenzyme binding first followed by the substrate (Raval and 
Wolfe, 1962; Silversteine and Sulebelele 1969). The nicotinamide ring of NAD and 
substrate are thought to be in close proximity to an essential histidine and aspartate 
which have been implicated in the hydride transfer reaction in dehydrogenase catalysis 
in the active site (Birktoft and Banaszak, 1983). Evidence for the importance of these 
residues comes from several observations. Sequence alignments of LDH and MDH 
indicate that these residues are invariant (Birktoft et al, 1982). The crystal structure of
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Fig 1.8: Conformation of NAD in the porcine cytoplasmic coenzvme binding site. 
Residues which participate in hydrophobic binding areas are shown schematically. 
Atoms that participate in direct and indirect hydrogen bonding are shown in stippled 
lines. O Indicates hydrogen bonded water molecules.
Reproduced from Birktoft et al, (1989).
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all MDHs so far characterised, indicate the presence of histidine and aspartate in the 
putative active site (Birktoft and Banaszak, 1982; Hall et al, 1992; Roderick and 
Banaszak, 1986). MDH can be inactivated by diethyl pyrocarbonate, a histidine 
specific reagent in a 1:1 stoichiometry. Enzyme inactivation is prevented in the 
presence of substrate or coenzyme indicating that the histidine residue is in the active 
site (Holbrook et al, 1974; Ijiama et al, 1986). Substitution of the aspartate of the 
histidine-aspartate pair, to a non hydrogen bonding neutral residue, alters catalysis in 
dehydrogenases (Clarke et al, 1988). Modelling studies have indicated that 
introduction of the coenzyme into the binding site does not significantly alter the 
conformation of the enzyme (Hall et al, 1992). Introduction of the substrate into the 
catalytic site, and associated hydrogen bonding with the C* carboxy moiety of arginine 
(E.coli residue 153), initiates a conformational change in the enzyme. The (3D/aD 
loop, which is solvent exposed in the holoenzyme complex {E.coli residues 76 to 8 6 ), 
collapses over the active site, shielding it from solvent molecules, and initiates contact 
of arginine 81 (E.coli) with the carboxy of the substrate (Fig 1.7) (Hall et al, 1992;
Trommer and Gloggler, 1979). Simultaneously, the imidazole ring of histidine 177 is 
thought to move towards the hydroxy moiety of the substrate allowing hydrogen 
bonding to occur. This results in the c£ carbon developing a partial positive charge, 
and hydrogen bonding between the carbon and position four of the nicotinamide 
ring (Bernstein and Everse, 1978; Birktoft and Banaszak, 1983; Hall et al, 1992). A 
localisation of the positive charge at position four of the nicotinamide ring results in 
the formation of NAD+ and L-malate, whereas a localisation of the positive charge on 
the imidazole e nitrogen leads to NADH and oxaloacetate. Binding of the coenzyme in 
the coenzyme binding site is both non-stoichiometric as well as non-equivalent 
(Weininger et al, 1977), with the binding of coenzyme in one subunit inhibiting the 
binding of coenzyme in the second subunit. It has been proposed that a-helices a2G 
and a3G which form part or the catalytic site and subunit interface, influence the 
binding of the coenzyme (Hall et al, 1992). Binding of the coenzyme in the coenzyme
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binding site causes a movement of these helices which inhibits binding of the of 
coenzyme in the second subunit via the subunit interface.
(1.8) Derivatization of MDH.
The project required that a unique coupling residue be placed on the surface of each 
subunit of E.coli MDH. Although lysine, arginine (amino groups), aspartate and 
glutamate (carboxyl groups) can de derivatized (M&nsson and Mosbach, 1992), they 
are all unsuitable for derivatization as they are abundant (20% of the E.coli MDH 
residues) and are solvent accessible (Bordo and Argos, 1991). The reduced cysteines 
in E.coli MDH on the other hand are not solvent accessible (Murphey et al, 1967) and 
cannot be derivatized. Introduction of a solvent accessible cysteine in the MDH would 
therefore allow specific ligand attachment Three common coupling reagents can be 
used to covalently bind a ligand to cysteine; the maleimides, alkyl halides and pyridyl 
disulphides (Fig 1.9). The pK of cysteine is 8.3 and at alkaline pH (pH>7.0) can 
undergo nucleophilic attack with the coupling reagents.
The presence of substituted solvent accessible cysteines can be ascertained by 
monitoring the change in an absorbance of a reporter molecule upon covalent 
attachment to thiols. N-Ethylmaleimide undergoes nucleophilic addition in a similar 
manner as described above (Fig 1.9) (Portis et al, 1983). Unbound N-ethylmaleimide 
has an absorbance at 305nm. The reaction of the N-ethylmaleimide with the thiol 
group can be monitored by measuring the decrease in absorbance at 305nm. However 
the low absorbance of N-ethylmaleimide (E305nm = 620 cm" 1m_1) and interference due 
to the absorbance of phenylalanine, tyrosine and tryptophan in proteins, monitoring 
coupling is impractical. Dithionitrobenzoate (DTNB) (Ellman, 1959) reacts with thiol 
groups in a similar manner as pyridyl disulfide (Fig 1.9). Reaction of DTNB with 
thiols releases thionitrobenzoate anion (TNB) which has a high absorbance at 412nm 
(E4121M1 = 136000 cm'lM"!). The coupling of DTNB to thiols can be monitored by
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Coupling reagent Method of covalent coupling
Maleimides i *0 °
< V Nx C °  ph>6-5-7-5 a O  ^
pr° t sh ^  * \ X r  — *  " Ck
l \-----'  f  S-PROT o/ T X S-PROT
Alkyle halides
0 pH>7.S 0
PROT— SH^» R-C—<jHt \ ------- - R—C—CH,-S— PROT + 1 --------► R_C —CHj-S---PROT + HI
Pyridyl disulphides
( T 5^ ) ^ 7'0 VPROT—SH + M| y ------ - PROT—S -S -R  ♦ 1 | l -------- PROT— S—S—R + 1
I s^ > s .
^  S-R  H
N-Ethylmaleimide CH,
CH, pH 6.5-7.5 h 
p r o t - s h  ^ Uy ^ °  ~ " C H , C H , - / ^
O
Dithionitrobenzoate < * - /  °vsc^ oh < * - /  °nnc^ oh
« O T -s »  .  ^ s - j  .
PROT
Fig 1.9: Covalent coupling of ligands to cvsteines.
The conditions for covalent coupling of ligands to cystines are indicated above. TNB is Thionitrobenzoate anion and PROT-SH is cysteine 
protein.
the formation of the TNB anion as no absorbance by the protein is observed at this 
wavelength.
(1.9) Substitution of codons in the MDH gene.
Two strategies can be employed in the mutation of genes; random mutagenesis and 
site-directed mutagenesis.
With random mutagenesis nucleotides are substituted randomly or semi-randomly. 
Common methods of generating random mutations include the use of chemical 
mutagens, ultraviolet light, ionising radiation and mutator strains of E.coli (Neidhardt 
et al, 1988; Winnacker, 1987). However random mutagenesis is unsuitable, because 
the project requires that the codons of specific residues determined by homology 
modelling are substituted.
Site-directed mutagenesis requires specific replacement of a small number of bases.
An oligonucleotide spanning the region to be altered is synthesised containing the 
altered (mismatched) bases. Flanking perfect match sequence serves to precisely align 
the substituted bases, and the remainder of the strand is synthesised enzymatically, 
using either the Klenow fragment of DNA Polymerase I or PCR. Strategies for 
oligonucleotide directed mutagenesis can be divided into two categories based on the 
form of the template: single stranded templates derived from filamentous phage vector 
such as M13 and double stranded templates from plasmid vector. In both systems the 
oligonucleotide is annealed to a single stranded template. An oligonucleotide, the 
sequence of which is complimentary to the DNA molecule to be mutagenised, apart 
from one or several specific and pre-determined base changes is hybridised to its 
complimentary sequence of a clone of single stranded template DNA. The 
oligonucleotide serves as a primer for in vitro enzymatic DNA synthesis (using the
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Klenow fragment of DNA Polymerase I) all or part of the template DNA to form a 
double stranded heteroduplex (Winnacker, 1987).
However this method of mutagenesis has the disadvantage that large amounts of 
template DNA are required for mutagenesis. The efficiency of mutation is low (40%) 
(Winnacker, 1987) and the entire vector has to be sequenced.
Mutagenesis using PCR mutagenesis has superseded the above for site-directed 
mutagenesis (Reidhaar-Olson and Sauer, 1988; Saiki et al, 1988). PCR amplification 
involves two oligonucleotide primers similar to those described above that flank a 
double stranded DNA segment to be amplified. Repeated cycles of heat denaturation 
of the DNA, annealing of the primers followed by extension of the annealed primers 
with thermostable DNA Polymerase. These primers hybridise to opposite strands of 
the target DNA so that synthesis by the Polymerase proceeds across the region 
between the primers doubling the amount of that DNA segment. Each successive 
round of target DNA replication doubles the amount of DNA synthesised in the 
previous cycle. Therefore primers nucleotide mismatches will be replicated with target 
DNA replication. This technique has the advantage that small amounts of double 
stranded target DNA can be used in a single step procedure. If the cassette 
mutagenesis method is employed (Reidhaar-Olson and Sauer, 1988), only the PCR 
product has to be checked for spurious mutations. This and the single mutagenesis 
step greatly decreases the time that a mutant can be generated.
(1.10) Purification of E.coli MDH.
Traditionally E.coli MDH has been purified to homogeneity using ammonium sulphate 
saturation precipitation of proteins followed by chromatography on DEAE-cellulose 
(Femely et al, 1981; Murphey et al, 1967). With the advent of affinity 
chromatography MDH has been purified in a single step, using NAD+ as the affinity
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ligand (Wright and Sundaram, 1979). These techniques are however relatively 
expensive, and have been replaced by dye affinity chromatography. The triazinyl dye 
Procion red H3-B has been covalently linked to agarose by the formation of an ether 
link between the triazine ring of the dye and the agarose hydroxyl groups (Atkinson et 
al, 1982) (Fig 1.10). Bacterial MDH has been purified by elution from a Procion red 
chromatography matrix with salt and in its ternary complex by elution with NAD+ and 
L-malate (Smith et al, 1982).
An alternative approach has been the use of thiol-affinity chromatography (Axen et al, 
1975) (Fig 1.10). Modified galactokinase and glucose dehydrogenase incorporating a 
cysteine affinity tag have been purified by thiol-affinity chromatography (Persson et al, 
1988; Persson et al, 1990). This technique would enable rapid purification of MDH 
with a solvent accessible reduced cysteine.
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Matrix Reaction
Procion Red/CL6-B 0 AGAROSE-O 
AGAROSE-OH NA N
• A X — -  ' A A
SOjH OH NH 'p OH NH ^ 
HOjS SOjH HOjS SOjH
Thiol group/CL6-B (1) CH
/ \
AGAROSE-OH ♦ l-Chloro-2 , 3-epaxyproptnc-----► AGAROSE-O-- CH, ^CH,
(2) /°\ .
AGAROSE-O-- CM, ^C H ^N i/S jO ,1" +HjO---► AGAROSE-^
CHrCKOHjCHrS^J, N* OH 
(3) AGAROSE'J) P T T» AGAROSE-O
CHr-CmOHJCHj-SjO, N» CHyCHKOHOCHy-SH
Fig 1.10: Preparation of chromatography matrices.
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CHAPTER TWO:
MATERIALS. EQUIPMENT AND METHODS.
(2.1) Materials.
Vectors pUC19 and M13mpl9, restriction endonucleases, DNA modifying enzymes 
and Lambda DNA - Hind in and Pst I molecular size markers were from Northumbria 
Biologicals Ltd., Cramlington, UK and Pharmacia LKB Ltd., Milton Keynes UK.
Agar, tryptone and yeast extract were from Difco, Michigan, USA. L-Leucine, 
L-Threonine, L-Tryptophan, Thiamine, Ampicillin and Streptomycin,were from Sigma, 
Poole, UK. IPTG and X-gal were from Northumbria Biologicals Ltd.
Nensorb™ nucleic acid purification cartridges were from DuPont, Stevenage, UK. 
Qiagen plasmid purification kits were from Diagen, Dusseldorf, Germany. Quickseal™ 
centrifuge tubes were from Beckman Instruments Inc., Palo Alto, USA. Agarose 
(normal and low melting point), was from Sigma. Sepharose CL6 -B was from 
Pharmacia LKB Ltd. Distilled Phenol was purchased from Rathbum Chemicals Ltd., 
Walkerburn, UK.
[a-3 2 P]dATP (5000 Ci/mmol), ty-3 2 P] ATP (3000 Ci/mmol) and [a-3 5 S]dATP (1000 
Ci/mmol) was from NEN, Stevenage, UK. Hybond™-N hybridisation membrane and 
Oligonucleotide-directed in vitro mutagenesis kits were from Amersham International. 
Electran grade acrylamide; TEMED; Silane A-140 adhesion promoter and 
Dimethyldichlorosilane solution were from BDH. Oligodeoxyribonucleotide 
sequencing primers and probes were synthesised on an Applied Biosystems 381A DNA 
synthesiser (Applied Biosystems, Foster city, USA) or were obtained from Andrew 
Garman at Imperial Chemical Industries, UK.
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Sequenase™ kits were from United States Biochemical Corporation, Ohio, USA. 
X-ray film was from Fuji photo film company, Japan.
Brij 58 was purchased from Aldrich Chemical company Ltd., UK. Visking dialysis 
membrane 3-20/32 was from Medicell International Ltd., London, UK. Protein 
molecular weight standards were from Pharmacia LKB Ltd. DTNB, NAD+, NADH, 
Oxalacetate and L-Malic acid were from Sigma, Poole, UK. All other chemicals were 
from BDH UK, Fisons UK or Sigma UK.
(2.2) Equipment.
Preparation of samples which required centrifugation, made use of either Beckman 
model L5-65 ultracentrifuge with a 70.1Ti rotor for purification of supercoiled DNA 
on caesium chloride equilibrium density gradients, DuPont Sorvall RC-5B refrigerated 
superspeed centrifuge for large volumes, an Eppendorf centrifuge or a refrigerated 
centrifuge (Ole Dich, Denmark) for small volumes. Milli-Q™ reagent grade water 
system was from Millipore Corp., Bedford, USA. DNA thermal cycler was from 
Perkin-Elmer-Cetus instrument's division, Norwalk, USA and Techne PHC-2 from 
Techne, Cambridge, UK. SP8-400 UV/Vis and CE272 spectrophotometers were from 
Pye Unicam, Cambridge, UK. and Cecil Instruments, Cambridge, UK respectively. 
Sonicator was supplied by Ultrasonics Ltd., Shipley, UK. Speedvac concentrator was 
from Stratech Scientific, London, UK. DNA sequencing apparatus was from BRL, 
Gothenburg USA. Falcon 0.22p,m bottle top filters were from Becton Dickinson, 
Plymouth, UK. The transilluminator was from UVP inc., Califonia USA. Flat bed gel 
scanner was from LKB, UK.
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(2.3) E.coli Strains and Culture conditions.
A freeze dried culture of E.coli strain W945T1-2 was a gift from Dr. K. D. Entian of 
the Institut fur Mikrobiologie, Goethe-Universitat, Frankfurt. This strain was used for 
expression of both wild type and mutant MDH. The culture was initially grown on 
(LB) agar under aerobic conditions. Further growth was under defined medium 
conditions. Stock medium solution consisted of:
(a) D-glucose (50%, 100 x stock) filter sterilised through a 0.22 fim (Falcon filter) into 
autoclaved bottles.
(b) Casamino acids (10 mg.ml‘1 ,10 x stock) sterilised by autoclaving.
(c) Thiamine (500 |ig.ml‘l, jq x stock), L-threonine (500 pg.ml-!, 10 x stock), 
L-leucine (500 |ig.ml"l, 10 x stock) and L-tryptophan (500 pg.ml“l, 10 x stock) were 
sterilised by autoclaving.
(d) M9 salts (10 x stock) of Na2 HPC>4 (60 g.H), KH2 P04  (30 g .l'1), NaCl (5 g .l'1) 
and NH4 CI (10 g.1'1) were sterilised by autoclaving. Each was added to give a
1 x final concentration, using sterile techniques, into previously autoclaved bottles. 
Powdered streptomycin (50 pg.ml'l final concentration) and autoclaved MgS04  
(0 .2 % final concentration) was added to defined medium and the volume made up with 
sterile water.
E.coli strain TGI was used as the host for groups of plasmids. TGI cultures were 
grown in undefined, sterile modified LB (NaCl 10 g.1'1, yeast extract 10 g .H , and 
tryptone 10 g.1'1) and 2 x LB media (NaCl 10 g.1'1, yeast extract 10 g.1'1 and 
tryptone 20 g.l"*). Solid agar (agar 1.5% w/v) and top agar (agar 0.8% w/v) media 
was made by dissolving agar in defined and undefined media to the required final 
concentration, supplemented with ampicillin (100 pg.ml'l) where necessary. Cell 
cultures were stored at -20°C and -70°C in pure glycerol.
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(2.4) General reagents.
General reagents were prepared as indicated below, sterilised where appropriate and 








24 : 1 Chloroform : Iso-amyl alcohol.
lOmg per ml and 1 mg per ml, stored at 4°C in dark.
Distilled Phenol equilibrated with (Tris. HC150 mM pH 8.0), 
stored at -20°C.
1: 1 Equilibrated Phenol: Chloroform.
Potassium acetate (3M): Glacial acetic acid (2M), pH 5.4 
(Autoclaved).
Tris. base, (0.89 M), Boric acid (0.89 M), EDTA (0.2 M) 
Tris. HC1 (100 mM), EDTA (1 mM) (autoclaved).
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(2.5) General Methods.
(2.5.1) Quantification of DNA.
DNA concentration and purity were assessed spectrophotometrically by recording a 
spectrum from 340nm to 240nm in a 1 cm path length quartz cuvette. One absorbance 
unit at 260nm was taken as equivalent to 50 fig.ml" 1 of double stranded DNA or 
33 jxg.ml" 1 of single stranded DNA. Pure DNA samples were characterised by a 
260nm absorbance peak with no trace of an absorbance shoulder at 280nm.
(2.5.2) Extraction of DNA with organic solvents.
(2.5.2.1) Phenol/Chloroform extraction of DNA.
An equal volume of equilibrated phenol/chloroform (Maniatis et al, 1982) was added 
to the aqueous DNA sample. The mixture was briefly vortexed and the two phases 
separated by centrifugation at 5,000g for 1 minute at room temperature. The upper 
aqueous phase containing the DNA was transferred to a fresh tube. The lower organic 
phase was discarded.
(2.5.2.2) Diethyl ether extraction of DNA.
Traces of phenol were removed from aqueous DNA samples by extracting three times 
with equal volumes of diethyl ether, followed by centrifugation at 5,000g for 1 minute 
at room temperature to separate the upper organic phase from the lower aqueous 
phase. The upper organic phase was discarded.
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(2.5.3) Precipitation of DNA using ethanol or isopropanol.
(2.5.3.1) Precipitation of DNA using ethanol.
A 0.1 volume of sodium acetate (3 M, pH 5.4) (Maniatis et a/, 1982) and 2.5 volumes 
of ice-cold absolute ethanol were added to aqueous DNA, briefly vortexed and 
incubated for 20 minutes at -20°C. The DNA was centrifuged at 15,000g for 
20 minutes at -20°C. The pellet was rinsed in 70% (v/v) ice-cold ethanol and 
re-centrifuged. DNA was dried under vacuum and dissolved in the desired volume of 
water.
(2.5.3.2) Precipitation of DNA using isopropanol.
DNA was precipitated by adding 0.6 volumes of isopropanol to aqueous DNA, briefly 
vortexed and incubated for 20 minutes at room temperature. The DNA was 
centrifuged at 15,000g for 20 minutes at room temperature. The supernatant was 
discarded and the pellet rinsed in 70% (v/v) ice-cold ethanol and dried under vacuum.
(2.5.4) Purification of DNA on "mini" spun columns.
(2.5.4.1) Sepharose CL6 -B spun columns.
The apex of a 0.5 ml eppendorf tube was pierced with a 19G needle and the cap 
removed. The tube was filled to a height of 4 mm with 0.4 mm diameter glass beads. 
450 p.1 (giving a bed volume of 350 p.1) of a suspension of Sepharose CL6 -B resin 
equilibrated with TE pH 8.0, was layered on top of the glass beads. The eppendorf 
tube was placed in a 1.5 ml eppendorf tube and centrifuged in a bench top centrifuge 
with swing out rotor at 3,000g for 4 minutes at room temperature. Water (25 |il) was 
layered on the surface of the column which was centrifuged as above. This was
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repeated twice. The DNA sample (25 jllI) was layered onto the column and the column 
placed in a fresh 1.5 ml eppendorf tube. The column was centrifuged as above and the 
eluate collected.
(2.5.4.2) Sephadex G-25 and G-50 spun columns.
The bottom of a 1 ml plastic syringe barrel was plugged with a small amount of 
siliconised glass wool and 1 ml of Sephadex G-25 (G-50) suspension equilibrated in 
TE (pH 8.0) pipetted into the barrel. Buffer was allowed to elute under gravity and the 
column topped up with the suspension until the bed volume was 1.0 ml. The syringe 
barrel was placed in a 15 ml Corex tube and centrifuged using a bench top centrifuge 
with swing out rotor at 3,000g for 4 minutes at room temperature. The packed volume 
of the Sephadex G-25 (G-50) column was approximately 0.9 ml. Water (80 pi) was 
added to the column, which was re-centrifuged at 3000g for 4 minutes at room 
temperature. This was repeated twice. The DNA sample (80 pi) was layered onto the 
column and the column re-centrifuged. The eluate was collected in a 1.5 ml eppendorf 
tube.
(2.5.5) Agarose gel electrophoresis.
Normal and LMP horizontal slab gels were made by suspending agarose powder in 
TBE (pH 8.3) and heating in a microwave until dissolved. The solution was left to 
cool to 55°C and ethidium bromide (0.5 pg.ml" 1 final concentration) added and mixed 
by gentle swirling. The sample was poured into a gel mould (11 cm x 11 cm) with gel 
comb affixed and allowed to set Before loading, the sample was mixed with 
5 x loading dye to a final DNA concentration of 10 ng.pl" 1 per band of DNA. To 
prevent smearing of the DNA no more than 200 ng of the desired DNA band per 
0.5 cm slot width of agarose gel was electrophoresed. The DNA was electrophoresed 
at a constant current of 80 mA in TBE.
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(2.5.6) Isolation of DNA from agarose gels.
Two methods have been routinely used to isolate DNA from agarose gels: (1) Freeze- 
squeeze (2) Geneclean® "kit".
(2.5.6.1) Freeze-squeeze.
The DNA sample was electrophoresed in an LMP agarose gel (2.5.5), illuminated with 
UV light and the required band excised. The apex of a 0.5 ml eppendorf tube was 
pierced with a 19G needle and plugged with a small amount of siliconised glass wool. 
Agarose containing the DNA was layered onto the glass wool and the eppendorf tube 
snap frozen in liquid nitrogen. The frozen eppendorf was placed inside a 1.5 ml 
eppendorf tube and centrifuged at 20,000g for 20 minutes at room temperature. Eluate 
containing the DNA that had exuded from the agarose, was collected in the larger tube.
(2.5.6.2) Geneclean.
All solutions and glassmilk were supplied in the kit. The required DNA band was 
excised as described above. TBE modifier (0.5 ml) and 4.5 ml of Nal (6 M) was added 
per gram of agarose. Agarose was dissolved by heating at 60°C for 2 minutes followed 
by rapid cooling on ice. Re-suspended glassmilk was added to the solution, briefly 
vortexed and the solution incubated on ice for 15 minutes then centrifuged at 5,000g 
for 30 seconds at room temperature. Supernatant was removed and the glassmilk 
re-suspended in 0.2 ml of Geneclean "New" wash solution, vortexed, and incubated on 
ice for 5 minutes. This was repeated twice. Glassmilk was dried under vacuum and 
re-suspended in 20 |il of water. This solution was incubated at 55°C for 3 minutes 
prior to centrifugation. The supernatant was removed and glassmilk re-suspended in 
20 |ul of water, and incubation at 55°C repeated. Combined water supernatant 
fractions containing eluted DNA were stored at -20°C.
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(2.5.7) Restriction digestion of DNA.
DNA was incubated with restriction endonucleases in specific restriction buffers or 
One-Phor-All buffer. Two to five units of restriction enzyme per jig of DNA was used 
in each digest. When several enzymes were used on a DNA sample, One-Phor-All 
buffer was used according to manufacturers instructions, or specific buffers were 
modified for optimal reaction conditions. All digests were for 1 hour at 37°C unless 
otherwise indicated.
(2.5.8) Ligation of DNA.
Ligation of DNA with recessed ends was carried out with equimolar amounts of vector 
and insert. Flush end ligations were prepared with a vector to insert ratio of 1:3. The 
ligation reaction in 20 pi of buffer (Tris-HCl 50 mM pH 7.8, MgCF) 6  mM,
DTT 20 mM, ATP 1 mM and BSA 100 pg.ml'l) with T4 DNA Ligase (0.1 U for 
recessed ends, 1 U for flush ends) and approximately 50 ng of vector were incubated 
for 15 hours at 16°C or 4 hours at room temperature.
(2.5.9) End-fill of recessed 3' end of DNA.
Recessed 3' ends of DNA were extended by incubating in the presence of 125 pM of 
each dNTP with 1 U of Klenow fragment of DNA Polymerase I in 30 pi of buffer 
(Tris-HCl 50 mM pH 7.2, MgSC>4 100 mM, DTT 0.1 mM and BSA 50 |ig m l'1) at 
room temperature for 30 minutes. The enzyme was inactivated by incubation at 70°C 




(2.6.1) Manipulation of E.coli cultures.
Manipulation of E.coli cultures were carried out in accordance with "good 
microbiological practice". Disinfection of equipment and ceil cultures was achieved by 
treating with 2% Hycolin solution.
(2.6.2) Preparation of E.coli competent cells.
Overnight cultures of TGI and W945T1-2 were prepared by inoculating a single 
colony from a glucose minimal medium plate or frozen stock into 5 ml of LB (TGI) or 
20 ml of defined media (W945T1-2) and shaken overnight at 37°C. Aliquots (2 ml) of 
the overnight cultures were transferred to 40 ml of LB (TGI) or 20 ml of defined 
media (W945T1-2) and incubated at 37°C in an orbital shaker (Gallenkamp) at 150 
cycles per minute. When an 0 0 5 9 5 ^  of 0.3 was reached, 0.5 ml of the TGI culture 
(2ml of W945T1-2) were transferred to 50 ml of appropriate medium (pre-warmed to 
37°C) and incubation continued. When this culture reached an 0 0 5 9 5 ! ^  of 0.3, the 
cells were immediately chilled in ice-water for 1 0  minutes and centrifuged in a 
pre-cooled rotor at 3,000g for 10 minutes at 4°C. The pellet was re-suspended in 
ice-cold sterile CaCl2  (50 mM), incubated on ice for 30 minutes, and re-centrifuged. 
Cells were re-suspended in 5 ml of CaCl2  (50 mM) and kept on ice until required. 
Competent cells were used within 8  hours.
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(2.6.3) Transformation of E.coli competent cells with plasmid and RF M13 DNA.
(2.6.3.1) Transformation of E.coli TGI and W945T1-2 cells with Plasmid
DNA.
Plasmid DNA (10 ng) was mixed with 300 pi of competent cells (2.6.2), and incubated 
on wet ice for 30 minutes. Cells were transferred to thin walled glass tubes 
(~1 mm diameter glass wall) and incubated for 2 minutes at 42°C. The transformed 
cells were allowed to recover in LB (1 ml) for 1 hour at 37°C without shaking. The 
cell culture was centrifuged at 3,000g. Supernatant was discarded, and the cells 
re-suspended in 150 pi of LB. Transformed cells (50 pi) were plated out on 
appropriate agar with appropriate antibiotics and 20 pi of IPTG (100 mM) and 50 pi of 
X-gal (2% w/v in dimethyl formamide) for p-galactosidase colour selection with lac Z 
plasmids.
(2.6.3.2) Transformation of E.coli TGI with RF M13 DNA.
Solid agar media was prepared, poured into culture plates and allowed to solidify.
Cells were transformed with RF M13 DNA (10 ng) in a similar manner to plasmid 
transformed cells. IPTG (20 pi ,100mM), X-gal (50 pi, 2% w/v), 200 pi of log phase 
cells and 50 pi of transformed cells were mixed by swirling with 3 ml of molten top 
agar (in lawn tubes) standing in a heating block at 45°C. The molten top agar was 
poured over the solid agar media, allowed to solidify and the plate incubated at 37°C.
(2.6.4) Preparation of phage stocks.
An aliquot (200 pi) of overnight TGI culture (2.6.2) was inoculated into 5 ml of LB 
and incubated for 30 minutes at 37°C on an orbital shaker (2.6.2). The culture was 
inoculated with a single plaque, and incubation continued for 15 hours. A 1 ml aliquot
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of the culture was transferred to a 1.5 ml eppendorf tube and centrifuged at 5,000g for 
10 minutes at room temperature. The supernatant was transferred to a clean reaction 
tube and the pellet discarded. Chloroform (50 pi) was added to the supernatant and 
the phage stock stored in the dark at room temperature.
(2.6.5) Small scale preparation of plasmid and RF M13 DNA.
(2.6.5.1) Plasmid DNA.
A 1 ml aliquot of an overnight culture of transformed cells carrying the desired plasmid
(2.6.2) was transferred to a 1.5 ml eppendorf tube and centrifuged at 5,000g for 
10 minutes at room temperature. The supernatant was discarded and the pellet 
re-suspended by briefly vortexing in 100 pi of an ice-cold solution of (Tris HC125 mM 
pH 8.0, glucose 50 mM and EDTA 10 mM), and incubating for 10 minutes at room 
temperature. Cells were lysed by adding 200 pi of a freshly prepared solution of 
NaOH (0.2 M), SDS (1% w/v), mixed by inversion, and incubated for 10 minutes on 
ice. Genomic DNA protein and SDS were precipitated by adding 150 pi of an ice-cold 
solution of potassium acetate (3M pH 4.8), gently vortexing and incubating on ice for 
10 minutes. The precipitate of chromosomal DNA and protein was pelleted by 
centrifugation at 20,000g for 10 minutes at 4°C. The supernatant was transferred to a 
fresh 1.5 ml eppendorf tube and the pellet discarded. Further purification and 
concentration of the DNA was achieved by phenol/chloroform extraction (2.5.2) and 
precipitation with ethanol (2.5.3).
(2.6.5.2) RF M13 DNA.
A 0.5 ml aliquot of overnight culture (2.6.2) was inoculated into 50 ml of 2 x LB and 
incubated at 37°C on an orbital shaker (2.6.2). When an 0 0 5 9 5 ^  of 0.3 was 
reached, 100 pi of phage stock (2.6.3) was inoculated into the culture and incubation
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continued for a further 10 hours at 37°C. The culture was transferred to a centrifuge 
tube and centrifuged at 5,000g for 10 minutes at room temperature. The supernatant 
was discarded and the pellet suspended in a 1 ml solution (Tris. HC125 mM pH 8.0, 
glucose 50 mM, EDTA 10 mM and lysozyme 5 |ig.ml“l), and incubated for 10 minutes 
at room temperature. Cells were lysed by adding 2 ml of (NaOH 0.2 M, SDS 1% w/v) 
solution, mixed and incubating for 10 minutes on ice. Genomic DNA protein and SDS 
were precipitated by adding 1.5 ml of an ice-cold solution of potassium acetate 
(3 M pH 4.8), gently vortexed and incubated on ice for 10 minutes. The precipitate 
was pelleted by centrifugation at 10,000g for 10 minutes at 4°C. Remaining protein 
was removed from the DNA by phenol/chloroform extraction (2.5.2) and DNA 
concentrated by precipitation of DNA with ethanol (2.5.3).
(2.6.6) Large scale preparation of plasmid and RF M13 DNA.
(2.6.6.1) Plasmid DNA.
An aliquot (0.5 ml) of overnight culture (2.6.2) harbouring plasmid was inoculated into 
500 ml of LB or 2 x LB containing appropriate antibiotics and incubated overnight at 
37°C on an orbital shaker at 150 cycles per minute. The culture was transferred to 
300 ml polyethylene centrifuge tubes and centrifuged at 5,000g for 10 minutes at room 
temperature. The supernatant was discarded and the cells re-suspended in a 10 ml 
solution of (Tris-HCl 25 mM pH 8.0, glucose 50 mM, EDTA 10 mM and 
lysozyme 5 jig.ml~l). Cells were transferred to MSE centrifuge tubes and incubated 
for 1 0  minutes at room temperature then lysed by adding a 2 0  ml solution of 
(NaOH 0.2 M, SDS 1% w/v), briefly vortexed and incubated for 10 minutes on ice. 
Genomic DNA protein and SDS was removed by adding 15 ml of an ice-cold solution 
of potassium acetate (3 M pH 4.8). This solution was gently vortexed and incubated 
for 10 minutes on ice, then centrifuged at 20,000g for 10 minutes at 4°C. The 
supernatant was transferred to two 30 ml Corex tubes and DNA precipitated with
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isopropanol (2.5.3). Plasmid DNA was purified using caesium chloride equilibrium 
density gradient centrifugation (2 .6 .1 0 ).
(2.6.6.2) RFM13 DNA.
A 3 ml aliquot of overnight culture (2.6.2) was inoculated into 500 ml of 2 x LB and 
incubated at 37°C on an orbital shaker at 150 cycles per minute. When an OD5 9 5 nm 
of 0.3 was reached, 1 ml of phage stock (2.6.4) was inoculated into the culture and 
incubation continued for a further 10 hours at 37°C. The culture was transferred to 
300 ml polyethylene centrifuge tubes and processed in a similar manner as plasmid 
DNA (2.6.6).
(2.6.7) Preparation of single stranded M13 DNA template.
(2.6.7.1) Small scale preparation of template DNA.
A 200 |xl aliquot of overnight TGI culture (2.6.2) was inoculated into 5 ml of 2 x LB 
and incubated for 30 minutes at 37°C on an orbital shaker at 150 cycles per minute. 
The culture was inoculated with 50 pi of phage stock (2.6.3) and incubation continued 
for 6  hours. Phage particles were separated from cells and debris by transferring the 
culture to a 15 ml Corex tube and centrifuging at 5,000g for 30 minutes at room 
temperature. The supernatant was transferred to 1.5 ml eppendorf tubes and the pellet 
discarded. Phage particles were precipitated by adding 0.15 volumes of PEG/NaCl 
solution (PEG 6000 20% w/v, NaCl 2.5 M), briefly vortexed and incubated for 
30 minutes at room temperature. The solution was centrifuged at 13,000g for 
30 minutes at 10°C and the supernatant discarded. The phage pellet was re-suspended 
in 1 ml of LB and transferred to a 1.5 ml eppendorf tube and precipitation of phage 
particles repeated with 500 |il of PEG/NaCl solution. The solution was centrifuged at 
20,000g for 10 minutes at room temperature and the supernatant discarded. Traces of
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PEG/NaCl were removed from the pellet by re-centrifuging at 20,000g for 1 minute at 
room temperature and removing PEG/NaCl from the sides of the pellet with a paper 
tissue. This was repeated until no further PEG/NaCl could be removed. The template 
DNA was removed from the phage protein coat by phenol/chloroform extraction
(2.5.2), and template DNA precipitated with ethanol (2.5.3).
(2.6.7.2) Large scale preparation of template DNA.
A 1 ml aliquot of overnight TGI culture (2.6.2) was inoculated into 100 ml of 2 x LB 
medium and incubated at 37°C on an orbital shaker at 150 cycles per minute. When an 
OD5 9 5 nm °f 0.3 was attained the culture was inoculated with 1 ml of phage stock 
(2.6.4) and incubation continued for 4 hours at 37°C. The culture was transferred to 
MSE centrifuge tubes and centrifuged at 5,0Q0g for 30 minutes at room temperature. 
The supernatant was transferred to a fresh centrifuge tube, the pellet discarded, and 
phage particles precipitated by adding 0.2 volumes of PEG/NaCl solution 
(PEG 6000 20% w/v, NaCl 2.5 M), briefly vortexing and incubating on ice for 1 hour. 
The solution was centrifuged at 5,000g for 30 minutes at 10°C and the supernatant 
discarded. Traces of PEG/NaCl were removed from the pellet by re-centrifuging at 
5,000g for 5 minutes at room temperature and wiping the sides of the pellet with a 
paper tissue. This was repeated until no further PEG/NaCl could be removed. The 
phage pellet was re-suspended in 500 pi of buffer (Tris-HCl 10 mM pH 8.0, EDTA 
0.1 mM) and transferred to a 0.5 ml eppendorf tube. Remnants of cell debris were 
removed by centrifuging at 5,000g for 10 minutes at room temperature and transferring 
the supernatant to a fresh 1.5 ml eppendorf tube. The pellet was discarded. Phage 
particles were re-precipitated with 200 pi of PEG/NaCl solution and centrifuged at 
20,000g for 5 minutes at room temperature in a microfuge. Traces of PEG/NaCl were 
removed from the phage pellet in a similar manner as above. The phage pellet was 
suspended in 500 pi of buffer and transferred to two 1.5 ml eppendorf tubes. The 
DNA template was removed from the phage protein coat by extracting: (1) twice with
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100 pi of phenol (2.5.2) with the upper aqueous phase being transferred to a fresh 
centrifuge tube each time. (2) four times with 250 |il of diethyl ether (2.5.2) with the 
top layer being discarded. (3) twice with 250 pi of chloroform, with the top layer being 
transferred to a fresh 1.5 ml eppendorf tube. The template DNA solutions were further 
split into two 1.5 ml eppendorf tubes and the DNA precipitated with ethanol (2.5.3).
(2.6.8) Purification of DNA using a Nensorb column.
A Nensorb column pre-wetted with 2 ml of methanol was washed with 2 ml of buffer 
(Tris-HCl 0.1 M pH 7.7, Triethylamine 10 mM and EDTA 1 mM). The DNA sample 
was loaded onto the column and slowly passed through the sorbent with the aid of 
slight pressure from a 10 ml syringe. The eluate was re-loaded twice. The sorbent was 
washed with 2 ml of buffer followed by elution of the DNA with 0.5 ml of methanol 
(50%), and dried under vacuum. The DNA was dissolved in the desired amount of 
water.
(2.6.9) Purification of DNA using a Qiagen column.
An overnight culture (2.6.2) of TGI (5 ml) harbouring plasmid was transferred to a 
15 ml centrifuge tube (Corex) and centrifuged at 3,000g for 10 minutes at room 
temperature. The supernatant was discarded and the pellet re-suspended in 300 pi of 
buffer (Tris-HCl pH 8.0,50 mM, EDTA 10 mM and RNAse A 400 pg.ml"l) and 
transferred to a 1.5 ml eppendorf tube. Cells were lysed by adding 300 pi of 
(NaOH 200 mM, SDS 1% w/v), gently vortexing and incubating for 5 minutes at room 
temperature. Genomic DNA protein and SDS were precipitated by addition of 300 pi 
of potassium acetate (2.55 M pH 4.8). The solution was centrifuged at 15,000g for 
15 minutes at room temperature and the supernatant layered onto Qiagen tip-20 resin 
pre-wetted with 1 ml of buffer (MOPS 50 mM pH 7.0, NaCl 0.75 M, and 
ethanol 15% v/v).The resin was washed with 2 ml of buffer (MOPS 50 mM pH 7.0,
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NaCl 100 mM, and ethanol 15% v/v) under gravity. DNA was eluted off the resin 
under gravity with 0.8 ml solution (MOPS 50 mM pH 8.0, NaCl 1.5 M and 
ethanol 15% v/v), then precipitated with isopropanol (2.5.3). The sample was 
dissolved in the desired volume of water.
(2.6.10) Caesium chloride equilibrium density gradient centrifugation.
Isolation of pure supercoiled plasmid DNA was achieved by dissolving 1 gram of 
caesium chloride and 80 fxl of ethidium bromide (10 mg.ml“l) per ml of impure DNA 
solution. The final density of the solution was 1.55 g.ml'l with 600 jug.ml'^ ethidium 
bromide. The solution was transferred to a polyallomer centrifuge tubes, sealed and 
centrifuged in a Beckman 70.1Ti rotor at 200,000g for 15 hours at 20°C. Supercoiled 
DNA was visualised as the lower band by illuminating the centrifuge tube with UV 
light. It was removed from the centrifuge tube by piercing the centrifuge tube at the 
top then at the side just below the band with a 19G needle, then drawing the 
supercoiled DNA band into a syringe attached to the needle. An equal volume of 
caesium chloride saturated 1-butanol was added to the DNA sample, mixed by 
inverting the syringe several times and the phases allowed to separate. The upper 
organic phase containing the ethidium bromide was discarded. This extraction process 
was repeated until the ethidium bromide had been removed from the aqueous phase. 
The sample was diluted with an equal volume of water and two volumes of absolute 
ethanol was added to this sample. The DNA was precipitated at room temperature for 
30 minutes, then centrifuged in a Corex tube at 10,000g for 30 minutes at room 
temperature. The supernatant was discarded and the pellet rinsed with ice-cold ethanol 
(70% v/v), re-centrifuged and dried under vacuum. The DNA was re-dissolved in 
water and re-precipitated with ethanol three times to remove traces of caesium chloride
(2.5.3).
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(2.6.11) Preparation of oligonucleotides.
(2.6.11.1) Design of oligonucleotides.
Oligonucleotides were synthesised, the sequence of which were complimentary to the 
DNA molecule to be mutagenised, apart from one or several specific and 
pre-determined nucleotide changes. These changes encoded codon changes and where 
appropriate introduced unique restriction sites. The nucleotide changes were designed 
to:
• Aid directional cloning of PCR fragments DNA.
• Aid in identification of mutations by either restriction fragment analysis or 
colony hybridisation.
(2.6.11.2) Synthesis and purification of oligonucleotides.
Oligonucleotides were synthesised on an Applied Biosystems 381A DNA synthesiser, 
in 0.2 (imol quantities on solid phase support or obtained from ICI Diagnostics in a 
ready to use form.
The support cartridge containing the oligonucleotide was removed from the 
synthesiser, and the oligonucleotide cleaved from the support with 1 ml of ammonia 
solution (sp. gr. 0.88). One syringe containing ammonia solution was attached to the 
inlet of the support cartridge and 300 pi drawn into the matrix with the aid of second 
syringe attached to the cartridge outlet. A further 200 pi of ammonia solution was 
drawn into the matrix every 20 minutes. The ammonia solution containing the 
oligonucleotide was placed in a 2 ml screw cap eppendorf tube and incubated for a 
minimum of 6 hours at 55°C. The ammonia solution was removed by drying the 
oligonucleotide under vacuum, followed by re-dissolving the oligonucleotide in 1 ml of 
water. Oligonucleotides were precipitated with addition of 3 volumes of ethanol and
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0.1 volumes of sodium acetate solution (3 M pH 4.8) (2.5.3), dried under vacuum and 
re-dissolved in water. The concentration of aqueous oligonucleotide was determined 
by recording a spectrum in the UV range (2.5.1). An absorbance unit of 1 at 260nm 
was equivalent to 37pg.ml"l of oligonucleotide.
(2.6.11.3) 5' End labelling of oligonucleotides with T4 Polynucleotide Kinase.
Oligonucleotide (25 pmol) was incubated with 1 unit of T4 Polynucleotide Kinase, 
with an equimolar amount of [y-32p] ATP (3000 Ci/mmol), in 20 pi of buffer 
(Tris-HCl 50 mM pH 7.6, MgCl2 100 mM, dithiothreitol 5 mM, spermidine 0.1 mM 
and EDTA 1 mM). After incubation for 30 minutes at 37°C, 1 fil of ATP (10 nmol) 
was added and the solution incubated for a further 15 minutes.
(2.6.11.4) Determination of size and purity of oligonucleotide.
Oligonucleotides were checked for purity by electrophoresis in a 20% (w/v) 
polyacrylamide gel of dimensions (15cm xl5cm x 0.35mm). Ammonium persulphate 
(8 pi per ml of 10%w/v) and 0.4 pi per ml of TEMED were added to Sequagel™ 
acrylamide solution and quickly mixed by swirling. Gels were cast by silanizing one 
side of the front glass plate with dimethyldichlorosilane solution and pouring 
acrylamide solution between the two plates whose edges were sealed (the silanized 
surface being in contact with the acrylamide solution). A rectangular toothed comb 
was inserted before polymerisation. The end-labelled oligonucleotide (3.75 pmol) was 
mixed with 5 x formamide loading dye (formamide 95%, EDTA 20 mM, bromophenol 
blue 0.05% and xylene cyanol FF 0.05% ) prior to loading and incubated for 2 minutes 
at 70°C. Oligonucleotides were electrophoresed in TBE at 16 W for 1 hour. The glass 
plates were separated, and the gel which adhered to the back plate was covered in 
Saran-wrap™, and exposed to pre-flashed X-ray film at -70°C with an intensifying
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screen. The quality of the oligonucleotide was assessed by observing the range of 
bands and their intensities in relation to known standards.
(2.6.12) Sequencing of DNA.
The sequencing protocol used was that of the USB corporation Sequenase™ kit as 
outlined below. This Kit is based on the dideoxynucleotide chain termination method 
of Sanger et al, (1977).
(a) Preparation of template DNA from Plasmid DNA.
Denaturing solution (5 pi of NaOH 1 M, EDTA 1 mM) was added to 20 pi of plasmid 
preparation (0.5 pg.pl" 1) and incubated for 5 minutes at room temperature. The 
denatured DNA solution was desalted by passing the solution through a Sepharose 
CL6-B column (2.5.4). A volume of 7 pi of the denatured DNA was used for one 
sequencing reaction.
(b) Annealing.
DNA solution (1 pg of single stranded DNA or 3 pg of denatured plasmid DNA) in a 
total volume of 7pl was mixed with 2 pi of 5 x sequencing buffer (Tris-HCl 200 mM 
pH 7.5, MgCl2 100 mM and NaCl 250 mM) and 1 pi of oligonucleotide primer 
(1 pmol) in a 1.5 ml eppendorf tube and incubated for 2 minutes at 65°C, followed by 
slow cooling (30 minutes) to 30°C in water.
(c) Labelling reaction.
Sequenase sequencing enzyme was diluted 1:8 just before use with ice-cold buffer 
(Tris-HCl 10 mM, DTT 5 mM and BSA 0.5 mg.ml‘1) and kept on ice. To the
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"annealing" reaction mixture was added 1 pi of DTT 0.1 M, 0.5 pi of 
5 pCi [a-35S] ATP, and 2 pi of labelling mix (dGTP 1.5 pM, dCTP 1.5 pM and 
dTTP 1.5 pM), mixed and equilibrated at 23°C in a water bath. Diluted Sequenase™ 
enzyme (2 |L il) was added to the labelling mixture, briefly mixed and incubated at 23°C 
for 3 minutes. Reaction tubes containing 2.5 pi of termination mixture (Nucleotides 
dATP 80 pM, dCTP 80 pM, dGTP 80 pM, dTTP 80 pM and NaCl 50 mM with 8 pM 
of one of the following dideoxynucleotides ddATP, ddCTP, ddGTP, ddTTP) were 
pre-warmed to 37°C in a water bath. To each of the termination mixes, 3.5 |il of the 
labelling reaction was added, gently mixed then incubated at 37°C for 5 minutes. Stop 
solution, (4 pi of formamide 95%, EDTA 20 mM, bromophenol blue 0.05% and 
xylene cyanol FF 0.05%) was added to the termination reaction, mixed by vortexing 
and stored at -20°C until required.
(2.6.13) Polyacrylamide gel electrophoresis (sequencing gel).
Sequencing reactions were analysed by electrophoresis in an 8% (w/v) polyacrylamide 
gel (33.3cm x 39.5cm x 0.4-1mm wedge spacers). Ammonium persulphate (8pl per ml 
of 10 % w/v) and 0.4 pi per ml of TEMED were added to Sequagel™ acrylamide 
solution and quickly mixed by swirling. One side of the front glass plate was treated 
with 2 % dimethyldichlorosilane solution, the gels cast by pouring acrylamide between 
the two glass plates whose edges were sealed (the treated surface being in contact with 
the acrylamide solution). The back of a shark tooths comb was inserted into the 
acrylamide before polymerisation.
Samples in stop solution (2.6.12) were heated to 70°C for 2 minutes. The sharks tooth 
comb was reversed and 3 pi of sample electrophoresed at 45W in TBE buffer for 
3 hours. The plates were separated, and the gel, attatched to the back plate, cross 
linked in (methanol 5%, acetic acid 5%) solution for 40 minutes, then washed in 
running water for 40 minutes and transferred to Whatman 3 MM paper. The gel was
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dried under vacuum at 70°C, then exposed to X-ray film at room temperature for 
24 hours to 1 week and developed.
(2.6.14) Site directed mutagenesis of the E.coli MDH gene.
Two methods were employed for site directed mutagenesis of the cloned E.coli MDH 
gene: (1) Oligonucleotide-directed in vitro mutagenesis (Amersham mutagenesis 
system version 2), and (2) Site directed mutagenesis using the polymerase chain 
reaction (Reidhaar-Olson and Sauer 1988).
(2.6.14.1) Mutagenesis of the E.coli MDH gene using the Amersham 
Oligonucleotide-directed in vitro mutagenesis system.
All solutions were provided in the Amersham Oligonucleotide-directed in vitro 
mutagenesis kit Single stranded M13 template (5|ig), 5' end labelled mismatched 
oligonucleotide (4.0 pmol) and buffer# 1 were mixed and made up to volume with 
water. The mismatched oligonucleotide was annealed to the positive strand template 
by incubating for 3 minutes at 37°C, then extended and ligated in a single reaction by 
addition of nucleotide ’’mix 1" (substituting dCTPaS), Klenow fragment of DNA 
Polymerase I (6 U) and T4 DNA Ligase (2 U) and incubating for 15 hours at 16°C. 
Closed circle heteroduplex DNA was separated from template DNA and partially 
synthesised heteroduplex DNA, by the addition of NaCl (0.62 M final concentration), 
and centrifuged at 500g for 10 minutes through a nitrocellulose membrane of a 
centrifuge cartridge. The heteroduplex DNA was precipitated with ethanol (2.5.3), 
dried under vacuum and dissolved in buffer#2.
The non-mutated positive strand of the heteroduplex DNA was partially digested by
first mixing heteroduplex DNA solution with buffer#3 and restriction enzyme
Nci I (5 U) and incubating for 90 minutes at 37°C. The nicked heteroduplex DNA was
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then mixed with buffer#4, NaCl (67 mM final concentration) and Exonuclease ID 
(50 U) and incubated for 30 minutes at 37°C. Homoduplex DNA was prepared by 
mixing the digested heteroduplex DNA with nucleotide "mix 2", MgCl2 solution, DNA 
Polymerase I (3 U) and T4 DNA Ligase (2 U), then incubating for 4 hours at 16°C.
The homoduplex DNA was precipitated using ethanol (2.5.3) and dissolved in 100 pi 
of water.
(2.6.14.2) Mutagenesis of the E.coli MDH gene using the PCR.
A sense and anti-sense oligonucleotide (1.0 pM final) were mixed with 10 pi of 
reaction buffer (Tris-HCl 100 mM, pH 8.3, KC1500 mM and gelatine 0.1% w/v) and 
dNTPs (200 pM) in a dimethyldichlorosilane treated eppendorf tube. Target DNA 
(approx. 2 x 108 copies) and MgCl2 (final concentration of 1 to 5 mM), were mixed 
and the volume made up to 100 pi with water. This solution was chilled on ice for 
10 minutes prior to addition of Ampitaq™ Taq DNA Polymerase (0.025 U.pH).
DNA amplification was allowed to proceed for 25 cycles. Amplification on the 
Techne PHC-2 DNA thermal cycler required 50 pi of light mineral oil (Sigma) to be 
layered onto the surface of the DNA solution. The time allowed for synthesis of 
template DNA depended on the size of the target DNA being amplified (Table 2.1).
(2.6.15) Colony hybridisation.
Recombinant clones of MDH mutants in either phage or plasmid were identified by 
hybridisation at high stringency with the oligonucleotide used to create them. Either 
colonies or plaques were picked and grown in 0.1 ml LB in titre plates overnight at 
37°C (2.6.3). Hybond™-N nitrocellulose membrane was placed on the surface of an 
agar plate and samples from each titre well streaked onto the membrane and incubated 
overnight at 37°C. The membrane was removed from the agar and placed colony side 








Template melting 1.5 94
Oligonucleotide annealing 1.25 50
Template DNA Synthesis 1.0 <400 72
1.25 >400 <700 72
2.0 >700 72
Table 2.1: Conditions used for PCR amplification with 25 cycles of amplification.
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NaOH 0.5 M) for 7 minutes at room temperature, then transferred to 3 MM paper 
soaked in neutralising solution (NaCl 1.5 M, Tris-HCl 0.5M, EDTA 10 mM) for 
3 minutes at room temperature. The membrane was washed in 2 x SSC and allowed to 
air dry. The membrane was covered in Saran-wrap and DNA fixed to the membrane by 
placing colony side down on a transilluminator and exposing to UV light for 4 minutes.
The membrane was pre-hybridised for 15 hours at 37°C in 25 ml of (5 x SSC,
5 x Denhartd's solution, and SDS 0.5 % w/v) on an orbital shaker set at 25 cycles per 
minute, then 25 pmol of [32p] end-labelled oligonucleotide was added and incubation 
continued for a further 15 hours at 37°C. The membrane was washed with wash 
solution (2 x SSC, SDS 0.1% w/v) for 10 minutes at 37°C, then covered in Saran-wrap 
and exposed to pre-flashed X-ray film at -70°C between two intensifying screens. The 
membrane was washed at increasing stringent conditions increasing temperatute and 
exposed to X-ray film. Generally strongly hybridising clones could be identified after 
washing the membrane at temperatures above the Tm of the oligonucleotide.
(2.7) Expression and purification of MDH.
(2.7.1) Expression and purification of plasmid encoded MDH.
(2.7.1.1) Preparation of Procion red H3-B/CL6-B matrix.
Procion red H3-B/CL6-B matrix was prepared using a modification of the method of 
Atkinson et al, (1982).
Moist Sepharose CL6-B slurry, water (5.5 ml per gram of slurry) and powdered 
Procion red (41 mg per gram of slurry) were mixed, and incubated for 10 minutes at 
37°C on an orbital shaker set at 75 cycles per minute. Sodium chloride (0.4 ml per 
gram of CL6-B of 5M) was then added to the suspension and incubation continued for
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30 minutes. NaOH (0.12 ml.ml‘1 of suspension of 5M) was added to the suspension 
and incubation continued for 48 hours at 37°C on an orbital shaker at 25 cycles per 
minute. Unbound Procion red was removed by washing sequentially with copious 
volumes of water, NaCl (1M) in 25% ethanol, a further washing in water and finally 
NaCl (1M). The derivatized Procion red/Sepharose matrix was stored in phosphate 
buffer (0.1M pH7.2) at 4°C.
This matrix was re-suspended in phosphate buffer (0.1 M pH 7.2) and packed into a
1.5 cm diameter chromatography column. Phosphate buffer (0.1M pH 7.2) was 
allowed to elute under gravity and the column topped up with suspension until a bed 
volume of 35ml was obtained. Prior to loading the dialysate of the ammonium sulphate 
purification step, the column was pre-equilibrated for 15 hours with phosphate buffer 
(0.1 M pH 7.2), containing P-mercaptoethanol (1 mM) at a flow rate of 2 ml per 
minute at 4°C.
(2.7.1.2) Preparation of modified Sepharose CL6-B matrix containing thiol 
groups.
Modified Sepharose matrix containing thiol groups was prepared using a modification 
of the method of Axen et al, (1975).
Moist Sepharose CL6-B was added slowly to a solution of sodium hydroxide 
(0.8 ml 1 M) containing l-chloro-2,3-epoxypropane (700 pmol) per gram of Sepharose 
and incubated for 1 hour at room temperature on an orbital shaker set at 75 cycles per 
minute. The temperature was increased to 60°C and incubation maintained for 
2 hours. The activated Sepharose was washed with copious amounts of water until the 
pH of the suspension was ~7.0. Activated Sepharose was washed in phosphate buffer 
(0.5 M pH 6.3), interstitial fluid removed from the Sepharose by filtration and 
re-suspended on 2 ml of phosphate buffer (0.5 M pH 6.3) per gram of Sepharose. A
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solution of sodium thiosulphate (1 ml of 2M per gram of Sepharose) was added and 
incubation continued for 6 hours at room temperature. The Sepharose was washed 
with copious amounts of water, interstitial fluid removed and the Sepharose 
re-suspended in a solution of sodium bicarbonate (2ml of 0.1 M per gram of 
Sepharose). To the suspension was added excess DTT and the suspension stored at 
4°C. The matrix was packed into a 0.5 cm diameter chromatography column. The 
buffer was allowed to elute under gravity and the column topped up with suspension 
until a bed volume of 1 m was obtained. Prior to loading the cell-extract the column 
was equilibrated with phosphate buffer (0.1 M pH 7.2).
(2.7.2) Preparation of cell-free extracts of plasmid encoded MDH.
(2.7.2.1) Small scale preparation of cell-free extract
An aliquot from an overnight culture (2.6.2) harbouring the plasmid was transferred to 
a 1.5 ml eppendorf tube and centrifuged at 5,000g for 10 minutes at room temperature. 
The supernatant was discarded and the pellet re-suspended by briefly vortexing in 1 ml 
of phosphate buffer (0.1M pH 7.2). The cell suspension was centrifuged at 5,000g for 
10 minutes at room temperature and the supernatant discarded. Cells were 
re-suspended in 200 pi of phosphate buffer (0.1 M pH 7.2) and the eppendorf tube 
packed in ice. Cells were sonicated at 50 W with a 3 mm probe for 15 seconds 
followed by a pause of 30 seconds. This was repeated 4 times. The gelatinous lysate 
was centrifuged at 5,000g for 10 minutes at room temperature and the supernatant 
transferred to a fresh eppendorf tube and stored at 4°C. The pellet was discarded.
MDH activity was ascertained under standard conditions at 30°C by optimising the 
method of Smith et al, (1982). A cell-free extract (lOpl) was added to 980 pi of 
phosphate buffer (0.1 M pH 7.2) containing NADH (0.14 mM final concentration) in a
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1 cm path length polystyrene cuvette, incubated at 30°C. Oxaloacetate (10 pi, 0.3 mM 
final concentration) was added and the solution mixed. The rate of decrease in 
absorbance at 340nm due to the oxidation of NADH to NAD+ was measured on a 
recording spectrophotometer. One unit of MDH activity was defined as catalysing the 
oxidation of 1 pmol NADH per minute at 30°C.
(2.12.2) Large scale preparation of cell-free extract.
An aliquot from an overnight culture (2.6.2) harbouring plasmid was inoculated into 
50 ml of defined medium containing appropriate antibiotics and incubated overnight at 
37°C on an orbital shaker at 150 cycles per minute. A 25 ml aliquot of this culture was 
inoculated into 2.5 1 of pre-warmed defined medium containing antibiotics and 
incubation continued for 16 hours at 37°C on an orbital shaker at 75 cycles per minute. 
The culture was transferred to 300 ml Sorvall polyethylene centrifuge tubes and 
centrifuged at 5,000g for 10 minutes at room temperature. The supernatant was 
discarded and the cells re-suspended in a 100 ml of phosphate buffer (0.1 M pH 7.2). 
Cell suspensions were pooled and centrifuged as above. MDH cell-free extracts were 
prepared by a modified method of Smith et al, (1982). The supernatant was discarded 
and the cells re-suspended in 20 ml of lysis buffer, (Tris-HCl 40 mM pH 8.0,
EDTA 5 mM and lysozyme 250 pg.ml"l) transferred to MSE centrifuge tubes, and 
incubated for 30 minutes at room temperature. A solution of Brij 58 and 
MgSC>4 (0.5% and 20 mM final concentrations) was added to the cell suspension, 
vortexed and incubation continued for 30 minutes at room temperature. The centrifuge 
tube was embedded in ice and the cell suspension sonicated at 50 W for 1 minute with 
a 3 mm probe, followed by a pause of 1 minute. This was repeated 6 times. The 
gelatinous lysate was centrifuged at 15,000g for 30 minutes at 4°C and the pellet 
discarded. The supernatant was transferred to a fresh MSE centrifuge tube, sealed 
with Nesco film and kept at 4°C until required.
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(2.7.3) Purification of MDH.
(2.7.3.1) Method I.
Initially the method used for purification of MDH from cell-free extract was a modified 
method of Smith et al, (1982). The cell-free extract (2.7.2) was layered onto the 
surface of the Procion red/Sepharose chromatography column and allowed to bind 
overnight at a flow rate of 2 ml per minute at 4°C. The column was washed with 
3 litres of phosphate buffer (10 mM pH 7.2) containing KC1 (20 mM), 200 ml of 
phosphate buffer containing L-malate (10 mM), 100 ml of phosphate buffer containing 
KC1 (20 mM), 350 ml of phosphate buffer containing KC1 (20 mM) and 
NAD+ (0.35 mM). The MDH was eluted from the column using phosphate buffer 
containing NAD+ (0.35 mM) and L-malate (10 mM). The active fractions were 
pooled and dialysed against phosphate buffer containing, P-mercaptoethanol (1 mM).
This method was found to be unsatisfactory because (1) The time required for large 
volumes of buffer to filter through the chromatography column was inconvenient, and 
(2) The cost of L-malate and NAD+ present in the large volumes of buffer was 
prohibitive. A less expensive and quicker method for purification of MDH from the 
crude extract was therefore developed.
(2.13.2) Purification of E.coli MDH by precipitation of proteins with 
ammonium sulphate.
The proteins in a cell-free extract (5 ml) were subjected to precipitation by saturation 
with ammonium sulphate on 20% increments at 4°C. The solution was centrifuged in a 
15 ml Corex tube at 10,000g for 20 minutes at 4°C, then the supernatant transferred to 
a fresh Corex tube and the pellet re-suspended on 0.5 ml of phosphate buffer 
(0.1 M pH 7.2). The pellet (50|ig) was electrophoresed in an SDS-polyacrylamide gel.
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(2.7.3.3) Purification of E.coli MDH by Procion red/CL6-B affinity 
chromatography.
Cell-free extract (10 ml) was added to a suspension of Procion red/CL6-B (bed volume 
10 ml) in phosphate buffer (0.1 M pH 7.2) and allowed to bind for 30 minutes at 4°C 
on an orbital shaker set at 25 cycles per minute. The suspension was centrifuged at 
5,000g for 5 minutes at 4°C and the supernatant discarded. The Procion red/CL6-B 
was washed in 3.5 volumes of phosphate buffer (0.1 M pH 7.2) at 4°C and 
re-centrifuged. The supernatant was discarded, then the protein eluted off the matrix in
3.5 volumes of phosphate buffer (0.1 M pH 7.2) containing NaCl (0-2  M). Protein 
was precipitated with 5 volumes of acetone and 50jig of protein electrophoresed in an 
SDS-polyacrylamide gel.
(2.7.3.4) Purification of E.coli MDH using modified Sepharose CL6-B matrix 
containing thiol groups.
Cell-free extract was dialysed in a solution phosphate buffer (0.1 M pH 7.2) at 4°C and 
the dialysate containing MDH separated from the precipitate. This solution was loaded 
onto the modified Sepharose CL6-B matrix and allowed to elute under gravity at 4°C. 
This solution was eluted twice through the matrix. The matrix was eluted with 5 ml of 
phosphate buffer containing (3-mercaptoethanol and the eluate stored at 4°C.
(2.7.4) Estimation of protein concentration.
Sample protein concentration was estimated according to the method of Bradford, 
(1976).
Control samples containing of 0-25fig of BSA in 100 \±\ phosphate buffer 
(0.1 M pH 7.2) were added to 900 fil of Bradford reagent in a 1 cm path length
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cuvette. The solution was mixed, and the absorbance at 595nm recorded. A 
calibration curve was constructed of A5 9 5 nm vs BSA concentration. Test protein 
samples were made up to 100 |il with phosphate buffer (0.1 M pH 7.2) and added to 
900 pi of Bradford reagent, mixed and the A5 9 5 nm recorded. Test protein sample 
concentration was estimated by calculating equivalent concentration of BSA at a given 
A595nm from the BSA standard curve.
(2.7.5) SDS-polyacrylamide gel electrophoresis.
Protein samples were analysed by electrophoresis in an SDS-polyacrylamide gel 
(16 cm x 20 cm x 0.5 mm). To prepare the resolving gel, ammonium sulphate and 
TEMED were added to 6.5 ml of 30% acrylamide solution, 6.0 ml of resolving buffer 
and 16.5 ml of water added, then mixed by swirling (Table 2.2). Gels were cast by 
pouring acrylamide between the two glass plates whose edges were sealed. Butan-l-ol 
was layered onto the acrylamide solution and the gel left to polymerise at room 
temperature. For the stacking gel, ammonium persulphate and TEMED were added to 
0.9 ml of 30% acrylamide solution, 2.4 ml of stacking buffer and 3.6 ml of water 
added, then mixed by swirling (Table 2.2). Butan-l-ol was removed from the surface 
of the resolving gel and the stacking gel poured onto the resolving gel. A rectangular 
toothed comb was inserted before polymerisation. The protein sample was precipitated 
with five volumes of 10% TCA and centrifuged at 15,000g for 5 minutes at room 
temperature. The supernatant was discarded and the protein re-suspended in 100 |il of 
water. Prior to electrophoresis 2 x loading dye (Tris-HCl lOOmM pH 6.8,
DTT 200 mM, SDS 4%, bromophenol blue 0.2% and glycerol 20%) was added and 
the protein solution and the protein solution incubated for 5 minutes at 80°C. The 
protein sample was electrophoresed at 25 mA in a solution of (Tris-HCl 50 mM,
SDS 1% w/v, glycine 0.4%) until the protein had run into the resolving gel then 
electrophoresed at 40 mA for 6 hours.. Glass plates were separated and the gel cross 
linked and stained overnight in Coomassie blue R250 (1%) in (methanol 15%, glacial
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acetic acid 5%) at 37°C. Excess stain was removed by soaking the gel in destain 
solution (methanol 15%, glacial acetic acid 5%) at 37°C.
(2.7.6) Determination of the properties of wild type and mutant MDH.
MDH activity was assessed at 30°C by a modified method of Smith et al, (1982).
MDH (100 pi) was added to 800 pi phosphate buffer (0.1 M pH 7.2) containing 
NADH (0 - 0.3 mM final concentration) in a 1 cm path length polystyrene cuvette, 
incubated at 30°C. To this solution was added 100 pi of oxaloacetate (0 -15 mM final 
concentration) and the solution mixed. The rate of decrease in absorbance at 340nm 
due to the oxidation of NADH to NAD+ was measured on a recording 
spectrophotometer.
(2.7.7) Derivatization of MDH with DTNB and N-ethylmaleimide.
(2.7.7.1) Derivatization of MDH with DTNB.
The MDH solution was desalted by passing through a Sephadex G-50 column (2.5.4). 
MDH (approximately 2 nmol) was added to de-gassed phosphate buffer 
(0.1 M pH 7.2) containing DTNB (150 nmol) in a 1 cm path length polystyrene 
cuvette. The solution was made up to volume (1 ml), mixed and the increase in 
absorbance at 412nm due to the formation of NTB measured on a recording 
spectrophotometer.
(2.7.7.2) Derivatization of MDH with N-ethylmaleimide.
Derivatization of MDH with N-ethylmaleimide was performed in a similar manner as 
derivatization of MDH with DTNB. MDH was added to phosphate buffer 
containingN-ethylmaleimide (0 to 5000 nmol). This solution was made up to volume
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(980 pi), mixed, then incubated for 20 minutes at room temperature. The rate of 
decrease in absorbance at 340nm due to the oxidation of NADH to NAD+ was 
measured at 30°C on a recording spectrophotometer according to method (2.7.2).
(2.7.8) Iso-electric focussing of MDH.
The MDH solution was desalted by passing through a Sephadex G-50 column (2.5.4). 
A protein sample (1 pg) in phosphate buffer (0.1 M pH 7.2) was loaded onto a 
pre-focused iso-electric focussing Phast gel™ and the protein electrophoresed under 
the conditions outlined. (Table 2.3). The gel was immersed in a solution of 
(L-malate 0.9 M, NAD+ 7.5 mM, Citrate synthase, Acetyl CoA 10 mM, NBT 3.7 mM, 
PMS 0.6 mM, Tris-HCl 50 mM pH 8.0) and activity stained for MDH at 37°C in the 
dark using a modified method of Smith (1976). The gel was rinsed in water, then 
cross-linked and stained overnight in Coomassie blue R250 (1%) in (methanol 15%, 
glacial acetic acid 5%) at 37°C. Excess stain was removed by soaking the gel in 
destain solution (methanol 15%, glacial acetic acid 5%) at 37°C.
(2.8) Homology modelling of E.coli MDH.
The primary structure of the E.coli MDH was used to model its tertiary structure 
based on the 3D co-ordinates of the porcine cytoplasmic MDH. These co-ordinates 
were used as a framework structure to build a model of E.coli MDH. This relied on 
the ability to superimpose the amino acids of E.coli MDH on the known crystal 
structure. Primarily, the amino acid sequence for a single polypeptide for E.coli MDH 
(Vogel et al, 1987) was manually aligned with the amino acid sequence of 
NAD-dependent eukaryotic and eubacteria MDHs. Conserved residues were given a 
greater weighting than conserved substitutions, which were in turn given a greater 
weighting than non-conserved substitutions. The alignment highlighted regions of
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Stacking Gel Composition Volume
Ammonium persulphate 10% (w/v) 76 |ll
TEMED 5 |il
Acrylamide 30% (acrylamide 19:1 bis-acrylamide) 0.9 ml
Stacking buffer Tris-HCl 1.0 M pH 6.8 and SDS 10% 2.4 ml
Water 3.6 ml
Resolving Gel
Ammonium persulphate 10% (w/v) lOOlAl
TEMED 26 |il
Acrylamide 30% (acrylamide 19:1 bis-acrylamide) 6.5 ml
Resolving buffer Tris-HCl 0.375 M pH 8.8, SDS 0.1% 6.0 ml
Water 16.5 ml
Table 2.2: Composition of SDS-PAGE stacking and resolving gels.
Step Voltage Current Power Volt/hour Temperature
(V) (mA) (W) (V/h) (°C)
Pre-focussing 2000 2.0 3.5 75 15
Sample application 200 2.0 3.5 15 15
Sample focussing 2000 5.0 3.5 410 15
Table 2.3: Conditions for iso-electric focussing.
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similarity and dissimilarity between the MDHs. An E.coli model was built by 
substituting residue side chains of the E.coli sequence for their counterpart residues of 
the porcine holoenzyme cytoplasmic co-ordinates in a single subunit using "INSIGHT 
(Biosym Technologies Inc., San Diego, CA, USA) modelling program. Regions where 
the E.coli sequence deviated from the porcine sequence were built using co-ordinates 
obtained from the Brookhaven protein data bank. The co-ordinates of polypeptides 
with an optimum number of residues and conformation were superimposed onto the 
co-ordinates of the porcine MDH at the initiation and termination points where 
sequence divergence occurred. Polypeptide conformations were chosen which did not 
clash with the protein structure were used to span the "gap" of the protein "backbone". 
Optimisation of the atomic co-ordinates to prevent steric clashing of residues was 
achieved using a potential energy minimisation program DISCOVER (Biosym 
Technologies Inc., San Diego, CA, USA). Solvent accessibility of each residue was 
determined by generating a "Connolly" surface. Atoms were designated solvent 
accessible if contact was made with a probe of radius 1.4A (calculated radius of a 







Fig 2.1: Two dimensional representation of a hypothetical protein composed of atoms 
1 to 10.
Connolly surface is generated by rolling hypothetical probe (R) of radius 1.4 A over 
the surface of the protein indicated by their van der Waals surface. Those parts of the 
protein surface that make contact with the probe are designated the solvent accessible 
surface. When the probe is simultaneously in contact with more than one atom, the 
probe interior surface defines the reentrant surface. The contact surface and the 
reentrant surface define the molecular surface.
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CHAPTER THREE:
PURIFICATION OF E M U  WILD TYPE MDH.
(3.1) Introduction.
E.coli wild type MDH was used as a model MDH for ascertaining the conditions used 
to purify subsequent E.coli MDH mutants. This chapter describes the work involved 
in the optimisation of conditions for purifying wild type MDH.
(3.2.1) Purification of E.coli MDH using ammonium sulphate.
The optimum concentration of ammonium sulphate for purification of wild type E.coli 
MDH was determined. Samples of cell-free extract were treated with ammonium 
sulphate in 20% increments and the amount of protein precipitated in each step 
determined using the Bradford assay. Samples of 50 |J.g of protein were then analysed 
by SDS-PAGE. In all cases MDH migrated as a 33kD subunit and is shown in 
(Fig 3.1). It was found that at concentrations below 60% ammonium sulphate, E.coli 
MDH accounts for less that 10% of the precipitated protein, but at concentrations in 
excess of 60% the E.coli MDH accounts for more than 50% of the precipitated 
protein.
The conditions chosen for purifying wild type and mutant E.coli MDH by precipitation 
with ammonium sulphate were by dialysis of the cell-free extract in a solution of 60% 
saturation ammonium sulphate, phosphate buffer (0.1 M pH 7.2) containing 
(3-mercaptoethanol (1 mM) at 4°C and separating the dialysate containing MDH from 
the precipitate.
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(3.2.2) Purification of E.coli MDH by Procion red H3-B affinity chromatography.
The MDH from E.coli cell-free extract was purified by chromatography using a 
Procion red matrix. Samples were loaded onto the column in phosphate buffer 
(0.1 M pH 7.2) containing p-mercaptoethanol (1 mM) and the protein eluted by using 
an increasing gradient of sodium chloride from 0.01 to 2 M. A comparison of protein 
content and MDH activity for each of the collected fractions indicated that the majority 
of the contaminants eluted at low (0.01M) NaCl concentrations whereas MDH eluted 
at 0.5 M NaCl (Fig 3.2). The optimum method for purifying wild type and mutant 
MDH depended therefore on washing the column with a large volume of phosphate 
buffer (0.1 M pH 7.2), P-mercaptoethanol (1 mM) containing 0.01M NaCl buffer to 
elute contaminants and then to elute the MDH using 1M NaCl in buffer.
(3.2.3) Purification of pUCWT MDH.
The MDH of E.coli W945T1-2 expressing pUCWT was purified from cell-free 
extracts in two steps, using ammonium sulphate (section 3.2.1) and affinity 
chromatography (section 3.2.2). At each purification step both the protein 
concentration and MDH activity were determined. This method was used throughout 
for the purification of MDH mutants.
A typical purification result is presented in table 3.1. There was an apparent increase 
in the total activity during purification, possibly because of the removal of an inhibitor 
from the crude preparation. The final specific activity of the wild type MDH protein 
preparation was 1000 |imol.min~l.mg of protein" 1, corresponding to a yield of 53% of 
the total activity. Analysis of the protein on SDS-PAGE (Fig 3.3) indicated that the 
MDH was approximately 70% pure, which would raise the specific activity of 
homogeneous wild type MDH to 1430 fimol.min'l.mg of protein" 1.
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Fig 3.1: SDS-PAGE analysis of fractions from the purification of E.coli MDH using 
ammonium sulphate.
Lanes 1 is Cell-free extract. Lanes 2 to 6 are protein after precipitation with 
ammonium sulphate in 20% increments, 20% (lane 2), 40% (lane 3), 60% (lane 4), 
80% (lane 5) and 100% (lane 6). 33kD MDH subunit is indicated on the right hand 
side.
Fig 3.2: SDS-PAGE analysis of fractions from the purification of E.coli MDH bv 
Procion red H3-B affinity chromatography.
Lanes: (1) Cell-free extract: 2 to 6 elution with phosphate buffer (0.1 M) containing, 
p-mercaptoethanol (1 mM) and 0.01, 0.1,0.5,1 and 2 M NaCl. 33kD MDH subunit 
indicated on right hand side.
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(|i mol.min'l.mg of protein" 1)
(1) 2 700 25 50 17500 350
(2) 8 860 2 16 1720 108
(3) 3 1240 25 75 31000 413
(4) 460 20 9200
(5) 6 6000 1000
(6) 1430
Table 3.1: Purification of E.coli wild type MDH.
Lanes: (1) Cell-free extract; (2) Precipitate of 60% saturation ammonium sulphate dialysis; (3) 60% saturation 
ammonium sulphate dialysate; (4) Eluate of Procion red matrix; (5) Precipitate of 100% saturation ammonium sulphate 
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Fig 3.3: SDS-PAGE analysis of fractions from the purification of wild type E.coli 
MDH by precipitation of protein with ammonium sulphate and Procion red 
H3-B affinity chromatography.
Lanes from left to right: (1 to 3 are of E.coli W945T1-2 ), (1) Cell-free extract;
(2) 60% saturation ammonium sulphate dialysate; (3) Precipitate of 60% saturation 
ammonium sulphate dialysis; (4 to 7 are E.coli W945T1-2 expressing plasmid MDH) 
(4) Cell-free extract: (5) 60% saturation ammonium sulphate dialysate; (6); Precipitate 
of 60% saturation ammonium sulphate dialysis; (7) Elution off Procion red matrix.
Left hand lane are standard molecular weight markers.
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(3.3) Discussion.
Precipitation of protein with ammonium sulphate indicated that below 60% saturation, 
E.coli MDH accounted for a small percentage of the precipitated protein, but at 
concentrations of 60% or greater the MDH was a major component of the precipitated 
protein. Similar qualtiative results have been observed by Ferneley et aly (1981) and 
Murphey et aly (1967)
Purification of the MDH by elution off a Procion red affinity chromatography matrix, 
indicated that at sodium chloride concentrations above 0.5 M the MDH was a major 
component of the eluted protein. At concentrations below 0.5 M sodium chloride it 
was less pure.
The calculated specific activity for the wild type MDH was 1430 |imol.min" 1 .mg of 
protein" 1 and a yield of 53%. These value compares favourably with that obtained by 
Smith et al, (1982) (1820 jimol.min~l.mg of protein" 1) and Nicholls et aly (1989) 
(1730 |imol.min'l.mg of protein" 1) with similar yields. However, this value is three 
and five times the specific activities observed by Femeley at 0 /, (1981) of 
350 jLtmol.min~l.mg of protein" 1 and Murphey et al, (1967) of 542 |imol.min~l.mg of 
protein" 1 (at 22°C).
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CHAPTER FOUR:
SUBSTITUTION OF ENDOGENOUS 
CYSTEINES IN E.COLI WILD TYPE MDH.
(4.1) Introduction.
The initial strategy was to create a mutant MDH with all three endogenous cysteines 
removed. Studies on the folding intermediates of proteins suggest that in some 
instances transient disulphide bonds "steer" the folding of a protein through 
intermediate structures into the final native conformation (Creighton, 1980; Konishi et 
al, 1981; Wetzel etaU 1988; Zale and Klibanov 1986). Introduction of solvent 
accessible cysteines into the wild type MDH could adversely influence the folding of 
MDH resulting in inactivation (Browning et al, 1986). Removal of endogenous 
cysteines could prevent incorrect folding upon introduction of solvent accessible 
cysteines into the MDH.
(4.2.1) Substitution of the cysteine 113 codon (113S).
The gene encoding wild type E.coli MDH was ligated into Hind III restricted 
RF M l3 mpl9 and 5|ig of DNA template prepared. This template was used to 
generate mutant 113S using sense oligonucleotide-1 via the oligonucleotide-directed 
in vitro mutagenesis system (Amersham) (Fig 4.1). Oligonucleotide -1 was designed 
to convert the codon for cysteine 113 to a serine and introduce a unique Nhe I 
restriction site. Clones were screened for the presence of the mutation by colony 







Screen for the presence of mutation by:
(1) Colony hybridisation
(2) Restriction fragment analysis
(3) Sequence the MDH gene
I
Clone mutant MDH into pUC19
I
Ligated MDH gene into M l3 1
Oligonucleotide-1
1
Sense Oligonucleotide-1 substitutes 
cysteine 113 to serine and introduces
a unique Nhe I restriction site
Express mutant in E .coli strain W945T1-2 
Fig 4.1: Flow diagram of steps used to generate mutant pUCl 13S.
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(4.2.2) Screening for the mutation in the codon for cysteine 113 (113S).
Plaques harbouring M13 virus were screened for the presence of the mutation by 
colony hybridisation (Fig 4.2). RF M13 was prepared from one of the strongly 
hybridising plaques and the mutated gene, excised and ligated into Hind III restricted 
pUC19. Plasmid pUCl 13S was then transformed into E.coli TGI. Restriction of 
pUCWT and pUCl 13S with Hind IE indicates that both plasmids contain a DNA 
fragment of similar size of approximately 1300 bp (Fig 4.3). Kpn I has two restriction 
sites in the pUC19/MDH gene: one in the polylinker and one in the gene at nucleotide 
position 848. Kpn I restriction will therefore produce two distinct DNA fragments 
which, depending on the orientation of the gene in pUC19, will be 1166 or 223 bp 
long. Restriction of wild type and 113S mutant with Kpn I excised a DNA fragment of 
1166 bp indicating a similar orientation of both genes. Restriction of 113S mutant and 
wild type plasmids with Nhe I produced a linearised plasmid with the 113S mutant, but 
did not cut the wild type MDH gene. This confirmed the presence of a unique Nhe I 
recognition site and therefore the presence of the 113S mutation.
Oligonucleotide-2 which hybridised at positions 251 to 267 of the gene was used as a 
sequencing primer to confirm the nucleotide substitutions introduced into pUC113S 
(Fig 4.4).
(4.2.3) Purification of pUC113S MDH.
Purification of mutant 113S produced a decrease in specific activity from 1810 
jimol.min-l.mg of protein"! in cell-free extract to 1185 |imol.min"!.mg of protein"! in 
the precipitated protein fraction, a decrease of 34% (Table 4.1). This indicated that 
the mutant was being inactivated upon purification. The final specific activity of the 
MDH preparation was 1185 |imol.min'!.mg of protein-!, corresponding to a yield of 
65%. Analysis of the protein preparation on SDS-PAGE (Fig 4.5) indicated that the
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Fig 4.2: Hybridisation of 113S MDH gene with 5'J^ Pl labelled oligonucleotide-1 
probe.
(1) Wash of Hybond-N membrane at 37°C for 10 minutes in 2 x SSC, 
SDS (0.1% w/v).
(2) Wash of Hybond-N membrane at 63°C for 10 minutes in 2 x SSC, 
SDS (0.1% w/v).

Fig 4.3: Restriction fragment analysis of wild type and 113S MDH gene in pUC1.9 on a
0.8% agarose gel.
Lane from left to right: (1 to 4 113S MDH gene in pUC19 restricted with), (1) Nhe I;
(2) Sal I; (3) Kpn I; (4) Hind III; (5) 113S MDH gene in pUC19. (6 to 9 wild type 
MDH gene in pUC19 restricted with), (6) Nhe I; (7) Sal I; (8) Kpn I; (9) Hind III; (10) 
wild type MDH gene in pUC19; (11) Lambda DNA restricted with Pst I; (12) Lambda 
DNA restricted with Hind III. The size of Hind III restricted Lambda is indicated on
T C C A
(AA107) Lys Thr Cys
319 5 'AAA ACC TGC
A l a
G









Fig 4.4: Dideoxv sequence analysis of mutant 113S gene using oligonucleotide-2 as 
primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates introduced Nhe I restriction 















(p mol.min'l.mg of protein" 1)
( 1 ) 2 3620 25 50 90500 1810
(2 ) 11 1280 2 2 2 2560 116
(3) 3 3330 25 75 83250 1 1 1 0
(4) 2570 2 0 51400
(5) 2 2370 1185
(6 ) 1261
Table 4.1: Purification of E.coli 113S MDH.
Lanes: (1) Cell-free extract; (2) Precipitate of 60% saturation ammonium sulphate dialysis; (3) 60% saturation 
ammonium sulphate dialysate; (4) Eluate of Procion red matrix; (5) Precipitate of 100% saturation ammonium sulphate 
dialysis; (6 ) Homogeneous MDH.
Fig 4.5: SDS-PAGE analysis of fractions from the purification of mutant 113S E.coli 
MDH by precipitation of protein with ammonium sulphate and Procion red 
H3-B affinity chromatography.
Lanes from left to right: (1) Wild type MDH (2 to 5 are of E.coli W945T1-2 
expressing plasmid 113S MDH); (2) Elution of Procion red matrix; (3) 60% saturation 
ammonium sulphate dialysate; (4) Precipitate of 60% saturation ammonium sulphate 
dialysis; (5) Cell-free extract; (6 to 9 are of E.coli W945T1-2); (6) 60% saturation 
ammonium sulphate dialysate; (7) Precipitate of 60% saturation ammonium sulphate 
dialysis; (8) Precipitated protein of cell-free extract; (9) Cell-free extract. Right hand 
lane are standard molecular weight markers.
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113S MDH was approximately 94% pure which would raise the specific activity of 
homogeneous 113S to 1261 pmol.min'l.mg of protein" 1. This compares favourably 
with the specific activity obtained for wild type MDH, a decrease of only 12%.
(4.3.1) Substitution of the codons for cysteines 109 and 113 (109S/113S).
The first mutation (113S) had required that the gene in M13 was shuttled into pUC19 
after mutagenesis for expression, and that the 1.3 kbp fragment was sequenced 
throughout to check for spurious mutations. To avoid these extra manipulations a 
different strategy was followed with subsequent substitutions being introduced into 
gene segments using cassette PCR mutagenesis (Reidhaar-Olson and Sauer 1988)
(Fig 4.6).
Substitution of the codons for cysteines 109 and 113 to serine was achieved using the 
scheme outlined in figure 4.6. The PCR was restricted with Sal I and Nhe I and ligated 
into appropriately restricted pUCl 13S vector, then transformed into E.coli TGI and 
selected for the presence of plasmid on agar plates. Clones were screened for the 
presence of the mutation by restriction fragment analysis and sequencing of the DNA 
(Fig 4.6).
(4.3.2) Screening for the substitutions in the codons for cysteine 109 and 113 
(109S/113S).
Restriction of wild type MDH gene in pUC19 and pUC109S/113S plasmid with 
Hind ID, indicated that the wild type excised a 1.3 kbp fragment, but pUC109S/l 13S 
was linearised (Fig 4.7). Restriction of the mutant with Sal I and Hind in  excised a 
DNA fragment of similar size to Hind HI restricted wild type, indicating successful 
removal of the Hind in  restriction site in the polylinker. Restriction with Nhe I 







Cysl09 Cysll3 Qjs251 Lys312
Hind IH | 
nucleotide 1 nucleotide 1066
Generate PCR DNA fragment with 
sense oligonucleotide-3 and anti-sense 
oligonucleotide-4.__________________
I





Ligate PCR fragment into pUCl 13S. |
1
Screen for the presence of the mutation by:
(1) Restriction fragment analysis
(2) Sequence the PCR fragment._________
s i
Express mutant MDH in Ecoli MDH' strain.
Fig 4.6: Flow diagram of steps used to generate mutant pUC109S/113S.
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Fig 4.7: Restriction fragment analysis of wild type and 1Q9S/113S MDH gene in 
pUC19 on a 0.8% agarose gel.
Lane: 1 to 5 are 109S/113S MDH gene restricted with; (1) Nhe I; (2) Sal I;
(3) Hind III; (4) Kpn I; (5) Hind III and Sal I; (6) 109S/113S MDH gene; 7 to 10 are 
wild type MDH gene restricted with; (7) Nhe I; (8) Sal I; (9) Kpn I; (10) Hind III; (11) 
wild type MDH gene; (12) Lambda DNA restricted with Pst I. The size of Pst I 
restricted Lambda is indicated on the right.
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type gene. The presence of the unique Nhe I and Hind IE restriction site, confirmed 
the presence of the 109S/113S mutation. Oligonucleotide-5 which hybridised to 
nucleotide positions -372 to -356 of the gene was used as a sequencing primer to 
confirm the nucleotide substitutions introduced into the polylinker. Oligonucleotide-2 , 
annealing to nucleotide positions 251 to 267 was used to confirm the nucleotide 
substitutions introduced into the codons of residues 109 and 113 by sequencing 
(Fig 4.8).
(4.3.3) Purification of pUC109S/113S.
In contrast to the purification of wild type and mutant 113S MDH the total activity of 
the cell-free extract of mutant 109S/113S only 125 |4,mol.min~l. This was only 0.8% 
and 0.1% of the activity in wild type and 113S MDH cell-free extracts (Table 4.2). 
Analysis of the protein on SDS-PAGE indicated that the 33kD band was not a major 
component of the cell-free extract (Fig 4.9). The precipitated protein from the 
dialysate (fraction 2) contained 14% of the protein from the cell-free extract and 10% 
of the activity. This indicated that 109S/113S was not being purified successfully 
using this procedure. The final specific activity of the 109S/113S MDH protein 
preparation was 18 pmol.miirl.mg of protein" 1 , corresponding to a yield of 16%.
This yield compares poorly with that observed for wild type (53%) and mutant 113S 
(65%). Gel scans of SDS-PAGE gels of this material showed 23% of the protein 
migrated at 33kD, this would raise the specific activity of homogeneous 109S/113S 
MDH to 78 pmol.min"l.mg of protein'!. This value is only 5% and 6 % of that 
calculated for wild type and 113S MDHs.
(4.4.1) Substitution of the cysteine codons 109,113 and 251 (109S/113S/251S).
Substitution of the codons for cysteines 109,113 and 251 to serine codons in the 
E.coli MDH gene was carried out according to figure 4.10. The PCR products were
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(AA307) Gin Val Ala 
310 5'CAA GTT GCG
Cys
T
Lys Thr S e r  
AAA ACC AGC 
Ala
G




S e r  H e  Gly 
AGC ATT GGT
Asn (AA116) 
<—  AAT3 ' 348
Fig 4.8: P idgQxy sequence analysis Qf mutant 1Q93/113S geng y^ing 
oligonucleotide-2 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates introduced Nhe I restriction site 















(|! molmin'l.mg of protein" 1)
(1 ) 2 5 25 50 125 3
(2 ) 7 1 0 1 7 1 0 1
(3) 2 1 0 6 12 60 5
(4) 1 2 0 2 0
(5) 4 70 18
(6 ) 78
Table 4.2: Purification of E.coli 109S/113S MDH.
Lanes: (1) Cell-free extract; (2) Precipitate of 60% saturation ammonium sulphate dialysis; (3) 60% saturation 
ammonium sulphate dialysate; (4) Eluate of Procion red matrix; (5) Precipitate of 100% saturation ammonium sulphate 
dialysis; (6 ) Homogeneous MDH.
Fig 4.9: SDS-PAGE analysis of fractions from the purification of mutant 109S/113S 
E.coli MDH by precipitation of protein with ammonium sulphate and Procion 
red H3-B affinity chromatography.
Lanes from left to right: (1) Standard molecular weight markers; (2) (2 to 5 are of 
E.coli W 945T1-2); (2) Cell-free extract; (3) Precipitated protein of cell-free extract;
(4) 60% saturation ammonium sulphate dialysate; (5) Precipitate of 60% saturation 
ammonium sulphate dialysis; (6 to 9 are E.coli W945T1-2 expressing plasmid 
109S/113S MDH); (6) Cell-free extract; (7) 60% saturation ammonium sulphate 
dialysate; (8) Precipitate of 60% saturation ammonium sulphate dialysate; (9) Elution 
of Procion red matrix; (10)Wild type MDH.
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<>s109C ys113 Q|s251 Lys312
nucleotide 1 nucleotide 1066
Generate PCR DNA fragment with 




31  T 5'




Nhe I Nde I
I
Ligate PCR fragments into pUC109S/l 13S. |
I
Screen for the presence of the mutation by:
(1) Restriction fragment analysis
(2) Sequence the PCR fragment.__________
I
Express mutant MDH in Ecoli MDH~ strain.
Fig 4.10: Flow diagram of steps used to generate mutant pUC109S/113S/251S.
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restricted with Nhe I, ligated then restricted with Hind III and Nde I. PCR products 
was ligated into appropriately restricted pUC109S/113S vector and transformed into 
E.coli TGI. Colonies harbouring plasmid were grown on agar plates.
(4.4.2) Screening for the substitutions for the codons of cysteines 109,113 and 251 
(109S/113S/251S).
Restriction of pUC109S/l 13S/25 IS with Hind III, Sal I or Nhe I linearised the 
plasmid, whereas restriction with Hind III and Sal I excised a DNA fragment of similar 
size to the Hind in  restricted wild type MDH gene in pUC19 (Fig 4.11). This 
confirmed the codon change to cysteines 109 and 113. Nde I has a restriction site in 
pUC19 at the nucleotide position 183. Introduction of a second Nde I site at 
nucleotide position 756 will produce a DNA fragment of 1304 bp, when restricted with 
Nde I. Restriction with Nde I produced a DNA fragment of 1300 bp, confirming the 
presence of the second Nde I site and therefore the substitution at cysteine 251.
Prior to confirmation of the sequence the gene was expressed in MDH" E.coli. No 
activity or protein band corresponding to the 33kD subunit was found. Subsequently, 
oligonucleotide-15 which hybridised at the nucleotide position 658 to 676 was used to 
sequence through the introduced Nde I  restriction site (Fig 4.12). An insertion at 
nucleotide position 768 of 5'TAT GTT GAA GGC had occurred 3' to the sense 
oligonucleotide which is identical to the nucleotide sequence between nucleotides 757 
to 767. This resulted in a silent mutation to codon glycine 256 from 5GGC to 5'GGT 
and a shift in the reading frame 3* with respect to this codon (Fig 4.13). Further 
attempts to locate the correct gene were unsuccessful.
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Fig 4.11: Restriction fragment analysis of 109S/113S/251S MDH gene in pUC19 on a 
0.8% agarose gel.
Lane: (1) 1 to 7 are pUC109S/113S/251S MDH gene restricted with, (1); Nde I and 
Hind 111; (2) Nhe I; (3) Nde I; (4) Sal I; (5) Hind III; (6) Hind III and Sal I; (7) Kpn I; 
(8) pUC109S/l 13S/25IS MDH gene; (9) Lambda DNA restricted with Pst I. The 
size of Pst I restricted Lambda is indicated on the right.
T C C A
(AA248) Val Val Glu 
742 5'GTT GTC GAA
Cys 
G C C 
S e r  Ala Tyr 
TCT GCA TAT
Val Glu Gly 
GTT GAA GGT
A T G T T G A A G G C
Asp Gly Gin 
GAC GGT CAG3
m
Fig 4.12: Dideoxy sequence analysis of mutant 109S/113S/251S gene using 
oligonucleotide-15 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates introduced Nde I restriction site 
and mutations. Italic uppercase indicate deviation in sequence. Corresponding triple 
letter amino acid code is indicated above codon.
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C GAA TCT GCA TAT GTT
(+739) 5 ' GGC GTT GTC GAA TCT GCA TAT GTT 3 ' (+762)
(AA 247) Gly Val Val Glu Cys Ala Tyr Val (AA 254)
GAA GG
(+763) 5 'GAA GGT ATG TTG AAG GCG ACG GTC 3 ' (+786)
(AA 255) Glu Gly M et L eu L y s A la T h r V a l (AA 262)
(+787) 5 ' AGT ACG TCC GTT TCT TCT CTC AAC (+810)
(AA 263) S e r T h r S e r V a l S e r S e r L eu A sn (AA270)
(+811) 5'CGC 3' (+813)
(AA 271) A r g  (AA 271)
Fig 4.13: Deduced amino acid sequence from dideoxv sequence of mutant 
109S/113S/251S.
Amino acids are indicated in three letter code with sequence deviation in italics; 
nucleotide insertion are indicated in uppercase, sequence deviation in italics; 
oligonucleotide is indicated in uppercase bold.
(4.5.1) Substitution of the cysteine codon 251 (25IS).
MDH mutant 25IS was constructed according to the scheme illustrated in Fig 4.14. 
No MDH activity or protein band corresponding to the 33kD subunit was found. This 
mutant was constructed using pUC109S/113S/251S as a vector (which was 
subsequently shown to contain an error). It is likely that the lack of observed mutant 
MDH is a result of the incorporated error.
(4.6) Discussion.
Conserved substitutions of cysteine to serine were made to the codons encoding 
cysteine 113 and 109, singularly and in tandem to produce two mutant MDHs. The 
gene encoding mutant 113S when expressed in the E.coli MDH" strain W945T1-2 
produced a high level of the 33kD MDH subunit in the cell-free extract, comparable 
with that observed for the expressed wild type MDH. This mutant had an apparent 
specific activity of 1261 |imol.min'l.mg of protein" 1 which is only marginally less 
(12.0%) than that calculated for the wild type MDH (1430 pxnol.min~l.mg of 
protein" 1). However the gene encoding the double mutation (109S/113S) when 
expressed, resulted in a lower level of the 33kD subunit observed in the cell-free 
extract and a lower specific activity of only 78 |imol.min'l.mg of protein" 1. These 
results suggest that the single substitution did not greatly affect the expression or 
activity of the MDH, whereas the double mutation did. The codon substitutions 
introduced for these and the other MDH mutants were designed not to increase "rare” 
codon usage in the gene (Vogel et al, 1987), introduce or delete potential stem loop 
structures which might influence protein synthesis (Winnacker, 1987). Decreased 
levels of expression and activity have been observed for many mutant proteins (Green 
et al, 1992; Mitehinson and Wells, 1989; Pakula et al, 1986). The decrease in the 
levels of expression have been attributed to an increased susceptibility of the mutant to 
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Fig 4.14: Flow diagram of steps used to generate mutant pUC251S.
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activity of these proteins has been attributed to conformational changes in the protein 
and increased flexibility as a result of mutation (Mitchinson and Wells, 1989). The 
increased susceptibility to degradation could be due to:
• Change in conformation of secondary structure caused by change the side chain 
area.
• Change in conformation of secondary structure caused by alteration of the
residue charge.
• Change in conformation of secondary structure caused by change in the residue
hydrophobicity.
• Change in conformation of secondary structure caused by loss of hydrogen
bonding interaction
• Incorrectly folded protein.
Serine (115A^) has a similar side chain (R) area to cysteine (135A2) and represents the 
most conserved substitution, from R = -SH to R = -OH a change of one atom and a 
decrease in side chain area of only 15% (Creighton, 1983). This small decrease in side 
chain area upon substitution is not likely to cause a large perturbation in the local 
conformation and are likely to be accommodated by small changes in the local 
conformation (Daopin et al, 1991; Matthews et aly 1987). However small changes in 
local conformation have been attributed in some instances to changes in protein 
activity and stability (Daopin et aly 1991). The rational for using serines as the 
substitution residues is further substantiated by the fact that amino acid sequence 
alignment of MDHs (Fig 6.1) indicate that serine is substituted for cysteine in the 
MDHs and that serine has been used by other workers as substituting residue for 
cysteine. For example Browning et aly (1986) has substituted a reduced cysteine 
which was thought to participate in disulphide scrambling of interleukin- 2  for serine 
and found that protein stability was enhanced.
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Both sulphur and oxygen are group six elements and are able to participate in similar 
side chain hydrogen bonding interactions. However analysis of the E.coli MDH crystal 
structure (Hall et al, 1992) indicates that the side chains of cysteines 109 and 113 do 
not participate in hydrogen bonding interactions, but only the backbone atoms of these 
residues participate in hydrogen bonding The oxygen and nitrogen of cysteine 109 with 
the nitrogens of residues 111, 112 and oxygen of residue 105, while the oxygen and 
nitrogen of residuel 13 hydrogen bond with the nitrogen of residue 74 and oxygen of 
residue 71 (Fig 4.15). Substitution with serines will not initiate new hydrogen bonding 
interactions between the side chains of the serines and the surrounding residues, or 
terminate any existing hydrogen bonds.
a-Helices possess a dipole moment due to the alignment of the backbone amide group 
along the axis, resulting in a positive charge developing at the N-terminus and a 
negative charge at the C-terminus (Hoi, 1985). This dipole in some instances is 
counteracted by charged residues. Richardson and Richardson (1988) have shown that 
some residues have a positional preference on a-helices. Serine has a greater 
preference for the N-terminus position than the C-terminal position. Cysteine does not 
have a marked preference for either the N- or C-terminus of a-helices. Cysteine 109 is 
located at the C-terminus of a-helix aDE (Hall et al, 1992). It is possible that 
substitution of cysteine 109 at the C-terminus of aDE destabilises the a-helix by 
influencing the dipole resulting in the destabilising the MDH (Ihara et al, 1982; 
Shoemaker et al, 1985; Shoemaker et al, 1987). If this is the case substitution into the 
wild type MDH of lysine which is positively charged at physiological pH should 
stabilise the a-helix, whereas substitution of aspartate which is negatively charged 
should destabilise the a-helix.
Analysis of MDH amino acid sequence alignments (Fig 6.1) indicates that cysteine 113 
is non conserved, with only two of the twelve aligned sequences having an equivalent 
cysteine, but cysteines 109 and 251 are conserved. Cysteine 109 had an equivalent
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Fig 4.15: Conformation of a-helix aD E. B-slrand 6F and turn aDE/BE in E.coli 
MDH crystal structure.
(1) Cysteines 109 and 113 are indicated by triple letter code and highlighted in black 
Stippled lines indicate proposed hydrogen bonding interactions.
(2) Substituted serines 109 and 113 are indicated by triple letter code and highlighted 
in black Stippled lines indicate proposed hydrogen bonding interactions.
Figure 4.15 indicates that the side chains o f residues 109 and 113 do not participate in 
hydrogen bonding.
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cysteine in eight out of twelve of the sequences and cysteine 251 had an equivalent in 
seven out of twelve of the sequences. Three out of four of the sequences which did 
not possess an equivalent cysteine to cysteine 109 did not have an equivalent cysteine 
for cysteine 251. This observation together with the fact that the largest decrease in 
protein expression is associated with the double mutation suggests that cysteine 109 
and 251 are involved in disulphide bond formation in a folded intermediate of the 
E.coli MDH (Creighton, 1980; Konishi et al, 1981; Wetzel et al, 1988; Zale and 
Klibanov, 1986). Removal of either cysteine 109 or 251 would prevent correct 
transient disulphide bond formation and alter the folding pathway of the protein. This 
would result in an increased susceptibility to degradation. Conformation that cysteine 
109 and 251 take part in a disulphide intermediate in E.coli MDH protein folding could 
be obtained by substituting cysteine 251 for serine. If no decrease in stability is 
observed then these residues do not take part in a disulphide bond formation.
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CHAPTER FIVE:
SI JBSTITIJTION OF CYSTEINES INTO THE 
E .C O U  MDH pP/aD SURFACE LOOP.
(5.1) Introduction.
Prior to building a model of the E.coli dimeric MDH, residues chosen as candidates for 
substitution to cysteine were determined by analysis of the porcine cytoplasmic MDH 
crystal structure and sequence alignment of MDHs. Comparison of the MDH crystal 
structures indicate that regions of high sequence identity have the most similar 
conformations (Birktoft et al, 1989). To gain confidence that solvent accessible 
residues in the porcine crystal structure would also be solvent accessible in the E.coli 
MDH only regions of high sequence identity in the sequence alignment were analysed. 
Sequence alignments (Fig 6.1) indicated that the pD/aD loop was highly conserved. 
This loop is also solvent accessible and constitutes part of the active site when in the 
"collapsed" state ( Hall et al, 1992). Analysis of the crystal structure indicated that the 
side chains of arginine 91, glycine 94 and leucine 100 of this conserved pD/aD surface 
loop were solvent accessible and in a suitable orientation for substitution to cysteines. 
Amino acid sequence alignment indicated that the corresponding E.coli MDH residues 
were arginine 81, glycine 84 and leucine 90. These residues were chosen for 
substitution to cysteine.
(5.2.1) Substitution of the codons for arginine 81, glycine 84 and leucine 90.
Substitution of the codons for residues 81, 84 and 94 was achieved using the scheme 
outlined in figure 5.1. Oligonucleotides (-9 and -10) were designed to utilise a unique 
Nae I restriction site. Oligonucleotide-9 allowed substitution of the codons for 
residues 81 and/or 84, while oligonucleotide-10 substituted the codon for residue 90. 








Cysl09Cyis 113 Cys251 Lys312
Hind m  
nucleotide 1 Nae I nucleotide 1066
Generate two PCR DNA fragment with 
sense oligonucleotide-3 and anti-sense 
oligonucleotide-9 or -10._____________
I
Cys81 and/or Cys84 Cys90
yPolylinker______________ I I 3* ^IPolylinker_______________________I 3'
•yPolylinker---------------------------------------- y --------------- ^.Polylinker--------------------------------------
N a e 1 N a e 1
1 I
Ligate PCR fragment into pUC109S/l 13S. 1
I
Screen for the presence o f the mutation by:
(1) Restriction fragment analysis
(2) Sequence the PCR fragment._________
I
Express mutant MDH in Ecoli MDH~ strain.
Fig 5.1: Flow diagram of steps used to generate mutant 
pC109S/113S(81C.84C90Q.
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Clones were screened for the presence of the mutations in a similar manner to MDH 
mutant 109S/113S.
(5.2.2) Screening for the substitutions in the codons for arginine 81, glycine 84 and 
leucine 90.
Transformation of E.coli TGI with pUCWT and pUC109S/113S containing the 
PD/aD substitutions resulted in a low number of transformed colonies. Plasmids from 
colonies were screened for the presence of the mutations by restriction fragment 
analysis with Sal I and Kpn I. If the PCR product was successfully ligated into the 
vector, restriction with Kpn I would excise a DNA fragment of 1166 bp. However, if 
it was unsuccessful, Kpn I restriction would excise a DNA fragment of 580 bp. 
Linearisation of the plasmid with Sal I would confirm the presence of the PCR 
product. Oligonucleotide-4 which annealed between nucleotides 319 to 347 was used 
to confirm the presence of nucleotide substitutions (Fig 5.2 to 5.4). Sequence analysis 
indicated that the introduced mutations were present in the pUC109S/l 13S, but absent 
in pUCWT. Further attempts to insert PCR product into pUCWT were unsuccessful.
(5.2.3) Purification of pUC109S/113S/81C, pUC109S/113S/84C and 
pUC109S/l 13S/90C MDHs.
E.coli W945T1-2 harbouring the mutants, grew poorly under the growth conditions 
used, MDH activity was not detected in the cell-free extract Analysis of the cell-free 
extract, precipitated dialysate and dialysate by SDS-PAGE showed that the 33kD 
subunit of MDH was absent
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(AA76) Ser Ala Gly
-227 5'TCT GCA GGC 
Arg 
C
Val Arg C ys  
GTA CGG TGT 
Lys Pro Gly 
AAA CCG GGT 
Met Asp Arg 
ATG GAT CGT 
ser Asp Leu 
TCC GAC CTG 
Phe Asn Val 
TTT AAC GTT 
Asn Ala Gly 
AAC GCC GGC 
H e  Val (AA98) 
ATC GTG3' 295
Fig 5.2: Dideoxv sequence analysis of mutant 109S/113S/81C gene using 
oligonucleotide-4 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates Nae I restriction site and 




















Fig 5.3: Dideoxy sequence analysis of mutant 109S/113S/84C gene using 
oligonucleotide-4 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates Nae I restriction site and 
mutations. Corresponding triple letter amino acid code is indicated above codon.
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T C C A
(AA76) Ser Ala Gly






ATG GAT CGT-m m Leu
' 'mmm CTG




— rr: Asn Ala Gly
AAC GCC GGC
H e Val Lys (AA99
ATC GTG AAA31 297
Fig 5.4: Dideoxy .sequence analysis pf mutant 1QSS/1133/9QC gene using 
oligonucleotide-4 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates Nae I restriction site and 
mutations. Corresponding triple letter amino acid code is indicated above codon.
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(5.3) Discussion.
Three cysteines were individually substituted into the conserved pD/aD loop of E.coli 
MDH mutant 109S/113S at residues arginine 81, glycine 84 and leucine 90. Attempts 
to introduce similar mutations into the wild type MDH failed to produce recombinant 
colonies. The genes encoding these mutations in 109S/113S MDH when expressed in 
E.coli MDH" strain W945T1-2, failed to exhibit MDH ’'like" activity in cell-extracts. 
No 33kD band corresponding to an MDH subunit was observed in the cell-extracts 
when analysed by SDS-PAGE. This suggests that the introduction of cysteines into 
the pD/aD loop of mutant 109S/113S made this mutant more susceptible to 
degradation. The increased susceptibility to degradation could be due to:
• An unforeseen error incorporated into the MDH gene.
• Change in conformation of secondary structure caused by change the side chain
area.
• Change in conformation of secondary structure caused by alteration of the 
residue charge.
• Change in conformation of secondary structure caused by change in the residue 
hydrophobicity.
• Change in conformation of secondary structure caused by loss of hydrogen 
bonding interaction.
• Incorrectly folded protein.
Although the gene was sequenced in the region of the introduced mutation and was 
found to be correct, regions of DNA sequence were "compressed" and difficult to 
read. These compressed regions of DNA sequence might contain errors which alter 
the genes reading frame or introduce a stop codon. This would manifest in the above 
observation.
103
Pakula et al, (1986) has reported that in general mutants bearing solvent exposed 
substitutions do not show a high degree of instability when compared to wild type. 
Substitution of arginine 81, glycine 84 and leucine 90 for cysteine resulted in a 6 6 % 
decrease, 44% increase and a 25% decrease in side chain area respectively (Creighton, 
1983). Residues with similar changes in side chain area have been introduced by other 
workers. Arginine 81 has been substituted by glutamine in E.coli MDH (Nicholls et al, 
1992) and glycine has been substituted by tryptophan in the homologous loop in lactate 
dehydrogenase (Waldman et al, 1988). These substitutions represent a 20% decrease 
and 340% increase in the side chain area respectively. Likewise these substitutions 
represent a similar array of charge and hydrophobicity. Wilks et al, (1992) has 
substituted this loop for longer and shorter loops in lactate dehydrogenase and 
maintained integrity. If it is assumed that the PD/aD loop in the native protein is 
initially in the "up” conformation upon completion of protein folding then instability in 
the MDH could be caused by loss of hydrogen bonding interactions in this 
conformation. The porcine cytoplasmic crystal structure indicates that the side chain 
of arginine 91 {E.coli arginine 81) hydrogen bonds with the side chain oxygen of 
aspartate 99 {E.coli aspartate 89) and the backbone oxygen of methionine 95 {E.coli 
methionine 85). Glycine 94 {E.coli glycine 84) did not hydrogen bond, while the 
backbone oxygen of leucine 100 {E.coli leucine 90) hydrogen bonded with the 
backbone nitrogen of lysine 109 {E.coli lysine 99) (Fig 5.5). If the conformation of the 
loop does not change upon substitution it would be expected that only the arginine 
substitution would affect hydrogen bonding. However, protein was not observed with 
all three substitutions, loss of hydrogen bonding in the loop is not likely to be the major 
cause of instability in the mutant. The introduced pD/aD loop cysteines could be 
influencing the folding of the protein (Browning et al, 1986), resulting in an incorrect 
folded protein which is susceptible to degradation (Pakula et al, 1986).
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Fig 5.5: Conformation of the BDaD loop in porcine cytoplasmic MDH.
Residues are indicated by triple letter code in black shade. Stippled lines indicate 
proposed hydrogen bonding interactions.
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CHAPTER SIX:
HOMOLOGY MODELLING OF E.COLI MDH.
(6.1) Amino acid sequence alignment
Amino acid sequence alignment of a single subunit of E.coli MDH with eukaryotic and 
eubacterial MDHs indicated a diversity of sequence identities (Fig 6.1). The 
cytoplasmic MDHs of porcine (18%), mouse (20%) and Thermus aquaticus (18%) 
have a low sequence identity when compared to E.coli MDH, but mitochondrial 
enzymes (porcine (55%), rat (56%), Saccharomyces cerevisiae, (49%), mouse (57%) 
and Citrullus vulgaris (53%)), Citrullus vulgaris (glyoxysomal) (51%) and 
Salmonella typhimurium MDH (87%) show high sequence identity. Saccharomyces 
cerevisiae (glyoxysomal) MDH exhibits an intermediate sequence identity of 35%. 
With the exception of the pD/aD loop (conserved region three, residues 146 to 153), 
regions of high sequence identity are located in the interior of the MDH subunit or at 
the subunit interface. Conserved region one, corresponds to residues in p-strand PA 
and a-helix aB of the coenzyme binding domain. This P-strand and a-helix are 
located at the subunit interface (Birktoft et al, 1989; Hall et al, 1992). Conserved 
regions two and five correspond to a-helices aC (coenzyme binding domain) and a3G 
(catalytic domain) and are located at the subunit interface. Conserved region four 
corresponds to a-helix a2F and is found in the active site of the MDHs and contains 
arginine 153 which interacts with the C^ carboxy moiety of the substrate and aspartate 
150 of the histidine-aspartate pair (Birktoft and Banaszak, 1983; Hall et al, 1992).
Two anomalies in the sequence alignment are apparent. E.coli MDH histidine 177 
associated with the histidine-aspartate pair (sequence alignment residue 257), is 
located on the PG/pH interior facing turn (Hall et al, 1992). The position of this 
histidine varies by one residue in the sequence alignment. In cytoplasmic MDHs and 
T. aquaticus the histidine is at position 258 with conserved residues glycine 256,
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(9 ) <AKD GAYRWEGLEINEFARKRMEITAQELLDEMEQVKALGLI
(1 0 ) <LLGKNGVEERKSIGTLSAFEQHSLDAMLDTLKKDIQLGEEIINK
(1 1 ) <RLGRNGIEEVYSLGPLNEYERIGLEKAKKELAGSIEKGVSFIRS
(12 ) <ADQLLPLVDGADYFAIPLTITTKGVSYVDYDIVNRMNDMERNQMLPICVSQLKKNIDKGL EFVASRSASS
Fig 6.1: Primary amino acid sequence alignment of eukaryotic and eubacterial MDHs.
Lanes: (1) MDH from E.coli; (2) cytoplasmic MDH from porcine; (3) cytoplasmic MDH from mouse; (4) mitochondrial MDH from porcine; (5) 
mitochondrial MDH from rat; (6) mitochondrial MDH from Saccharomyces cerevisiae (yeast); (7) precursor mitochondrial MDH from mouse;
(8) precursor mitochondrial MDH from Citrullus vulgaris (watermelon); (9) MDH from Thermus Aquaticus (SUBSP. Flavus); (10) MDH from 
Salmonella typhimurium; (11) precursor glyoxysomal MDH from Citrullus vulgaris and (12) mitochondrial MDH from Saccharomyces 
cerevisiae (yeast). Conserved regions 1 to 5 are underscored. Constructed loop regions are indicated as Loops 1 to 5 in bold. Regions of non 
sequence similarity are indicated by gaps in sequence. E.coli MDH amino acid sequence numbering is indicated in bold italics with sequence 
alignment numbering indicated above.
threonine 261 and proline 264 located on either sides in the sequence alignment 
Complimentary alignment of the histidines could only be achieved by insertion of a 
space between residues 254 and 255 in the E.coli and mitochondrial sequence 
alignments, consequently removing conservation of the threonine and proline residues. 
The second anomaly is apparent with residues asparagines 188,191 and proline 189 in 
the E.coli sequence. Alignment of the asparagines and proline could only be achieved 
with the insertion of one "gap" between residues 192 and 193 thus moving residues 
185 to 192 to the left in the cytoplasmic and T aquaticus MDHs and out of sequence 
alignment.
(6.2) E.coli MDH model
Sequence alignment highlighted seven regions of deviation between E.coli and porcine 
cytoplasmic MDH (Fig 6.1). These regions of sequence deviation were constructed 
with five loops.
Loop-1 was built to bridge E.coli MDH leucine 16 and alanine 17 using glutamine 14 
and leucine 19 as the initiation and termination points of the loop. To span the gap 
(16A) with four residues, it was necessary to use a polypeptide with an extended 
conformation (translation of an a-helix and p-strand are 1.5A and 3.4A respectively 
between Ca atoms, Creighton, 1983). This resulted in a deviation to the local 
environment from a-helix to an extended sheet (Fig 6.2).
Loop-2 was built between E.coli residues, alanine 129 and leucine 132 using isoleucine 
127 and lysine 134 as the initiation and termination points on the loop. A polypeptide 
of six residues was used to span the gap of 6 A. This polypeptide maintained the 
a-helix conformation (Fig 6.3).
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Fig 6.2: Superposition of constructed E.coli model Loop-1 with template Porcine
structure.
E.coli polypeptide backbone is in blue between residues 12 and 30 and template 
porcine structure in green between residues 134 and 153, indicating a change in 
conformation from a-helix to (3-strand.
Fig 6.3: Superposition of constructed E.coli model Loop-2 with template Porcine 
structure.
E.coli polypeptide backbone is in blue between residues 124 and 145 and template 
porcine structure in green between residues 134 and 153, indicating a conservancy of 
a-helix conformation.
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Loop-3 was built between E.coli residues, glutamine 188 and valine 189 using leucine 
186 and glycine 191 as the initiation and termination points of the loop. The gap was 
bridged using a polypeptide of four residues which maintained the (3-strand 
conformation (Fig 6.4).
Loop-4 was constructed between residues glutamine 197 and lysine 204 with initiation 
and termination points at residues phenylalanine 194 and isoleucine 206. This gap 
could only be bridged with a polypeptide of eleven residues, changing the 
conformation from (3-strand to an extended conformation (Fig 6.4).
Loop-5 was built between residues, glutamine 259 and phenylalanine 263 with 
initiation and termination points between residues 257 and 265 using a polypeptide of 
7 residues. This maintained the P~turn conformation (Fig 6.5).
The side chains of residues of the E.coli MDH sequence were substituted for their 
counterparts in the modified porcine MDH template to produce a modelled 
non-energy minimised E.coli MDH subunit. Prior to optimisation of the atomic 
co-ordinates by potential energy minimisation (Karplus, 1987), the modelled subunit 
was duplicated and superimposed onto the original porcine MDH template to produce 
a non-energy minimised dimeric E.coli MDH model. The potential energy minimised 
dimeric model had a mean deviation of the polypeptide backbone from the porcine 
MDH template of only 0.3A (Fig 6 .6 ) and a potential energy in the expected range. 
Visual examination of the polypeptide "backbone" of the E.coli model superimposed 
onto the porcine MDH template indicated that regions of greatest deviation occurred 
around the introduced loops (loops 1 to 5) (Fig 6 .6 ).
I ll
Fig 6.4: Superposition of constructed E.coli model Loop-3 and Loop-4 with template
porcine structure.
E.coli polypeptide backbone is in blue between residues 186 and 206 and template 
porcine structure in green between residues 194 and 222, indicating a conservancy of 
p-strand of Loop-3, but change in conformation for Loop-4.
Fig 6.5: Superposition of constructed E.coli model Loop-5 with template porcine 
structure.
E.coli polypeptide backbone is in blue between residues 252 and 267 and template 
porcine structure in green between residues 268 and 287, indicating a conservancy of 
p-tum motif.
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Fig 6.6: Superimposition of constructed E.coli model (subunit) with template pQrcing
structure (subunit).
The superposition of E.coli model (magenta) with Porcine template (green) with mean 
deviation of 0.3 A is indicated. The positions of generated loop 1 is indicated by 
number 1, loop 2 by number 2, loops 3 and 4 by number 3 and loop 5 by number 4.
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(6.3) Identification of suitable residues for substitution to cysteine.
The residue chosen as the ligand coupling residue was cysteine. To minimise the 
possibility of perturbation of the E.coli MDH structure upon substitution of surface 
residues it was necessary to target residues which have the most similar characteristics 
to cysteine. Serine is the most similar residue to cysteine (Chapter four), however to 
maximise the number of potential substituting residues, other residues were appraised 
for their suitability for substitution. Bordo and Argos (1991) have suggested that 
cysteines are most often substituted with threonine, proline, valine, leucine and 
isoleucine. Cysteine has a predicted surface area of 135A^ (Creighton, 1983). 
Threonine (140A^), proline (145A2), valine (155A2), leucine (170A^) and isoleucine 
(175A2) all have surface areas larger than that of cysteine (Creighton, 1983).
Threonine and proline have the most similar surface area to cysteine. However proline 
is less similar than threonine when the residues hydropathy is considered (Kyte and 
Doolittle, 1982; Roseman, 1988). Proline is associated with disruption of secondary 
structure (Hall et al, 1992; Richardson and Richardson, 1988). This makes proline 
unsuitable for use as a target residue for substitution. Conversely threonine is not 
associated with disruption of secondary structure. The rational for using threonine as a 
target residue for substitution to cysteine is further substantiated by the fact that 
threonine has successfully been substituted for cysteine by other workers. For example 
Wells and Powers (1986) have substituted threonine for cysteine in Bacillus 
amyloliquefaciens subtilisin. This residue took part in disulfide bond formation. Serine 
and threonine residues were chosen as target residues for substitution to cysteine.
The radius of an antibody combining site is approximately 15A (Davies and Padlan, 
1990). Attachment of an antibody to a ligand which is within 15 A  of the |3D/aD loop 
residue 85 (determined to be the apex of this catalytically important loop) could inhibit 
this loop and/or prevent movement of the substrate into the active site (Rowley et al, 
1975). Attachment of an antibody to a ligand greater than 15A from residue 85 could
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hinder catalysis by preventing conformation change of the enzyme which occurs during 
catalysis. Two residues were chosen, one within a radius of 15A and one outside the 
15A radius. A Connolly surface prediction indicated that eleven serine and threonine 
residues had a solvent accessibility greater than 60A^ (approximate surface area of two 
methyl groups) in the E.coli model, as did their counterparts in the porcine cytoplasmic 
crystal structure (Table 6.1). Analysis of the model indicated that serines 88 and 222 
were within 15A of residue 85. However, serine 88 was in a conserved region of the 
model making this residue unsuitable for substitution. Serine 222 is in a non-conserved 
loop of the model making it suitable for substitution. The remaining residues were 
outside the 15A radius. Threonine 203 was in a conserved region making this residue 
unsuitable for substitution. Serine 193 was in a constructed loop region (loops 3 and 
4), resulting in low confidence in the prediction of solvent accessibility. Residues 308 
and 312 were determined to be part of a secondary structure motif making these 
unsuitable for substitution. Of the remaining residues threonine 64 was determined to 
be in an optimum conformation on a non-conserved loop suitable for substitution. 
Residues 64 and 222 were chosen as candidates for substitution to cysteine (Fig 6.7).
(6.4) Appraisal of the model.
The energy minimised model had a similar shape and volume to that of the porcine 
crystal structure. Confidence was further gained in the model as it had an average 
deviation from the porcine crystal structure of only 0.3A (Fig 6.6). Comparison with 
the recently published E.coli MDH ternary model (crystal structure) indicated regions 
of similarity and dissimilarity. The ternary model was based upon an energy minimised 
crystal structure of E.coli MDH (Hall et al, 1992). The directory of secondary 
structure in proteins (DSSP) (Kabsch and Sander, 1983) output of secondary 
structure of the E.coli model, crystal structure and porcine crystal structure alignment 
against the E.coli MDH primary structure indicated that the majority of the a-helices 























a, p, t or *
22 Thr 42.46 131 32 Asp 1 2 1 N t
64 Thr 34.43 97 74 Glu 99 N t
8 8 Ser 6.19 1 0 0 98 Lys 167 Y *
193 Ser 41.60 128 2 0 2 Gin 199 N t
203 Thr 22.97 6 6 216 Ser 96 Y t
2 2 2 Ser 11.488 107 238 Lys 139 N t
280 Ser 35.45 1 0 0 300 Glu 103 N Me
283 Thr 34.82 133 303 Pro 97 N Me
285 Ser 32.14 65 305 Asn 70 N Me
308 Ser 21.99 79 328 Glu 147 N a
312 Ser 24.58 71 332 Ser 76 N a
Table 6.1: Comparison of solvent accessibility of residues in E.coli model and porcine template structure.
Residue solvent accessibilities for the E.coli model and porcine template were determined via a Connolly surface prediction. The distance of 
residues from (3D/aD loop residue 85 with a solvent accessibility of greater than 80% is given in table 5.5. Secondary structure was determined 
by DSSP, a  signifies a-helix, (3 signifies P-strand, t signifies turn and * signifies not determined.
Fig 6.7: Alpha carbon representation of a single subunit of the E.coli MDH model
The relative positions and side chain orientation of residues 64 and 222 (cyan) relative to residue 85(yellow) are indicated. The
model predicts that the side chains of residues 64 are outwardly pointing from the interior and solvent accessible.
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Fig 6.8: Comparison of DSSP predictions of E.coli model MDHs and E.coli
and porcine cytoplasmic MDH crystalstmcUires aligned against E xpli MDH primary
structure^
(1), (2) and (3) signify secondary structure prediction of E.coli crystal structure, E.coli model and 
Porcine cytoplasmic crystal structure; E = |3-strand; H = a-Helix; G = 3/10 Helix; T = Turn and 
S = Bend/Kink. Initiation and termination of secondary structure is indicated below with 
a  signifying a-Helix and (3 signifying (3-strand.
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termination points of the a-helices were less well predicted. Five out of nine of the 
a-helices initiation points were correctly modelled, but only one out of nine 
termination points were correctly modelled. This trend is mirrored with the modelling 
of the P-strands. The majority of the cores of the P-strands were correctly modelled, 
but the points of initiation and termination are less well predicted. Connolly solvent 
accessibilities predictions (Connolly, 1983) of the E.coli model and crystal structure 
indicate that threonine 64 and cysteine 222 have different solvent accessibilities. In the 
model the predicted solvent accessibilities were 97 A^ for threonine and 107A2 for 
serine, whereas in the crystal structure these residues had solvent accessibilities of 
42A2 and28A2. T he£ .coli MDH model and crystal structure DSSP indicated that 
model residue 64 was in the middle of turn pC/aC', whereas in the crystal structure it 
was positioned at the C-terminus of the turn. However comparison of the model and 
crystal structure suggests that the decrease in solvent accessibility is due to the 
surrounding secondary structure (Fig 6.7 and 6.9). The secondary structures project 
further into the solvent than in the model, decreasing solvent accessibility of residue 
64. Serine 222 is found on a turn motif (a2G/a3G) in both the model and the crystal 
structure. However, in the the model it is positioned at the N-terminus and in the 
crystal structure it is positioned in the middle of the turn. This results in serine 222 
repositioning from the surface to a position at the mouth of the active site cleft
Structural alignment of the E.coli model and crystal structure and comparison with the 
sequence identity of the porcine cytoplasmic MDH (Fig 6.1) (based on the Dayhoff et 
a/,1983 mutation matrix) indicated the closeness of fit to the crystal structure in 
relation to sequence identity (Fig 6.10$). The majority of the regions in E.coli MDH 
which had high sequence identity with the porcine sequence had a corresponding low 
deviation between the E.coli model and crystal structure (< 2 .0 A ). Regions of low 
sequence identity have larger deviations between the model and crystal structure. 
However, in several instances regions of high sequence identity have large deviations
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Fig 6.9: Alpha carbon representation of a single subunit of the E.coli MDH crystal structure.
The relative positions and side chain orientation of residues 64 and 222 (cyan) relative to residue 85(yellow) are indicated. The
model predicts that the side chains of residues 64 are outwardly pointing from the interior and solvent accessible.
Fig 6.10: Comparison of sequence homology between E.coli and porcine cytoplasmic MDHs and deviation in conformation of the E.coli model 
and crystal structure.
"Seq homology" is a comparison of the sequence identity between the porcine cytoplasmic and E.coli MDHs based on the Dayhoff mutation 
matrix (1983) according to the sequence alignment indicated below. "Mod vs. X-ray" is the deviation in conformation between the superimposed 
E.coli model and crystal structure based on this sequence alignment. The X axis represents the residue number in the sequence alignment while 
residues indicated as text refer to the E.coli MDH polypeptide sequence. Score window length was five residues.
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Fig 6.10: Comparison of sequence hom ology between the E.coli and porcine cytoplasm ic M DHs and deviation  
in conform ation o f  the E.coli m odel and crystal structure.
between the crystal structure and model. This can be attributed to surface turn motifs 
which show a high degree of variation and frame shift in the sequence alignment
(6.5) Discussion.
It is generally regarded that ~20% sequence identity is the limit that homology 
modelling can be used to construct a 3D model. The sequence identity between the 
porcine and cytoplasmic and E.coli MDH was 18%. Comparison of the E.coli model 
and crystal structure show several anomalies which can be attributed to the low 
sequence identity:
Regions of deviation in sequence necessitate the introduction of gap(s) in the sequence 
alignment. These gaps are bridged with polypeptides obtained from the Brookhaven 
protein data bank. Due to the limited number of structures available these 
polypeptides represent the best available fit to bridge the gap as opposed to the 
optimum fit. At the present moment the Brookhaven protein data bank contains about 
600 unique crystal structures. The number of deposited crystal structures is however 
increasing. This will result in a greater polypeptide repertoire to choose from and 
therefore better polypeptides to bridge gaps.
Low sequence identity increases the difficulty in correctly aligning polypeptide 
sequences. This will result in frame shifts in the sequence alignment which will alter 
the initiation and termination of the gap(s) and secondary structure.
The low sequence identity means that the secondary and tertiary structures of E.coli 
and porcine cytoplasmic MDH although similar will not be identical. Modelling of the 
E.coli MDH on the porcine crystal structure will therefore bias the modelled structure 
to the template conformation.
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CHAPTER SEVEN:
SUBSTITUTION OF THREONINE 64 AND SERINE 222 
FOR CYSTEINES IN E.COLI WTUD TYPE MDH.
(7.1) Introduction.
Threonine 64 and serine 222 were uniquely substituted for cysteines in the wild type 
MDH gene according to the scheme illustrated (Fig 7.1 and 7.2). Colonies harbouring 
plasmid were screened for the presence of the substitutions by colony hybridisation, 
restriction fragment analysis and DNA sequencing. Plasmids possessing these 
substitutions were expressed in MDH* strain W945T1-2.
(7.2.1) Screening for the substitution in the codon for threonine 64 (64C).
Plasmid from colonies were screened for the presence of the mutation by colony 
hybridisation using 5' [32p] labelled oligonucleotides-11 and -13 as probes (Fig 7.3). 
The plasmid from the colony which showed strong hybridisation to the probes at 74°C 
was subjected to restriction fragment analysis. Restriction with Hind III and Sph I, 
linearised the plasmid, indicating successful removal of the polylinker Hind III and 
Sph I restriction sites (as the polylinker Sph I restriction site was removed by 
oligonucleotide-11) (Fig 7.4). Restriction with Hind III/Sal I excised a DNA fragment 
of similar size to Hind III restricted pUCWT. The presence of the unique Sph I and 
Hind III restriction sites and the excision of the correct size DNA fragment with 
Hind Ill/Sal I restriction, confirmed the substitution of the codon for threonine 64 to 
cysteine. An oligonucleotide-4 hybridised to nucleotide positions 319 to 347 of the 
gene and was used as a sequencing primer to confirm the nucleotide substitutions 
introduced into the codon of residue 64.
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 I______________ 1________ .3’
nucleotide 1066
Generate two PCR DNA fragments 
with paired oligonucleotides-11 and 











Ligate PCR fragments into pUC 19. |
4
Screen for the presence o f the mutation by:
(1) Colony hybridisation
(2) Restriction fragment analysis
(3) Sequence the PCR fragment._________
4
Express mutant MDH in Ecoli MDH" strain.
Fig 7.1: Flow diagram of steps used to generate mutant pUC64C.
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5'Oligonucleotide-15









Hind III | 
nucleotide 1 nucleotide 1066
Generate two PCR DNA fragments 
with paired oligonucleotides-3 and 













Ligate PCR fragments into pUC19. |
I
Screen for the presence o f the mutation by:
(1) Colony hybridisation
(2) Restriction fragment analysis
(3) Sequence the PCR fragment_________
I
Express mutant MDH in Ecoli MDH' strain.
Fig 7.2: Flow diagram of steps used to generate mutant pUC222C.
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Fig 7.3: Hybridisation of 64C MDH gene with 5' l~22pi labelled oligonucleotides-11 and -13 probes.
(1) Hybridisation with probe -11; Wash Hybond-N membrane at 37°C for 10 minutes in 2 x SSC, SDS (0.1% w/v), (2) Wash of Hybond-N 
membrane at 74°C for 2 minutes in 2 x SSC, SDS (0.1% w/v). (3) Hybridisation with probe -13; Wash of Hybond-N membrane at 37°C for 10 
minutes in 2 x SSC, SDS (0.1% w/v); (4) Wash of Hybond-N membrane at 74°C for 2 minutes in 2 x SSC, SDS (0.1% w/v).
I
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Fig 7.3: Restriction fragment analysis of 64C MDH gene in pUC19 on a
0.8% agarose gel.
Lanes: 1 to 5 are pUC64C MDH gene restricted with; (1) Sph I and Hind III;
(2) Sph I; (3) Hind III and Sal I; (4) Sal I; (5) Hind III; (6) pUC64C MDH gene. 
Lanes 7 to 9 are pUCWT restricted with; (7) Sph I and Hind III; (8) Sph I;
(9) Hind III; pUCWT MDH gene. The right hand lane is lambda DNA restricted with
(7.2.2) Purification of pUC64C MDH.
The mutant MDH of pUC64C expressed in E.coli W945T1-2 was purified from the 
cell-free extract (Table 7.1). There is an apparent increase in the total activity during 
purification. The final specific activity of the 64C MDH protein preparation was 
293 pmol.min~l.mg of protein" 1, corresponding to a yield of 70% of the total MDH 
activity. Densitometry scanning of the protein after SDS-PAGE gel electrophoresis 
indicated that the protein was 23% pure (Fig 7.5), which would raise the specific 
activity of homogeneous 64C MDH to 1274 pmol.min~l.mg of protein" 1. This value 
is approximately 8 8 % of that of homogeneous wild type MDH.
Attempts to couple mutant 64C MDH to the Sepharose CL6 -B thiol affinity matrix 
were unsuccessful. The mutant MDH would not bind, possibly indicating that cysteine 
64 was not available to the coupling reagent.
(7.3.1) Screening for the substitutions of the codon for serine 222 (222C).
Plasmid from colonies were screened for the presence of the mutation by colony 
hybridisation (Fig 7.6). Colonies that showed strong hybridisation to the 
5 * [32pj labelled oligonucleotide at 6 6 °C were subjected to restriction fragment 
analysis with Hind III, Sal I and Fsp I (Fig 7.7). Hind III or Sal I restriction of 
pUC222C produced a linearised DNA fragment, but restriction with Hind III and Sal I 
excised a DNA fragment of similar size to Hind HI restricted pUCWT. This indicated 
successful removal of the Hind ID restriction site in the polylinker. Fsp I has two 
recognition sites in pUC19: one at the nucleotide position 251 and one at the 
nucleotide position 1919. Restriction of pUCWT with Fsp I will produce two DNA 
fragments of approximately 1000 bp and 3000 bp. Introduction of an Fsp I restriction 
site into the MDH gene at nucleotide position 6 6 6  will result in the excision of three 















(|LL mol.min" mg of protein" 1)
( 1) 3 60 25 75 1500 2 0
(2 ) 23 1 1 0 1 23 1 1 0 5
(3) 3 1 1 0 25 75 2750 37
(4) 70 15 1050
(5) 3 880 293
(6 ) 1274
Table 7.1: Purification of 64C MDH.
Lanes: (1) Cell-free extract; (2) Precipitate of 60% saturation ammonium sulphate dialysis; (3) 60% saturation 
ammonium sulphate dialysate; (4) Eluate of Procion red matrix; (5) Precipitate of 100% saturation ammonium sulphate 
dialysis; (6 ) Homogeneous MDH.
Fig 7.5: SDS-PAGE analysis of fractions from the purification of mutant 64C E.coli 
MDH bv precipitation of protein with ammonium sulphate and Procion 
red H3-B affinity chromatography.
Lanes from left to right: (lanes 1 to 4 are of Ecoli W945T1-2): Cell-free extract; (2) 
Precipitate of cell-free extract; (3) Supernatant of 60% saturation ammonium sulphate 
dialysate; (4) Precipitate of 60% saturation ammonium sulphate dialysate. (lanes 5 to 9 
are of E.coli W945T1-2 expressing plasmid 64C MDH); (5) Cell-free extract: (6) 
Precipitate of Cell-free extract; (7) Supernatant of 60% saturation ammonium sulphate 
dialysate; (8) Precipitate of 60% saturation ammonium sulphate dialysate; (9) Elution 
of Procion red matrix; (10) Preparation of wild type MDH. 33kD band of MDH 
subunit is indicated on the right hand side with .
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Fig 7.6: Hybridisation of 222C MDH gene with 51 f22Pl labelled oligonucleotide-15 
probe.
(1) Wash of Hybond-N membrane at 37°C for 10 minutes in 2 x SSC,
SDS (0.1% w/v).
(2) Wash of Hybond-N membrane at 6 6 °C for 2 minutes in 2 x SSC, SDS (0.1% w/v).
•  •
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Fig 7.7: Restriction fragment analysis of wild type and 222C MDH gene in 
pUC19 on 3 Q.g% agqrQgg ggl.
Lanes: 1 to 6 are pUC222C restricted with; (1) Fsp I; (2) Nhe I; (3) Nde I; (4) Hind III 
and Sal I; (5) Sal I; (6) Hind III; (7) pUC222C; 8 to 13 are pUCWT restricted with (8) 
Fsp I; (9) Nhe I; (10) Nde I; (11) Hind III and Sal I; (12) Sal I; (13) Hind III; (14) 
pUCWT; (15) pUC19 restricted with Hind III; (16) pUC19. Right hand lane is Pst I 
restricted Lambda DNA.
132
pUC222C with Fsp I generated three DNA fragments of the predicted sizes. This 
confirmed the presence of a third Fsp I recognition site and therefore the presence of 
the 222C mutation. Oligonucleotide- 6  which annealed between the nucleotides 747 
and 767 of the MDH gene was used as a sequencing primer to confirm the nucleotide 
substitutions introduced into pUC222C (Fig 7.8).
(7.3.2) Purification of pUC222C MDH.
The mutant MDH of pUC222C expressed in E.coli W945T1-2, exhibited different 
characteristics to the wild type and mutant 64C MDH when purified from the cell-free 
extract (Table 7.2). The mutant showed a loss of 85% of activity from 1000 
}imol.min'l (fraction 1) to 150 |imol.min"l (fraction 4) upon purification and a 25% 
loss in specific activity. This decrease in the specific activity indicated that the mutant 
was being inactivated during purification. The final specific activity of the MDH 
preparation was 30 jimol.min'l.mg of protein" 1. Densitometric scanning of the 
protein after SDS-PAGE gel electrophoresis (Fig 7.9) indicated that the 222C mutant 
was 60% pure which would raise the specific activity of homogeneous 222C to 
50 |imol.min"l.mg of protein"!. This value is only 3% of that observed for the wild 
type MDH and 9% of that observed for mutant 64C.
Attempts to couple mutant 222C MDH to the Sepharose CL6 -B thiol affinity matrix 
were unsuccessful. The mutant MDH would not bind, possibly indicating that cysteine 
2 2 2  was not available to the coupling reagent.
(7.4) Derivatization of MDH.
Murphey et al, (1967) has shown that wild type E.coli MDH thiols are not 
derivatizable with p-hydroxymercuribenzoate indicating that these residues were not 
accessible to this derivatizing agent. Derivatization of protein samples containing wild
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Fig 7.8: Dideoxv sequence analysis of mutant 222C gene using 
oligonucleotide-6 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates introduced Fsp I restriction site 















(|i mol.min"l.mg of protein" 1)
(1 ) 1 40 25 25 1 0 0 0 40
(2 ) 5 2 1 5 2
(3) 2 4 25 50 1 0 0 2
(4) 1 0 15 150
(5) 1 30 30
(6 ) 50
Table 7.2: Purification of 222C MDH.
Lanes: (1) Cell-free extract; (2) Precipitate of 60% saturation ammonium sulphate dialysis; (3) 60% saturation 
ammonium sulphate dialysate; (4) Eluate of Procion red matrix; (5) Precipitate of 100% saturation ammonium sulphate 
dialysis; (6 ) Homogeneous MDH.
Fig 7.9: SDS-PAGE analysis of fractions from the purification of mutant 222C E.coli 
MDH by precipitation of protein with ammonium sulphate and Procion red 
H3-B affinity chromatography.
Lanes from left to right: (1 to 4 are E.coli W945T1-2); (1) Cell-free extract; (2) 
Precipitate of cell-free extract; (3) 60% saturation ammonium sulphate dialysate; (4) 
Precipitate of 60% saturation ammonium sulphate dialysate; (lanes 5 to 9 are E.coli 
W945T1-2 expressing plasmid 222C MDH); (5) Cell-free extract; (6) Precipitate of 
cell-free extract; (7) 60% saturation ammonium sulphate dialysate; (8) Precipitate of 
60% saturation ammonium sulphate dialysate; (9) Elution of Procion red matrix; (10) 
Wild type preparation. Left hand lane are standard molecular weight markers.
type, mutants 113S and 109S/113S with excess DTNB or N-ethylmaleimide did not 
alter the activity of the enzyme. However, derivatization of a wild type MDH protein 
sample (~0.3 nmol MDH, 120 |ig of total protein) with DTNB produced 3 nmol of 
NTB within 60 seconds of the addition of DTNB (Fig 7.10). This value was 40% 
above that calculated if all MDH thiols were derivatized, indicating that non-MDH 
thiols were available for derivatization. Derivatization of mutant 222C with DTNB or 
N-ethylmaleimide resulted in a 95% loss of activity. Derivatization of this mutant 
MDH (285 pg or 570 pg of total protein) with DTNB resulted in the formation of 
12.5 nmol and 24 nmol of NTB respectively (Fig 7.10). If an assumption is made that 
the formation of NTB in the wild type MDH sample was due to the derivatization of 
non-MDH protein, then derivatization of mutant 222C produced an equivalent of 44% 
more NTB than the wild type MDH protein sample. The decrease in activity and 
increase in NTB upon derivatization of 222C, indicates that thiol(s) are being 
derivatized in the mutant MDH. Derivatization of mutant 222C (56pg) with 5 nmol of 
N-ethylmaleimide resulted in a 98% loss of MDH activity (Fig 7.11). Addition of 
5000 nmol of N-ethylmaleimide resulted in a further 1% decrease in activity.
Initial results suggest that MDH mutant 64C protein samples did not show a decrease 
in activity when derivatized by DTNB or N-ethylmaleimide, or liberate NBT in a 
similar manner to that observed for mutant 222C protein samples. This indicated that 
the introduced cysteine at residue 64 was not available for derivatization with DTNB.
Protein samples of wild type, mutant 64C and 222C MDHs were electrophoresed in an 
iso-electric focusing gel paired with their derivatized (DTNB) counterparts. Activity 
staining of the gel indicated that the samples developed at approximately equal rates to 
produce a major and several minor bands in both derivatized and non-derivatized 
samples (Fig 7.12). However on several occasions (not shown) an extra band was 
apparent in the mutant 222C derivatized MDH sample. Coomasie blue staining of the 
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Fig 7.10: Liberation of NTB upon derivatization of wild type and mutant 222C MDHs 
with time.
WT Prot is protein sample containing wild type MDH; 222C Prot is protein sample 
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Fig 7.11: Decrease in MDH activity upon derivatization of protein sample (56 fJ-g) 







Fig 7.12: Iso-electric focussing of wild type mutants 64C and 222C MDHs.
Gel 1 is MDH activity stain, Lanes: (1) Mutant 222C derivatized with DTNB; (2) 
Mutant 222C; (3) Wild type MDH derivatized with DTNB; (4) Wild type MDH;(5) 
Mutant 64C derivatized with DTNB; (6 ) Mutant 64C.
Gel 2 is Coomasie blue stain, Lanes: (1) Mutant 222C derivatized with DTNB; (2) 
Mutant 222C; (3) Wild type MDH derivatized with DTNB; (4) Wild type MDH;(5) 
Mutant 64C derivatized with DTNB; (6 ) Mutant 64C.
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wild type or mutant MDHs.
(7.5) Kinetic studies on wild type, mutant 64C and 222C MDHs.
Measurement of single data points of initial rates in the absence of product using 
NADH and oxaloacetate as coenzyme and substrate suggest that mutant 64C and 
222C have different characteristics to wild type MDH. Varying the concentration of 
NADH at fixed concentrations of oxaloacetate, maximum wild type MDH activity was 
obtained at an oxaloacetate concentration of 0.1 mM (Fig 7.13). Increasing the 
oxaloacetate concentration to 0.26 mM did not increase the observed activity. At each 
fixed oxaloacetate concentration, increasing the NADH concentration did not inhibit 
the MDH activity. Qualitatively similar results were obtained using fixed NADH 
concentrations while varying the oxaloacetate concentration (Fig 7.14). Mutant 64C 
exhibited different characteristics to the wild type MDH. Varying the NADH 
concentration (0 to 0.3 mM) at fixed oxaloacetate concentrations indicated that 
maximum 64C MDH activity was obtained with 1 mM oxaloacetate as opposed to 
0.1 mM oxaloacetate with wild type MDH (Fig 7.15). No plateau in activity was 
reached, possibly suggesting that the affinity of the MDH for oxaloacetate had 
decreased. The observed initial rates at a fixed oxaloacetate concentration of 0.1 mM, 
displays anomalous behaviour, having less activity than the MDH at fixed oxaloacetate 
concentrations of 0.07mM. At a fixed oxaloacetate concentration of 1 mM the MDH 
appeared to show a decrease in activity at NADH concentrations of 0.2 mM. Varying 
the oxaloacetate concentration at fixed NADH concentration , maximum rate was 
observed at approximately 0.125 mM to 0.2 mM NADH (Fig 7.16). Further increases 
in the concentration of NADH resulted in decreased MDH activity. Varying the 
concentration of NADH at several fixed concentrations of oxaloacetate, indicated that 
mutant 222C displayed maximum activity at an oxaloacetate concentration of 7.5 mM 
(Fig 7.17). At oxaloacetate concentrations above 7.5 mM no increase in activity was 
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Fig 7.13: Rate concentration plot for wild type MDH of activity with varying NADH 
at fixed oxaloacetate concentration.
Where ■ = 0.26 mM oxaloacetate, + = 0.16 mM oxaloacetate, * = 0.10 mM 
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Fig 7.14: Rate concentration plot for wild type MDH of activity with varying 
oxaloacetate at fixed NADH concentration.
Where ■ = 0.28 mM NADH, + = 0.14 mM NADH, * = 0.08 mM NADH,
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Fig 7.15: Rate concentration plot for mutant 64C MDH of activity with varying 
NADH at fixed oxaloacetate concentration.
Where + = 1.0 mM oxaloacetate, * = 0.30 mM oxaloacetate, □ = 0.10 mM 
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Fig 7.16: Rate concentration plot for mutant 64C MDH of activity with varying 
oxaloacetate at fixed NADH concentration^
Where ■ = 0.25 mM NADH, + = 0.20 mM NADH, * = 0.13 mM NADH,
□ = 0.05 mM NADH, x = 0.03 mM NADH and ▲ = 0.01 mM NADH.
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Fig 7.17: Rate concentration plot for mutant 222C MDH of activity with varying 
NADH at fixed oxaloacetate concentration,
Where ■ = 12.5 mM oxaloacetate, + = 10.0 mM oxaloacetate, * = 7.5 mM 












Fig 7.18: Rate concentration plot for mutant 222C MDH of activity with varying 
oxaloacetate at fixed NADH concentration.
Where ■ = 0.25 mM NADH, + = 0.20 mM NADH, * = 0.125 mM NADH and 
□ = 0.05 mM NADH.
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decrease in activity. This decrease in activity appears to be more pronounced with 
increasing concentration of oxaloacetate. At varying concentrations of oxaloacetate 
and fixed concentrations of NADH maximum MDH activity was observed at 0.125 
mM to 0.2 mM NADH (Fig 7.18). Increasing the NADH concentration to 0.25 mM 
appeared to cause inhibition of mutant 222C at the oxaloacetate concentration used. 
However at each fixed NADH concentration no inhibition was observed with 
increasing oxaloacetate. Attempts to obtain the Km and Vmax from linear and 
non-linear plots of the data were unsuccessful. However estimations of the Km from 
initial rates verses substrate concentration indicated that the Km for NADH on did not 
vary between the wild type and mutants, but the Km for oxaloacetate with mutant 
222C had increased from 0.04 mM (wild type and mutant 64C) to 0.94 mM (Fig 7.19).
(7.6.1) Increasing the yield of mutant 222C MDH.
As mutant 222C appeared promising for use in the EMIT assay (i.e. the MDH was 
derivatizable) it was desirable to increase the concentration of the MDH in the 
cell-free extract for further characterisation. This was achieved by shuttling the 222C 
MDH gene into an expression vector as outlined (Fig 7.20).
(7.6.2) Screening for the substitution in 222C.
Plasmids from colonies were screened for the presence of the gene by colony 
hybridisation (Fig 7.21). Colonies that showed strong hybridisation to the 5' [32p] 
labelled oligonucleotide at 47°C were subjected to restriction fragment analysis with 
EcoR I and Hind III. Restriction with EcoR I and Hind III excised a DNA fragment of 
approximately lOOObp, indicating the presence of the gene. An oligonucleotide-5 
which hybridised at nucleotide positions -372 to -356 on the vector was used as a 
sequencing primer to confirm the truncation of the MDH gene (Fig 7.22).
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Wild type 0.04 0 .0 2
64C 0.04 0 .0 2
222C 0.94 0.03
810 3 0.03 Nicholls et al, 1992
Wild type 0.04 0.05 Nicholls et al, 1992








nucleotide 1 nucleotide 1066







Fsp I Hind III
I
Ligate PCR fragment into pMEX.
I
Screen for the presence of the mutation by:
(1) Colony hybridisation
(2) Restriction fragment analysis
(3) Sequence the PCR fragment._________
I
Express mutant MDH in Ecoli MDH' strain.
Fig 7.20: Flow diagram of steps used to generate mutant pMEX222C.
147
Fig 7.21: Hybridisation of 222C MDH gene in pMEX with 5' r22pi labelled
oligonucleotide-16.
(1) Wash of Hybond-N membrane at 37°C for 10 minutes in 2 x SSC, 
SDS (0.1% w/v).
(2) Wash of hybond-N membrane at 47°C for 10 minutes in 2 x SSC, 
SDS (0.1% w/v).
I 2____ 3_ _S____ g_ 6 7 8_____9






Fig 7.22: Dideoxy sequence analysis of pM EX222C usin g oligonucleotide-5 as primer.
Lanes from left to right: Thymine (T); Guanine (G); Cytosine (C); Adenine (A) with 
corresponding codon usage. Bold uppercase indicates introduced EcoR I restriction 
site and mutations. Corresponding triple letter amino acid code is indicated above
(7.6.3) Purification of pMEX222C MDH.
No increase in the MDH activity was observed im the cell-free extract upon induction 
with IPTG (1 mM) above that of the control. Restriction digestion with EcoR I and 
Hind III of plasmid preparation from the culture indicated that the pMEX222C was 
present in the E.coli.
(7.7) Discussion.
(7.7.1) Substitution of threonine 64 to cysteine.
Expression of the gene encoding mutant 64C in E.coli MDH' strain W945T1-2 
resulted in MDH activity in the cell-free extract <of 1500 pmol.min'1. This was 
equivalent to 9% and 2% of that of wild type and mutant 113S MDHs. The 33kD 
subunit of MDH was determined to be only a minor component of the cell-free extract 
when analysed by SDS-PAGE. Specific activity of this mutant was 
1274 jamol.min"l.mg of protein' 1, which is similar to that obtained for mutant 113S 
and only slightly less than that of the wild type MDH. These results suggest that the 
substitution of threonine 64 for cysteine increased the susceptibility of MDH to 
degradation but did not greatly affect catalysis. Attempts to couple this mutant to a 
thiol affinity matrix or derivatize with a thiol specific reagent were unsuccessful. This 
indicated that cysteine 64 was not accessible to the thiol of the matrix or derivatizing 
agent.
Substitution of cysteine for threonine 64 resulted in a decrease of solvent accessible 
side chain surface area from 42 A^ tto 37 A^. The surface area of a methyl group is 
30A2 (Bordo and Argos, 1991) (Fig 7.23). It is possible that the small surface area 
of cysteine presented to the thiol matrix and derivatizing agent was too small to allow 
derivatization under similar conditions to those used for mutant 222C. However this
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Fig 7.23: Connolly surface prediction of cysteine 64 in the E.coli MDH crystal structure.
Figure 7.23 is a surface view of a Connolly surface. It indicates that the side chain of cysteine 64 is solvent accessible as depicted by stippled 
surface (green).
does not account for the decrease in the amount of MDH observed in the cell-free 
extract.
Possible reasons why substitution of a residue could increase susceptibility to 
degradation is discussed in chapter five. Cysteine and threonine show only a small 
change in hydropathy and side chain area (Creighton, 1983; Kyte and Doolitle, 1982; 
Roseman, 1988). It is unlikely that these small changes would cause large perturbation 
in the secondary structure surrounding the substituted residue. However these changes 
in some instances have been associated with an increased susceptibility of a protein to 
degradation (Pakula et al, 1986).
The increased susceptibility to degradation could be due to a change in the folding 
pathway as a result of this mutation (Browning et al, 1986). However, this is unlikely, 
as cysteine 64 is greater than 20A from cysteines 109, 113 and 251, if substituted into 
the E.coli MDH crystal structure. Any disulphide bond (~3A) or intermediate which 
could form between cysteine 64 and an endogenous cysteine would be expected to 
cause a major perturbation of the protein structure which would disrupt the active site. 
This could be tested by substituting threonine 64 for valine. Valine has a similar 
surface area (155A2) to threonine (140A^) and has been observed in some instances to 
be substituted for threonine (Bordo and Argos, 1991). Provided that valine 
substitution does not perturb the protein secondary structure, a protein with a similar 
level of expression to the wild type MDH would indicate that cysteine 64 is in-fact 
influencing the folding pathway of the MDH.
Threonine 64 is the second residue (from the N-terminus) of the small a-helix aC 1 
(Hall et al, 1992). This region of the protein has a high degree of flexibility, possibly 
indicating that these residues are not tightly packed (Hall et al, 1992). Threonine and 
cysteine have similar preferences to this position on a-helices (Chapter five) 
(Richardson and Richardson, 1988).
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The E.coli crystal structure indicates that threonine 64 is in a region of high negative 
charge with its nearest neighbours being aspartate 62, glutamate 6 8  and glutamine 104. 
The crystal structure indicates that cysteine could take part in similar hydrogen 
bonding as threonine 64. However, substitution of cysteine might alter the charge in 
that region. Roseman (1988) has indicated that the charge on an individual residue in a 
protein is determined by the environment that the residue is found. This is amply 
illustrated with the observed differences in the pK of histidine in different proteins. 
Therefore introduction of cysteine 64 could result in two forms of residue; -SH and -S“ 
(The pK of cysteine in water is ~8.3). If the predominant form of this residue is -SH, 
then substitution of this residue should not perturb the local secondary structure 
surrounding the substitution. If the cysteine is in the -S" form then it would increase 
the negative charge in the region of the substitution. To minimise this charge effect 
aC' could possibly re-orientate in the protein, minimising the effect of the negative 
charge, but increasing the susceptibility of the MDH to degradation. However, as aC  
is a small helix at the extremities of the coenzyme binding domain, the disruption 
associated with aC' might not affect catalysis. This could be tested by substituting 
threonine 64 for a positive and a negative charged residue. Substitution of the lysine 
which is positively charged at physiological pH and has a surface area of 170A2 should 
enhance stability of the protein. Whereas substitution of aspartic acid which is 
negatively charged at physiological pH and surface area of 150A^ should destabilise 
the MDH increasing susceptibility to degradation.
(7.7.2) Conclusion.
Mutant 64C appeared to be more susceptible to degradation than the wild type MDH. 
The inability to derivatize this mutant under similar conditions to mutant 222C 
suggests that substituted residue 64 was not accessible to the derivatizing agent. This 
is likely to be due to a local change in conformation surrounding residue 64. This 
change in local conformation making this residue more susceptible to degradation.
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(7.7.3) Substitution of serine 222 to cysteine.
The MDH gene containing cysteine 222 when expressed in E.coli W945T1-2 produced 
a similar level of the 33kD subunit in the cell-free extract as wild type and mutant 113S 
MDH when analysed by SDS-PAGE. Mutant 222C could be derivatized by thiol 
specific derivatizing agents but could not be bound to a thiol affinity matrix, when the 
matrix free thiol group was bound to a "short" linker arm. This suggests that although 
cysteine 222 was solvent exposed it was not predominant on the protein surface. The 
specific activity of this MDH was only 3.5% and 4.0% of that observed for the wild 
type and 113S MDH. Kinetic data suggests that the reduced specific activity is due to 
a reduced affinity for substrate (oxaloacetate).
The E.coli crystal structure indicated that serine 222 is located at the entrance of the 
active site cleft Substitution of serine 222 for cysteine in the crystal structure 
indicated that the cysteine side chain could be accomodated without perturbation of 
the active site (Fig 7.24 and 7.25). The -SH group displayed a small movement of
0.2A  and 0.1 A  away from the carbon of malate and the NAD ribose unit This 
residue is shielded from the catalytically important histidine and aspartate (Hall et ah 
1992) by malate (Fig 7.26). Residue 2 2 2  is 9A and 12A  from this histidine and 
aspartate making direct perturbation of these residues by the substitution unlikely 
(Fig 7.26). Nicholls et al, (1992) has substituted arginine 81 of E.coli MDH for 
glutamine. This arginine participates in a salt bridge with the carboxy moiety of 
malate upon pD/aD loop closure, while the glutamine participates in a weaker 
hydrogen bond (Hall et al, 1992; Nicholls et al, 1992). Kinetic data suggests that this 
mutant MDH has a reduced affinity for oxaloacetate, but the affinity for coenzyme 
remains undiminished (Nicholls et aly 1992). This decrease in affinity for substrate is 
similar in magnitude to that observed for mutant 222C and has been attributed to the 
loss of the salt bridge between arginine 81 and malate and the large hydration potential 
of arginine which excludes water from the active site upon interaction with the
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Fig 7.24: Space filled model of E.coli MDH crystal structure active site.
Figure 7.24 indicates that L-malate (yellow), coenzyme (orange) and serine 222 (magenta) are in close proximity to each other. The distance of 
serine 222 from the closest point of coenzyme, substrate and adjacent residues is indicated in green and distance given in A.
Fig 7.25: Space filled model of E.coli MDH crystal structure active site with serine 222 substituted for cysteine.
Figure 7.25 indicates that L-malate (yellow), coenzyme (orange) and cysteine 222 (magenta) are in close proximity to each other. The distance of 
cysteine 222 from the closest point of coenzyme, substrate and adjacent residues is indicated in green and distance given in A.
Fig 7.26: Spatial orientation of serine 222 in E.coli MDH active site in relation to coenzvme. substrate, histidine 177 and aspartate 150,
Figure 7.26 indicates that L-malate and coenzyme interject between serine 222 and the catalytically important histidine 177 and aspartate 150. 
The distances of serine 222 from the closest point of the histidine and aspartate are indicated in green and distances given in A.
substrate. Exclusion of water from the active site is thought to increase the 
electrostatic interactions between substrate and substrate binding residues.
If the cysteine is in the -S‘ form in the active site, the extra negative charge could 
result in a hydration shell surrounding exposed cysteines. If upon loop closure this 
extra water due to the hydration of cysteine is not removed from the active site, it may 
result in weaker interactions between the substrate and the substrate binding residues. 
This will manifest in a lower substrate affinity. It is possible that substitution of serine 
2 2 2  reduces the affinity for substrate by preventing removal of water from the active 
site upon loop closure. If the pertubation of the affinity for oxaloacetate is due to the 
-S" form in the active site it would be expected that substitution of glutamate which is 
negatively charged for serine 2 2 2  would decrease the enzymes affinity for substrate. 
However, substitution of serine 222 for threonine which represents a similar side chain 
area increase as the cysteine substitution would not affect substrate binding in the 
active site.
(7.7.4) Conclusion.
Substitution of serine 222 for cysteine did not increase the susceptibility of this mutant 
to degradation when compared to the wild type MDH. This mutation did however 
alter the affinity of the enzyme for oxaloacetate. This decrease in affinity could be due 
to the enzymes inability to exclude water from the active site upon PD/aD loop 
closure. The introduced negative charge in the active site hinders expulsion of water 




IMPLICATIONS OF RESULTS ON EMIT
(8.1) Implications of results on EMIT.
The ability to express plasmid encoded wild type E.coli MDH in E.coli and purify this 
enzyme made this MDH ideal candidate to ascertain the potential of modified MDHs in 
EMIT. The lack of non solvent accessible cysteines per MDH made cysteine a suitable 
residue to investigate the coupling of ligands to the surface of the MDH. Initially it 
was planned to remove the endogenous cysteines from the wild type MDH (to ensure 
that endogenous cysteines could not interact with introduced cysteines, altering the 
folding pathway), then substitute cysteines into the pD/aD surface loop. However, 
results indicate that MDHs with endogenous cysteines removed were less prevalent in 
the cell-extracts. This inability to generate a mutant devoid of cysteines restricted the 
potential of this MDH for use in EMIT. Introduction of cysteine into the PD/aD 
surface loop of a mutant with cysteines 109 and 113 substituted for serine resulted in 
no MDH being present in the cell-extracts. However, substitution of residues 64 and 
222 for cysteines in the wild type MDH resulted in active MDHs. Only the mutant 
bearing the 222C substitution was capable of derivatization. This enzyme had a 
diminished specific activity when compared to the wild type enzyme, which was 
attributed to a reduced affinity for oxaloacetate. Attempts to covalently bind this 
enzyme to a thiol on a short linker arm of a thiol affinity matrix were unsuccessful 
indicating that this cysteine was not predominant on the protein surface. The E.coli 
crystal structure confirms that cysteine 2 2 2  is not directly solvent accessible and is 
situated in the active site cleft. For an antibody to form an antibody-ligand enzyme 
complex, the ligand bound to cysteine 2 2 2  would have to be on a linker arm which 
would allow the ligand to protrude out of the active site cleft This linker could block 
the active site cleft preventing the movement of substrate into and out of the active 
site, or prevent collapse of the pD/aD surface loop over the active site. Therefore
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MDH mutant 222C is not suitable for use in EMIT. The E.coli crystal structure (Hall 
et al, 1992) indicates that glycine 220 is on the surface of the MDH at the apex of 
a2G/a3G turn. Provided that the change in hydrophobicity and surface area upon 
substitution of cysteine does not perturb the structure, or influence the folding 
pathway, it might be possible to produce a modified MDH suitable for use in EMIT. 
Native thermophilic enzymes are less susceptible to degradation than their mesophilic 
counterparts (Menendez.-Arias and Argos, 1989) and as such are more able to tolerate 
mutations. An alternative approach would be to substitute cysteine residues into a 
wild type thermophilic MDH. The gene encoding the dimeric MDH of Thermus 
aquaticus B has been cloned (Nicholls et ah 1990). This protein contains a unique 
cysteine and has a high sequence identity to porcine cytoplasmic MDH. Substitution 
of this cysteine will produce a mutant devoid of cysteine. Further introduction of 
cysteine into this mutant will not be influenced by disulphide bond intermediates. This 
mutant when expressed in E.coli can be rapidly purified by the method of Nicholls et 
ah (1990). The high sequence identity with the cytoplasmic MDH enables accurate 
modelling of the T. aquaticus B MDH.
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[a-3 2 P]dATP [a-3 2 P] 2'-Deoxyadenosine 5'-triphosphate
[y-3 2 P] ATP [y-32p] 2'-Deoxyadenosine 5'-triphosphate
[a-3 5 S]dATP [a-3 3 S] 2'-Deoxyadenosine 5'-triphosphate
ddATP 2' ,3’ -Dideoxyadenosine 5'-triphosphate
dCTPaS 2’-Deoxycytidine 5'-(athio) triphosphate
dCTP 2'-Deoxyctidine 5'-triphosphate
ddCTP 2' ,3' -Dideoxyctidine 5’-triphosphate
dGTP 2'-Deoxyguanosine 5'-triphosphate
ddGTP 2' ,3' -Dideoxyguanosine 5'-triphosphate
dNTP 2' -Deoxynucleotide 5’-triphosphate
ddNTP 2' ,3' -Dideoxynucleotide 5'-triphosphate
DSSP Directory of secondary structure prediction
dTTP 2'-Deoxythymidene 5'-triphosphate
ddTTP 2' ,3* -Dideoxythymidene 5'-triphosphate
DTT Dithiothreitol








EMIT Enzyme multiplied immunoassay technique
Fsp I Restriction endonuclease from Fischeralla ssp
g Gravity
X-gal 5-bromo-4-chloro-3-indolyl-p-D-galactoside
Hind III Restriction endonuclease from Haemophilus influenza
IPTG Isopropyl-P-D-thiogalactoside
kb 1 0 0 0  bases
kD 1000 Daltons
Km Michaelis constant
Kpn I Restriction endonuclease from Klebsiella pneumonia
LB Luria Bertani (Broth)
LDH Lactate dehydrogenase
LMP Low melting point
M13 Filamentous bacteriophage (M13)
MDH Malate dehydrogenase
MOPS 4-Morpholinepropanesulphonic acid
MSE Measuring and scientific equipment
Nae I Restriction endonuclease from Nocardia aerocolonigenes
NAD Nicotinamide-adenine dinucleotide
NAD+ Nicotinamide-adenine dinucleotide (oxidised form)
NADH Nicotinamide-adenine dinucleotide (reduced form)
NBT Nitro blue tetrazolium
Nci I Restriction endonuclease from Neisseria cinarea
Nde I Restriction endonuclease from Neisseria denitrificans




PCR Polymerase chain reaction
PAGE Polyacrylamide-gel electrophoresis
PEG Polyethylene glycol
pH = -log [Proton]
pK = log [dissociated acid/undissociated acid]
pMEX222C Expression vector (pMEX) containing 222C MDH gene
PMS Phenazine methosulphate
Pst I Restriction endonuclease from Providencia stuarti
pUC19 Plasmid of pUC19
pUCWT Plasmid of pUC19 containing wild type MDH gene
pUC64C Plasmid of pUC19 containing 64C MDH gene
pUCl 13S Plasmid of pUC19 containing 113S MDH gene
pUC109S/l 13S Plasmid of pUC19 containing 109S/113S MDH gene
pUC109S/113S/81C Plasmid of pUC19 containing 109S/113S/81C MDH gene
pUC109S/l 13S/84C Plasmid of pUC19 containing 109S/113S/84C MDH gene
pUC109S/l 13S/90C Plasmid of pUC19 containing 109S/113S/90C MDH gene
pUC 109S/113S/251S Plasmid of pUC 19 containing 109S/113S/25IS MDH gene




RMS Root mean square
RNA Ribonucleic acid
RNAse Ribonuclease A
Sal I Restriction endonuclease from Streptomyces albus G
SDS Sodium dodecyl sulphate
Sph I Restriction endonuclease from Streptomyces
phaeochromogenes 
SSC 0.15 M sodium chloride and 15 mM sodium citrate
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TBE Tris base-boric acid-EDTA
TCA Tricarboxylic acid cycle
TE Tris-EDTA
TEA Triethylamine
TEMED N ,N ,N',N' tetramethylethylene diamine
TGI E.coli strain TGI: genotype K12 A (lac, pro) supE, thi,
hsdD5/F'traD36, proAB+> laclQ lacZAM\5 
TNB Thionitrobenzoate





W945T1-2 E.coli strain W945T1-2: genotype (thi thr leu lac gal trp
mtl str^t F")
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Restriction endonuclease Recognition site
T




p SJ) j .  5 ' TGCGCA3 '










5 ' GGTACC3' 
3 ' CCATGG5' 
A




N(j e  j .  5 ' CATATG3 '
3 ' GTATAC5' 
A
▼
ISJhp T‘ 5 ' GCTAGC3 '
3 ' CGATCG5' 
A
▼
5 ' GTCGAC3' 
3 ' CAGCTG5' 
A
▼
5 ' GCATGC31 
3 *CGTACG5' 
A
Appendix A : Restriction endonucleases with restriction endonuclease recognition
sites.Positions of "nick" sites on 5' and 3’ DNA are indicated by ▼ and A .
174
Appendix B: Restriction map of pUC19 and location of restriction endonuclease sites,
Esp3  I 2 6 8 3  
E coO 109  I 2 6 7 4  
A a t  H 2 6 1 7
S sp  I 2501
Eco57 I 2381  
Xm n  I 2 2 9 4
B eg  I 2215  
S ea  I 2177
Esp3 I 51 
Drd 191
HgtE II 181 ®
N de  I 183  
N ar I / K a s  I 2 35  
Bgl I 2 4 5  
' Fsp I 2 5 6  *  
P u l l  I 2 7 6  
^  Puu II 3 0 6
BeeF I 3 8 7
Puu I 20 6 6  
Aua II 2059-n
Fsp I 1919
Ava  II 1837  
Bgl I 1813  
Bpm  I 1784  
BsrF  I 1779  
JBsa I 1766
E a m llO S  I 1694
Z l Puu II 6 2 8  
Ij 'T y n  641  
S a p  I 6 8 3
I 781  
A /I m  8 0 6
Drd I 9 0 8
Mme I 9 9 6  ®
| HgiE II 1387  
Eco57 I 1333
Mme I 1180 ® 
AlivN  I 1217  
B ceF I 1292 ®
P o ly lin k er  
clon in g  s ite s
3 9 6 -4 5 4
400 420 440 460
E cI1 3 6  I X m a I
S a c  I S m a  I X ba  I P s t I H ind  m
agtgaattCG AGCT CGGT ACCCGGGG AT CCT CT AG AGT CGACCT GC AGGCAT GC AAGCTT GGcgtaatcatggtcat 
EcoR  I K pn  I Bam H  I S a l  I S p h  I
A po I A c c 6 5 1  Hinc n
A ce  I
BspM  I
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Appendix C: Sense and anti-sense codon table.
Amino acid Sense codon Anti-sense codon Amino acid Sense codon Anti-sense codon Amino acid Sense codon Anti-sense codon Amino acid Sense codon Anti-sense codon
Phe F UUU AAA S UCU AGA Tyr Y UAU AUA Cys C UGU ACA
F UUC GAA S UCC GGA Y UAC GUA , C UGC GCA
Leu L UUA UAA S UCA UGA Ter * UAA UUA Ter * UGA UCA
L UUG CAA S UOG OGA * UAG CUA Tip w UGG CCA
L CUU AAG Pro P e c u AGG His H CAU AUG Arg R CGU ACG
L c u e GAG P CCC GGG H CAC GUG R CGC GOG
L CUA UAG P OCA UGG Gin Q CAA UUG R GGA UGG
L CUG CAG P COG CGG Q CAG CUG R CGG COG
lie I AUU AAU Thr T ACU AGU Asn N AAU AUU Ser S AGU ACU
I AUC ‘ GAU T ACC GGU N AAC GUU S AGO GCU
I AUA UAU T ACA UGU Lys K AAA UUU Arg R AGA UCU
Met M AUG CAU T ACG CGU K AAG CUU R AGG e c u
Val V GUU AAC Ala A GCU AGO Asp D GAU AUC Giy G GGU ACC
V GUC GAC A GCC GGC D GAC GUC G GGC GCC
V GUA UAC A GCA UGC Glu E GAA UUC G GGA UGG
V GUG CAC A GOG CGC E GAG c u e G GGG CCC
Appendix D: Table of oligonucleotides.
N u m b er N u m b er o f  
nucleo tides
S en se /an ti-sen se F u n c tio n O ligonuc leo tide
1 26 sense In tro d u ce  Nhe I re s tr ic tio n  
site  a n d  substitu te  cysteine 
113 fo r serine.
G T
(326) 5' GC CCG AAA GOT AGC ATT GGT AAT ATC3' (351)
Cys
(AA107) Thr Cys Pro Lys Ala Ser lie Gly Asn lie Thr Asn (AA119)
2 17 sense S equenc ing  o ligonucleo tide (243) 5'AAA CCG GGT ATG GAT CGT3' (261)
3 36 sense R em ove p o ly lin k e r 
Hind III re s tr ic tio n  site.
H in c II 
A cc I
BamH I S a l I Sph I GC 
(-314) 5'GATC CTCTAGAGTC GACCTGCAGG CATGCAAATT TC3' (-279) 
Xba I P s t I H in d III
4 29 an ti-sen se In troduce  Nhe I re s tric tio n  
site  a n d  substitu te  cyste ines 
109 an d  113 fo r  serines.
A C  A 
(347) 5'TT ACC AAT GCT AGC TTT CGG GCT GGT TTT3' (319)
Cys Cys 
(AA118) Thr lie Asn Gly lie Ser Ala Lys Pro Ser Thr Lys Ala Val (AA105)
5 17 sense S equenc ing  o ligonucleo tide. (-372) 5'GTTTTCCCAGTCACGAC3' (-356)
6 21 an ti-sen se In tro d u ce  Nde I re s tr ic tio n  
site  a n d  substitu te  cysteine 
251 fo r serine .
G G C
(767) 5' CC TTC AAC ATA TGC AGA TTC G3' (747)
Cys
(AA258) Gly Asp Gly Glu Val Tyr Ala Ser Glu Val Val Gly (AA 247)
7 21 sense In tro d u ce  Nde I re s tric tio n  
site.
C C
(747) 5'C GAA TGT GCA TAT GTT GAA GG3' (767)
(AA247) Gly Val Val Glu Cys Ala Tyr Val Glu Gly Asp Gly (AA258)
8 16 an ti-sen se S equenc ing  o ligonucleo tide. (1066) 5 1AACAGCTATGACCATG3 ' (1051)
9 59 an ti-sen se In troduce  Nae I re s tric tio n  
s ite  a n d  substitu te  a rg in in e  
81 a n d  o r  g lycine  84  fo r 
cysteine(s).
(291) 5' GAT GCC GGC GTT AAC GTT AAA CAG GTC GGA
(AA99) Lys Val lie Gly Ala Asn Val Asn Phe leu Asp Ser
C G 
ACG ATC CAT ACA CGG TTT ACA CCG TAC GC3' (233)
Gly Arg 
Arg Asp Met Cys Pro Lys Cys Arg Val Gly Ala Ser (AA76)
10 32 an ti-sen se In troduce  Nae I re s tric tio n  
site  a n d  substitu te  leuc ine  90  
fo r  cysteine.
CAG
(294) 5 'CAC GAT GCC GGC GTT AAC GTT AAA GCA GTC GG31 (263)
Leu
(AA100) Asn lys Val lie Gly Ala Asn Val Asn Phe Cys Asp Ser Arg Asp (AA86)
»
11 36 sense R em ove p o ly lin k e r 
Hind III  a n d  Sph I 
re s tr ic tio n  sites.
H in c II 
A c c I
BamH I S a l I Sph I GC 
(-314) 5'GATC CTCTAGAGTC GACCTGCAGG GATGCAAATT TC31 (-279) 
Xba I P s t I C H in d III
12 22 an ti-sen se In troduce  Sph I re s tric tio n  
site  an d  substitu te  
th reo n in e  64  fo r cysteine.
AGT C
(200) 5' AG CGC CGG GCA TGC ATC TTC AC3' (179)
Thr
(AA69) Gly Glu Leu Ala Pro Cys Ala Asp Glu Gly Ser Phe (AA58)
13 22 sense In troduce  Sph I re s tric tio n  
site  a n d  substitu te  
th reo n in e  6 4  fo r  cysteine.
G ACT
(179) 5' GT GAA GAT GCA TGC CCG GCG CT31 (200)
Thr
(AA58) Phe Ser gly glu Asp Ala Cys Pro Ala Leu Glu Gly (AA69)
14 20 an ti-sen se In troduce  Fsp I re s tric tio n  
site  a n d  substitu te  
se rin e  2 2 2  fo r cysteine.
AG
(675) 5' CAC GGT TGC GCA CCC GCC AC3' (656)
Ser
(AA227) Met Ser Leu Thr Ala Cys Gly Gly Gly Ala Lys (AA217)
15 19 sen se In tro d u ce  Fsp I  re s tric tio n  
site  a n d  su bstitu te  
se rin e  2 2 2  fo r  cysteine.
CT
(658) 5'GGC GGG TGC GCA ACC CTG T3• (676)
Ser
(AA218) Ala Gly Gly Gly C y» Thr Leu Ser Met Gly (AA228)
16 29 sense T ru n ca te  M D H  g en e  an d  
in tro d u ce  EcoR I re s tric tio n  
site.
AT AA T
(-26) 5'GT TTA TCA GAA TTC AAA GGA TTT AGG ATG3' (3)
(AAl)Met Lys Val (AA3)
Restriction endonuclease sites and substituted nucleotides are indicated in bold, while corresponding residues to codons are indicated in triple letter code.
Appendix E: Properties of Amino acids.
Amino acid Accessible 
surface area
(A2)
Sid? chain pK Structure of amino acid
\
Ala (A) 115 • O X n O 1 X 0 —0 —0
1z<nX+
A rg(R ) 225 12.5
+ CM
■ x  i
8  | X X X I  II xo —o—o —o —o —z —o —z
1z
X+
Asn (N) 160 b f  .  /O X So —o—o —o
k  zX x+
Asp (D) 150 3.9
f
b x « o ;O X Oo—o—o —o 
1
X+
Cys(C) 135 8.3 O ^ CM ;
4X j+ 1
G ln(Q ) 180
1
O =F CM CM P  1o x  X S  i o—o—o—0 —0 i
\  !
i  z !x  X I+ \




Gly (G) 75 o T
u—o—i
1z«X+
His (H) 195 6 .0 A ,  \
8  I i  i io—o— O—0 = 0  X 
1z«•>X+
ne(i) 175







Lys (K) 2 0 0 1 0 .8 O ?  N N N N J? o  X  X  X  X  x  o—O—o—O—O—O—Z
1zB
X+
Met (M) 185 f a x  JU I N N W 




Phe (F) 2 1 0 8 i i j  \
° - r oHv _ /
t
Pro (P) 145
(N (M1 X x xO  v 0 — 0
o  \  /  1 
0 — 0  \ 1 z —CJ
x  X+









§ 1 1  


















Appendix F: Ammonium sulphate addition table.
Final concentration of ammonium sulphate, % saturation at 0°C
In itia l co n cen tra tio n  o f  
am m o n iu m  su lpha te ,
%  sa tu ra tio n  a t  0 °C
20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
G ram s o f  so lid  am m o n iu m  su lp h a te  to  ad d  to  100 m l o f  so lu tio n
0 10.6 13.4 16.4 19.4 22 .6 25 .8 29.1 32 .6 36.1 39 .8 43 .6 47 .6 51 .6 55 .9 60 .3 6 5 .0 6 9 .7
5 7 .9 10.8 13.7 16.6 19.7 22 .9 26 .2 29 .6 33.1 36 .8 40 .5 44 .4 4 8 .4 52 .6 57 .0 61 .5 66 .2
10 5.3 8.1 10.9 13.9 16.9 20 .0 23.3 26 .6 30.1 33 .7 3 7 .4 41 .2 4 5 .2 49 .3 53 .6 58.1 6 2 .7
15 2 .6 5.4 8 .2 11.1 14.1 17.2 20 .4 23 .7 27.1 30 .6 34.3 38.1 4 2 .0 46 .0 50 .3 54 .7 59 .2
20 0 2 .7 5.5 8.3 11.3 14.3 17.5 20 .7 24.1 27 .6 31 .2 34 .9 3 8 .7 42 .7 46 .9 51 .2 55 .7
25 0 2 .7 5.6 8 .4 11.5 14.6 17.9 21.1 24 .5 2 8 .0 31 .7 35 .5 39 .5 43 .6 4 7 .8 52 .2
30 0 2 .8 5 .6 8 .6 11.7 14.8 18.1 21 .4 24 .9 28 .5 32 .3 36 .2 40 .2 44 .5 4 8 .8
35 0 2 .8 5 .7 8 .7 11.8 15.1 18.4 21 .8 2 5 .4 29 .1 32 .9 3 6 .9 4 1 .0 45 .3
4 0 0 2 .9 5 .8 8.9 12.0 15.3 18.7 22 .2 2 5 .8 2 9 .6 33 .5 37 .6 4 1 .8
45 0 2 .9 5.9 9 .0 12.3 15.6 19.0 2 2 .6 36 .3 30 .2 34 .2 38 .3
50 0 3.0 6 .0 9 .2 12.5 15.9 19.4 2 3 .0 2 6 .8 3 0 .8 34 .8
55 0 3 .0 6.1 9.3 12.7 16.1 19.7 23 .5 27 .3 31.3
60 0 3.1 6 .2 9 .5 12.9 16.4 20 .1 23 .9 2 7 .9
65 0 3.1 6 .3 9 .7 13.2 16.8 20 .5 2 4 .4
70 0 3 .2 6 .5 9 .9 13.4 17.1 20 .9
75 0 3 .2 6 .6 10.1 13.7 17.4
8 0 0 3.3 6 .7 10.3 13.9
85 0 3 .4 6 .8 10.5
9 0 0 3 .4 7 .0
9 5 0  . 3 .5
100 0
